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ABSTRACT 
 
Fibroblast growth factor receptors (FGFRs) regulate fundamental cellular processes, 
including proliferation, differentiation and angiogenesis and have emerged as growth 
factor receptors central to oncogenesis. This study developed a live-cell assay system for 
studying FGFR endocytosis and trafficking by employing both confocal and total internal 
reflection fluorescence (TIRF) microscopy in cells expressing a previously characterised 
GFP-tagged FGFR2 construct. Data from this work have demonstrated that endocytosis of 
activated FGFR occurs through clathrin-mediated endocytosis. Interestingly, FGF 
treatment also significantly increased the number of CCPs as well as the number of 
clathrin-mediated endocytic  events. However, treatment of cells with the Src family 
inhibitor Dasatinib or depletion of Src kinase target Eps8, prevents the FGF induced 
increase in plasma membrane clathrin and reduces the internalization of FGFR. This study 
also shows that both Src and Eps8 are required for receptor to exit from EEA1 positive 
peripheral compartment into the perinuclear recycling and the lysosomal degradative 
compartments. Eps8 depletion also inhibits the early phases of ERK activation in response 
to FGFR activation, placing this signalling event early in the trafficking pathway of the 
receptor. Thus, these results have identified the endocytic pathway for endocytosis of 
FGFR2 and described Eps8 and Src as key mediators of the early phases of activated FGFR 
trafficking and signalling. 
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CHAPTER 1 
INTRODUCTION 
 
1.1 Receptor tyrosine kinases 
Transmission of extracellular signals into the cell is a fundamental process mediated by 
molecules on the plasma membrane that act as receptors for soluble extracellular 
ligands, generating specific intracellular physiological events. One of the largest and most 
important families of membrane-bound receptors involved in signal transduction is the 
receptor tyrosine kinase (RTK) family, which includes receptors for insulin and for 
essential growth factors, such as epidermal growth factor receptor (EGFR), fibroblast 
growth factor receptor (FGFR), platelet-derived growth factor receptor (PDGFR), vascular 
endothelial growth factor receptor (VEGFR), and nerve growth factor receptor (NGFR) 
(Lemmon and Schlessinger 2010, Mason I. 2007). 
RTKs mediate a wide variety of cellular responses, both during embryonic development 
and in adult tissue (Mason I. 2007, Ullrich A. and Schlessinger 1990). Cell proliferation, 
cell differentiation, cell migration, and apoptosis are only a few of the physiological 
processes regulated by RTKs (Lemmon and Schlessinger 2010). Further, many 
pathological conditions, including cancer, diabetes, and atherosclerosis, are linked to RTK 
signalling (Cotton et al. 2008, Jang et al. 2001, Slamon 1987).  
RTK signalling is critical for proper functioning of multicellular organisms. Humans have 
58 known RTKs, divided into 20 subfamilies (Robinson D. R. et al. 2000), all sharing a 
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similar molecular architecture (Figure 1.1): an extracellular N-terminal domain containing 
the ligand and recognition-binding site, a single hydrophobic transmembrane α-helix, and 
a cytoplasmic C-terminal domain consisting of a juxtamembrane region (just after the 
transmembrane helix), followed by the tyrosine kinase catalytic domain (TKD) and a 
carboxy-terminal tail. This molecular architecture, which reflects a shared mechanism of 
RTK activation, is highly conserved throughout evolution from the nematode C. elegans 
to humans (Popovici et al. 1999). Numerous RTKs have been also identified in the 
genomes of unicellular organisms (Manning et al. 2008, Suga et al. 2012). The overall 
architecture of these RTKs possesses similar features as metazoan RTKs in spite of a low 
sequence homology (Schultheiss et al. 2013).   
Most RTKs exist as monomers in the absence of ligand. In this conformation, the tyrosine 
kinase domain is cis-autoinhibited by intramolecular interactions specific to each class of 
receptor (Lemmon and Schlessinger 2010). Oligomerization induced by ligand binding 
brings 2 TKDs together in a stable dimer; by promoting allosteric effects, this releases cis-
autoinhibition and triggers the intrinsic activity of the receptor (Nolen et al. 2004) (Figure 
1.1). The originally proposed model for RTK dimerization suggests that a bivalent ligand 
induces dimerization by simply binding to 2 receptor molecules at the same time, cross-
linking them together (Leppanen et al. 2010, Wiesmann et al. 1999). This model, 
however, is valid only for some receptors, such as NGFR and VEGFR, whose ligands exist 
as homo-dimeric molecules. In the case of a monomeric ligand, as in the case of EGFR, 
receptor dimerization seems to be driven mainly by receptor–receptor interaction: ligand 
binding induces conformational changes that expose a previously occupied dimerization 
site on the monomeric receptor, resulting in its enhanced affinity for another ligand- 
 3 
 
  
 
Figure 1.1 Molecular architecture and mechanism of activation of RTKs 
All RTKs comprise an N-terminal extracellular domain containing the ligand-
binding site, a single hydrophobic transmembrane α helix, and an intracellular 
domain which includes a region with tyrosine-kinase activity and a carboxy-
terminal tail. Ligand binding promotes dimerization of RTKs, resulting in 
conformational changes in the intracellular domain critical for activation of 
the kinase domain. In turn, each receptor monomer phosphorylates a number 
of tyrosine residues in the cytoplasmic domain of its dimer partner (trans-
phosphorylation). The resulting phospho-tyrosines function as docking sites 
for other scaffold and signalling proteins involved in the RTK signalling 
cascade.  
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bound monomer (Bouyain et al. 2005). Following ligand binding, a number of tyrosine 
residues are phosphorylated in a precise order within the activation loop (A-loop) of the 
TK domain (Favelyukis et al. 2001, Furdui et al. 2006), and the receptor becomes fully 
activated. Exceptions to catalytic enhancement via dimerization include the insulin 
receptor (IR), which already exists as a stable disulfide-bonded dimer of α/β pairs. In the 
case of IR, ligand binding induces conformational rearrangements in the α/β chains, in 
turn stimulating kinase activity of the receptor (Ward et al. 2007). 
Following receptor activation, additional tyrosines are autophosphorylated in other parts 
of the cytoplasmic region of RTKs, generating docking sites for the recruitment of 
multiple cytoplasmic molecules containing Src homology-2 (SH2) and phosphotyrosine-
binding (PTB) domains (Lemmon and Schlessinger 2010) (Figure 1.1). These molecules are 
either signalling or scaffold proteins; they can themselves be phosphorylated by RTKs and 
are responsible for the initiation of various intracellular signal–transduction cascades, 
including Ras/mitogen activated protein kinase (MAPK) cascade, phosphatidylinositol-3-
OH kinase (PI3K)/AKT cascade, and phospholipase-C (PLC)/protein kinase C (PKC) cascade 
(Lemmon and Schlessinger 2010). 
Consistent with the key roles RTKs play in organisms, their activity is subject to very tight 
temporal and spatial regulation. The first regulation steps occur during the activation 
process itself, when the receptor goes through several trans-autophosphorylation events 
within the TK domain. These events play a critical regulatory role in most RTKs, and they 
can increase receptor kinase activity up to 200-fold, as in the case of IR (Cobb et al. 1989). 
Exceptions to regulation via catalytic-domain phosphorylation include EGFR. Mutation of 
the only tyrosine residue in the EGFR’s TK domain (Tyr845) to phenylalanine, does not 
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have any effect on the autophosphorylation activity of the receptor (Tice et al. 1999). In 
the case of EGFR, however, catalytic activity seems to be enhanced by an allosteric 
mechanism driven by ligand binding (Burgess et al. 2003). RTKs are also regulated by the 
activity of protein tyrosine phosphatases (PTPs) (Ostman and Bohmer 2001) as well as 
protein kinases (Ullrich A. and Schlessinger 1990). By modulating the phosphorylation 
status of RTKs and the downstream signalling and adaptor molecules associated with 
RTKs, these proteins can modulate the activated signalling response. A further level of 
regulation is the negative feedback mechanism achieved by the activity of inhibitors of 
RTK signalling that are transcriptionally induced downstream of the RTK signalling 
pathway itself (Amit et al. 2007). This is a very robust response mechanism of regulation, 
by which the cell is able to adjust the final RTK response to an appropriate level, directly 
sensing the current activated pathway (Avraham and Yarden 2011).  
A more complicated mechanism cells employ to finely modulate the activity and level of 
RTKs is internalization of activated receptors from the cell surface and their subsequent 
trafficking to intracellular compartments. These 2 processes have long been considered 
principally mechanisms of signal attenuation: the former by physically removing from the 
plasma membrane the receptor pool available for activation, the latter by sorting the 
internalized receptors into the intralumenal vesicles of multivesicular  bodies (MVBs), 
where receptors are degraded and signalling is terminated (Beguinot et al. 1984, 
Stoscheck and Carpenter 1984). However, a number of RTKs have been found that are 
able to cycle back to the plasma membrane upon internalization, and this process 
provides rapid recovery of cellular signalling responsiveness. Further, accumulating 
evidence suggests that signalling from activated RTKs persists along their  endocytic 
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pathway after internalization (Jiang and Sorkin 2002, Li H. S. et al. 2005, Sorkin and Von 
Zastrow 2002). In fact, regulated endocytosis and intracellular trafficking 
compartmentalise RTKs and their associated signalling proteins within specific, spatially 
localized subcellular domains, thus exerting a powerful influence on the spatial and 
temporal dynamics of RTK signalling (Di Fiore and De Camilli 2001, Disanza et al. 2009, 
Polo and Di Fiore 2006, von Zastrow and Sorkin 2007). The interplay between RTK 
trafficking and signalling is discussed in greater detail in Section 1.3.3, Crosstalk between 
RTK endocytosis and signalling.  
  
1.2 The FGFR family 
FGFRs represent a subfamily of RTKs and play an important role in a wide spectrum of 
cellular processes, including differentiation, apoptosis, angiogenesis, migration, and 
survival (Powers et al. 2000, Turner and Grose 2010). The FGFR family consists of 4 
distinct gene products (FGFR1, FGFR2, FGFR3, and FGFR4), each composed of an 
extracellular ligand-binding domain, a transmembrane helix domain, and a cytoplasmic 
domain that hosts the kinase activity (Figure 1.2). The 4 FGFRs are highly homologous, 
with some regions, such as the kinase domain, having sequence identity of up to 90% 
(Johnson D. E. and Williams 1993). A fifth member, FGFR5 or FGFRL1 (fibroblast growth 
factor receptor-like 1) was recently identified (Wiedemann and Trueb 2000); it is the 
most distantly related member of the FGFR family, showing approximately 30% amino 
acid identity to other FGFR proteins. Unlike other members of the FGFR family, FGFR5 
lacks the intracellular domain required for signal transduction (Sleeman et al. 2001) 
(Figure 1.2) and is believed to function as a negative regulator of the activity of the other 
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FGFRs, by binding and sequestering FGF ligands (Sleeman et al. 2001, Steinberg et al. 
2010) or by dimerizing with a conventional FGFR and inhibiting trans-phosphorylation 
events. 
1.2.1 The fibroblast growth factor family of ligands 
The fibroblast growth factors (FGFs) comprise a large family of developmental and 
physiological signalling molecules that mediate a wide range of cellular responses, such 
as cell growth, cell differentiation, cell survival, and cell migration (Beenken and 
Mohammadi 2009). Over the past 35 years, genes coding for FGFs have been found in 
both vertebrates and invertebrates, with 3 genes indentified in Drosophila melanogaster 
(branchless, pyramus, and thisbe) and 2 in Caenorhabditis elegans (Itoh and Ornitz 2004, 
Ornitz and Itoh 2001). In humans and mice, the FGF family of ligands includes 23 
members, 18 of which exert their function primarily through their high affinity 
interactions with cell-surface FGFRs; they all contain a conserved 120–amino acid residue 
core, with 30–60% amino acid identity (Itoh and Ornitz 2004).  
Because FGFRs exhibit overlapping recognition and redundant specificity for different 
FGFs (Table 1.1), the developmental and tissue-specific distribution of FGFs and FGFRs 
ensures the specificity of cellular response generated in different cell types and in 
different developmental stages by different FGFs. This cell-specific ‘competence’ is 
typified, for instance, by FGF7 which, unlike FGF2, is mitogenic for keratinocytes but not 
for endothelial cells (Rubin J. S. et al. 1989). In addition to their receptors, FGFs show high 
affinity for heparin and heparin sulphate-like glycosaminoglycans (HLGAGs) (Klagsbrun 
1990), acid polysaccharides containing sulphate groups attached throughout their  
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Figure 1.2 Domain structure of FGFR isoforms 
Ig: Immunoglobulin-like domain; HBS: heparin binding site; TM: 
transmembrane domain; JM: juxtamembrane domain; TK: tyrosine 
kinase domain; KI: kinase insert  
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polysaccharide chains, found in the extracellular matrix and on the cell surface. 
Physiologically, the binding of the FGFs to heparin or HLGAGs has 2 relevant 
roles:protection of the FGFs from degradation (Damon et al. 1989, Sommer and Rifkin 
1989), and creation of a local reservoir of growth factors critical to strict spatial regulation 
of FGF signalling (Gould et al. 1995). In the context of FGFRs, extensive research defines 
the role of heparin in receptor activation.  
Yayon et al., show that in HLGAG-deficient mutant CHO cells, FGFR1 loses the ability to 
bind FGF2, and that binding ability is restored by addition of heparin or heparan sulphate 
(Yayon et al. 1991). Cell surface HLGAGs have also been demonstrated to promote 
binding of FGFs to FGFR2 (Mansukhani et al. 1992), triggering a consequent mitogenic 
and angiogenic response (Aviezer et al. 1994, Rapraeger et al. 1991). These and other 
observations demonstrate that heparin and HLGAGs function as accessory molecules in 
the regulation of FGF binding and receptor activation (Ornitz and Itoh 2001) through 
different mechanisms, including promoting FGF oligomerization (Herr et al. 1997, Ornitz 
et al. 1992, Spivak-Kroizman et al. 1994), regulating the ligand diffusion rate (Dowd et al. 
1999, Flaumenhaft et al. 1990) and driving the specificity of FGF–FGFR interaction 
(Guimond and Turnbull 1999, Kan et al. 1999, Pye and Kumar 1998).   
By binding heparan sulphates with high affinity, most FGFs become trapped within the 
extracellular matrix of tissues and act locally as paracrine or autocrine ligands of FGFRs 
(Beenken and Mohammadi 2009). However, the 3 members belonging to the FGF19 
subfamily (FGF19, FGF21, and FGF23) bind to heparan sulphates with low affinity and can 
diffuse from the secretion tissue into the circulation and act in an endocrine fashion on 
distant tissues. Once the target tissues have been reached, the endocrine FGFs bind to a  
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- 
- 
- 
- 
- 
+ 
- 
- 
- 
+ 
+ 
+ 
- 
+ 
FGFR3c 
+ 
+ 
- 
+ 
- 
- 
- 
+ 
+ 
- 
- 
- 
- 
- 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
- 
+ 
FGFR4 
+ 
+ 
- 
+ 
- 
+ 
+ 
+ 
- 
- 
- 
- 
- 
- 
+ 
- 
+ 
+ 
+ 
+ 
+ 
- 
+ 
 
 
 
Table 1.1 Specificity of FGF/FGFR interaction 
Data were adapted from (Cotton et al. 2008, Mason 2007)  
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 co-receptor, known as klotho (Kurosu et al. 2006). The klotho proteins appear to play a 
similar function to HLGAGs: by interacting with both the endocrine FGF ligand and their 
cognate receptor, they increase FGF-FGFR affinity and function as cofactor necessary for 
FGF signalling activation (Kurosu et al. 2007, Kurosu et al. 2006, Lin B. C. et al. 2007, 
Urakawa et al. 2006). 
Most FGFs contain classic N-terminal signal peptides required for secretion (FGFs 3–8, 10, 
17–19, 21, and 23) or use an un-cleavable hydrophobic N-terminal sequence as an 
unconventional signal for secretion (FGFs 9, 16, and 20) (Ornitz and Itoh 2001). On the 
contrary, FGF1 and FGF2 lack any signal peptides, thus they cannot be secreted and are 
instead passively released from damaged cells (Ornitz and Itoh 2001). FGFs 11–14 also 
lack signal peptides, but they are not even released and remain intracellular, functioning 
within cells in a receptor-independent manner (Schoorlemmer and Goldfarb 2001). 
All FGFs adopt a β-trefoil structure consisting of 12 antiparallel β-strands (β1–β12) 
arranged in 3 repetitions of 4-stranded β-sheets (Murzin et al. 1992) (Figure 1.3A). The 
main interaction surface between FGF and heparin utilises a Lysine/Arginine–rich region 
on FGF, which includes the β1–β2 loop and parts of the region between the β10 and β12 
strands, and negatively charged groups on heparin (Faham et al. 1996) (Figure 1.3B). 
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 Figure 1.3 Structure of FGF2 and interaction surface between FGF2 
and heparin 
A. The secondary structure of FGF-2 shows a β-trefoil fold made up of 
three sets of four anti-parallel β-strands (PDB coordinates: 2FGF).  B. 
Stereo view of the binding surface between FGF2 and heparin. The 
sidechains of the FGF2 residues involved in the interaction are 
represented by thick blue lines (PDB coordinates: 1BFC). These images 
were obtained from PDB and labelled using Adobe Photoshop. 
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1.2.2 FGFR structure and alternative splicing 
 
1.2.2.1 Extracellular domain 
All FGFR family members share the same overall architecture in the extracellular portion, 
consisting of 3 immunoglobulin (Ig)-like domains (D1–D3) connected by ﬂexible linkers 
(Plotnikov et al. 1999). The region between D1 and D2 consists of an acidic, serine-rich 
region of 8 amino acids, called “Acidic Box” (AB). The D2 domain contains a highly 
conserved, negatively charged sequence that has high affinity for heparin, forming the 
heparin binding site (HBS) (Kan et al. 1993).  
The crystal structure of domains D2 and D3 of different FGFRs in complex with the FGFs 
ligands has been solved and demonstrates that D2 and D3 are necessary and sufficient for 
specific ligand binding (Plotnikov et al. 2000, Stauber et al. 2000, Yeh et al. 2003). The D2-
D3 domain of FGFR1 in complex with FGF2 is shown in Figure 1.4A and consists of 2 FGF2-
D2-D3 units in a 2:2 stoichiometry, with the ligands localizing on opposite sides of the 
dimer. Each ligand interacts extensively with D2-D3 and the intervening linker between 
them, and the whole dimeric structure is stabilized by direct D2–D2 interactions and 
interactions that the ligand forms with the domain D2 of the other receptor in the dimer. 
While the D2–D3 domain is necessary for ligand binding, the D1 domain and the AB are 
thought to participate in binding regulation. The AB region is highly conserved among 
FGFR family members and consists of a glutamate, aspartate, and serine-rich sequence 
that mimics the negative potential surface of heparin, and thus its avidity interacts with 
the HBS on the D2 domain of the FGFRs (Kalinina et al. 2012). When FGF is present at low 
concentrations, the AB region intramolecularly binds the HBS, while the D1 domain folds 
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back and interacts with the D2–D3 region, which represents the ligand-binding site on 
FGFR. In this conformation, the receptor is in a ‘close’ state, the interaction with heparin 
and FGF is sterically inhibited, and the initiation of biological response is suppressed 
(Kalinina et al. 2012, Olsen et al. 2004, Wang F. et al. 1995a).  
The crystal structure of the entire extracellular domain of FGFR in complex with FGF and 
heparin is shown in Figure 1.4C and is based on the ‘two end’ model proposed by 
Schlessinger et al. (Schlessinger et al. 2000). According to this model, heparin plays a dual 
role in driving the assembly of a 2:2:2 stoichiometry FGF:FGFR:heparin complex: first, it 
induces formation of a stable 1:1:1 FGF:FGFR:heparin ternary complex, by interacting 
with both FGF and FGFR via heparin non-reducing ends. This then drives recruitment of a 
second 1:1:1 FGF:FGFR:heparin ternary complex to the first complex. Contact between 
the 2 complexes is stabilized by direct FGFR:FGFR interaction, by secondary interactions 
between the FGF molecule in one ternary complex and the FGFR molecule in the other 
complex, and by indirect contact between the FGFR monomers mediated by heparin 
(Schlessinger et al. 2000).  
Multiple FGFR isoforms that differ in the extracellular domain are generated by 
alternative splicing of FGFR transcripts. The main event of alternative splicing in FGFR1–3 
involves exon encoding for the D3 domain, and this represents the main mechanism for 
regulating ligand-binding specificity of FGFRs (Yeh et al. 2003) (Figure 1.5). The exons (7–
9) that, combined, codify for the 3 D3 isoforms (designated IgIIIa, IgIIIb and IgIIIc) are 
contiguous in fgfr1, fgfr2, and fgfr3 (Chellaiah et al. 1994, Johnson D. E. et al. 1991). Exon 
7 unequivocally encodes for the N-terminal portion of D3 (IgIIIa), while exon 8 and exon 9 
are alternatively translated for the second half of D3 (generating IgIIIb or IgIIIc, 
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Figure 1.4 View of ligand binding domain and kinase domain structure of 
FGFR1 and representation of two-end model of FGF:FGFR:heparin complex  
A. Ribbon diagram of domains D2 (in blue) and D3 (in green) of FGFR1 in 
complex with FGF2. Each FGF2 localizes on opposite sides of the dimer and 
interacts with D2, D3, and with the intervening linker (in grey) between them 
(PDB coordinates: 1DJS).  B. Ribbon diagram of the kinase domain of FGFR1, 
comprising an N-terminal lobe formed by five anti-parallel β strands (β1-β5) 
and one α helix (αC) and a C-terminal lobe comprising two β strands (β7, β8) 
and seven α helices (αD, αE, αF, αG, αH, αI) (PDB coordinates: 1FGK).  C. 
Molecular surface representation of 2:2:2 stoichiometry FGF:FGFR:heparin 
complex. The complex is viewed from the top, with the two heparin chains 
fitting in the heparin binding canyon. The images in (A) and (B) were obtained 
from PDB and labelled using Adobe Photoshop. The image from (C) was 
adapted from Schlessinger et al. 2000. 
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respectively). The IgIIIa splice variant generates a truncated soluble protein which cannot 
activate any signal transduction, but nevertheless appears to play a specific role in 
generating biological activity, probably functioning as a negative regulator of the other 
FGFRs by binding and sequestering FGF ligands (Guillonneau et al. 1998) (Figure 1.5). A 
truncated soluble FGFR1IIIa, for instance, has been found to be differentially expressed in 
the adult murine retina compared to full-length FGFR1IIIc, suggesting, for this isoform, a 
specific role in development of the retina (Guillonneau et al. 1998). On the contrary, 
differential expression of the IgIIIb and IgIIIc variants results in the epithelial ‘‘b’’ and 
mesenchymal ‘‘c’’ isoforms of FGFRs, respectively (Jin et al. 2004, Orr-Urtreger et al. 
1993), which possess different ligand-binding specificities (Mohammadi et al. 2005, Olsen 
et al. 2006, Yayon et al. 1992, Yeh et al. 2003). For example, FGFR2IIIb 
binds FGF7 and FGF10, but not FGF2, whereas the FGFR2IIIc isoform binds FGF2, but 
not FGF7 and FGF10 (Dell and Williams 1992, Miki et al. 1992). This alternative splicing 
event occurs in a tissue-specific fashion, guarantying the isoform-specific responses 
generated in different cell types, which is particularly important for this development. For 
instance, the FGFR2b isoform is specifically expressed in epithelial cells, whereas the 
FGFR2c isoform is specifically expressed in mesenchymal cells (Orr-Urtreger et al. 1993).   
Consistent with lineage-specific expression of FGFR2 isoforms, a class switch from 
FGFR2b to FGFR2c has been shown to occur during progression of prostate cancer and 
bladder cancer from a non-malignant, stromal-dependent, epithelial tumour to an 
invasive, stromal-independent tumour (Yan et al. 1993). Another major alternative 
splicing event involves the exons encoding for D1 and the AB-containing region between 
D1 and D2. FGFR isoforms lacking D1 and the D1–D2 linker region possess higher affinity 
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for FGF and heparin, with consequent increased signalling capability, further supporting 
the observation that these extracellular domains are involved in receptor autoinhibition 
(Olsen et al. 2004, Roghani and Moscatelli 2007, Shi et al. 1993, Shimizu et al. 2001, Wang 
F. et al. 1995a). Consistent with their altered signalling capacity, FGFR isoforms lacking D1 
domain or AB region have been shown to be associated with cancer (Bruno et al. 2004, 
Onwuazor et al. 2003, Tomlinson and Knowles 2010, Yamaguchi F. et al. 1994a). 
1.2.2.2 Transmembrane domain 
Similar to other RTKs, the transmembrane region of FGFRs consists of an α-helix of 
approximately 20 amino acids with a number of hydrophobic residues oriented outside 
the α-helical core and interacting with the membrane lipid bilayer, therefore conferring 
stability to the protein (Creighton 1984). The existence of multiple mutations in the TM 
domain on FGFRs is associated with cancer and skeletal malformations (further discussed 
in Section 1.2.4.2) as result of increased receptor activation, suggesting that the TM could 
also be involved in the process of receptor dimerization (Li E. et al. 2006). 
A number of soluble FGFR isoforms have been described that include truncated 
molecules that lack the TM domain or that harbour the N-terminal half of IgIII domain 
fused to the first 3 aminoacids of the TM domain (Duan et al. 1992, Hanneken 2001). 
Similarly to the IgIIIa splice variants, these soluble FGFR isoforms have been show to act 
as negative regulator of FGFR signalling in vitro and in vivo (Wheldon et al. 2011). 
1.2.2.3 Cytoplasmic domain 
The cytoplasmic domain of FGFRs comprises a juxtamembrane domain (JM), 2 tyrosine 
kinase subdomains (TK1 and TK2) interrupted by a short kinase insert (KI), and a C-
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terminal tail (CT) (Eswarakumar et al. 2005). The juxtamembrane domain of FGFRs is 
considerably longer compared to that of other RTKs and contains a very highly conserved 
sequence of 12 amino acids (aa 419-430 in FGFR1), including a valine and threonine, 
known as the ‘VT site’ (Val427-Thr428 In FGFR1) (Gillespie et al. 1995). The presence of 
these 2 residues is very important for initiation of signal transduction from FGFRs, since 
they serve as binding sites for the PTB domain of the adaptor protein FGF receptor 
substrate-2 (FRS2), which links FGFRs to the downstream MAPK signalling pathway 
(Burgar et al. 2002). In FGFR1 and -2, the 3′ end of exon 10, encoding the VT site, is 
subject to alternative splicing, generating 2 different isoforms of FGFRs, containing or 
excluding this motif (denominated VT+ and VT−, respectively) (Burgar et al. 2002). The 
VT- isoforms of FGFRs have been shown to be incapable of generating any mitogenic 
response, further supporting the key role of the 2 residues in driving the interaction of 
FRS2 to the receptor. Two members of the FRS2 family have been identified, FRS2α (or 
FRS2, or SNT1) and FRS2β (or FRS3 or SNT2), which share high homologies in amino acid 
sequence and structure domains and are expressed with a differential spatial/temporal 
pattern (Kouhara et al. 1997). Both FRS2α and FRS2β have been shown to be involved in 
signal transduction from FGFRs by means of direct interaction with the VT site of receptor 
(Kouhara et al. 1997, Meakin et al. 1999, Xu et al. 1998). This interaction is constitutive 
and does not depend on receptor activation at basal level (Ong et al. 2000), even though 
recent studies demonstrate that FGFR1-FRS2α binding, but not FGFR1-FRS2β binding, 
could be tyrosine-phosphorylation regulated  (Zhang et al. 2008). 
The only potential site for FGFR-mediated phosphorylation identified thus far in the 
juxtamembrane region is the residue Y463. When phosphorylated, Y463 has been shown 
 19 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5 FGFR isoforms generated by alternative splicing of FGFR transcripts 
The two main isoforms of FGFR are generated by alternative splicing of exons 8 
and 9. Exon 7 unequivocally encodes for the N-terminal part of D3 (IgIII), while 
exons 8 and 9 are alternatively translated in the second half of D3, generating 
IgIIIb or IgIIIc, respectively. An IgIIIa splice variant is also possible, when only a 
part of exon 8 is translated. IgIIIa variant generates a truncated inactive soluble 
protein. 
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to interact with the SH2 domain of the docking molecule Crk, which mediates Jun N-
terminal Kinase (JNK) and ERK1/2 signalling in FGF2-stimulated endothelial cells (Larsson 
et al. 1999). 
The TKD of FGFRs is split in 2 lobes, similarly to that of platelet-derived growth factor 
(PDGF), with a very short KI region of 14 amino acids. Autophosphorylation of a number 
of tyrosines throughout the TKD is essential for both the catalytic activity of tyrosine 
kinase and for subsequent initiation of the signalling cascade (Mohammadi et al. 1996b). 
The X-ray crystal structure of the TK domain of FGFR1 has been solved (Figure 1.4B) and 
comprises an N-terminal lobe formed by a curled β sheet of 5 antiparallel β strands (β1-
β5) and one α helix (αC) and a C-terminal lobe comprising two β strands (β7, β8) and 7 α 
helices (αD, αE, αF, αG, αH, αI) (Mohammadi et al. 1996a). The relative orientation of the 
N- and C-lobes to each other changes between the active and inactive forms of the 
kinase, and it displays a more open disposition in the unphosphorylated inactive FGFR 
(Johnson L. N. et al. 1996). The C-terminal lobe allocates the activation loop of the kinase, 
where 2 conserved tyrosine residues (Y653/Y654) are trans-phosphorylated to fully 
activate the kinase function (Furdui et al. 2006). Autophosphorylation of Tyr653 and 
Tyr654 of FGFR1 enhances the rate of substrate catalysis up to 500-fold (Furdui et al. 
2006). In the absence of ligand, the majority of RTKs are maintained in an inactive state 
by residues in the activation loop that sterically block substrate access to the active site. 
In FGFRs, however, the activation loop is disposed so that substrate access to its binding 
site is not blocked by Y653 and Y654, but by other residues, such as Arg-661 (in FGFR1) 
(Mohammadi et al. 1996a). A different autoinhibitory mechanism has been described for 
FGFR2 (Chen H. et al. 2007) and involves a triad of residues (E565, in the kinase hinge 
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region, N549 in the loop between the αC helix and the β4 strand, and K641 in the β8 
strand). By interacting with each other, these 3 residues form a network of hydrogen 
bonds that inhibits movements of the N-terminal lobe towards the C-terminal lobe, 
keeping the kinase in an autoinhibited state. Consistent with this, a number of pathogenic 
mutations within the triad E565/N549/K641 have been identified in FGFR2, which result 
in ligand-independent activation of receptor (Chen H. et al. 2007).  
Several kinase-deficient FGFR variants have been described in cells that express FGFR 
active forms. Since kinase-deficient and active isoforms of the receptor can hetero-
dimerize, generating non-functional receptor dimers and down-regulating FGF signal 
transduction, the kinase-deficient FGFR isoforms are thought to be involved in a 
mechanism of regulation of FGFR activity (Shi et al. 1993). 
The carboxyl terminal tail of FGFR contains the residue Y766, which is one of the major 
autophosphorylation sites in all FGFRs. Once phosphorylated, this tyrosine and its 
ﬂanking sequences act as a high affinity binding site for one of the SH2 domains of 
Phospholipase-Cγ (PLCγ) (Mohammadi et al. 1991), recruiting this molecule at the plasma 
membrane, where it can catalyse the hydrolysis of Phopshatidylinositol-4,5 bisphosphate 
PI(4,5)P2 and generate diacylglycerol (DAG) and  inositol 1,4,5-trisphosphate (IP3) 
(Mohammadi et al. 1992, Peters et al. 1992). 
 
1.2.3 Evolution 
Genes encoding for FGFRs have been identified in many multicellular organisms, ranging 
from human (Homo sapiens) to mouse (Mus musculus) to nematode (Caenorhabditis 
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elegans), but not in unicellular organisms. The expansion of the FGFR gene family is 
strictly linked with that of their ligand FGFs and is thought to be achieved from a common 
ancestral gene by 2 large-scale gene/genome duplications only during early vertebrate 
evolution (Itoh and Ornitz 2004). Identification of an FGFR gene in the species Hydra 
vulgaris (Sudhop et al. 2004) reveals that signalling by FGFRs arose early in the evolution 
of metazoans (Figure 1.6). Using a bioinformatic approach, Rebscher et al. were able to 
trace FGFR back to the placozoan, showing that already in this phylum the predicted level 
of organization of FGFR shows its full modular structure, with 3 Ig-like domains, a TM 
region, and a bi-lobed TK domain present (Rebscher et al. 2009). However, protein 
domain analysis predicted for both the Placozoa and Cnidaria phyla the lack of AB 
between IgI and IgII, suggesting that the acidic domain evolved in the last common 
ancestor of triploblasts (Figure 1.6).  Further, outside the Deuterostomia, no alternative 
splicing of IgIII has been found. This is consistent with the fact that alternative splicing in 
the extracellular Ig-like domains, which determines ligand-binding specificity, significantly 
increased FGFR functional diversity in more complex phyla, such as that of Deuterostomia 
(McKeehan et al. 1998). The Rebscher study cited above also revealed the presence of 
more than 3 Ig-like loops within the insect group, although their function remains 
unknown (Beermann and Schroder 2008, Klambt et al. 1992). In the C. elegans genome, 
only one FGFR homologue (egl-15) was identified (DeVore et al. 1995), while 2 FGFR 
proteins, DFR1 and DFR2, have been described in Drosophila melanogaster (Shishido et 
al. 1993) (Figure 1.6). All invertebrate FGFRs contain Ig-like domains and they share only 
30% and 60% amino acid identity with their vertebrate homologues in the extracellular 
ligand-binding domain and the intracellular kinase domain, respectively. However,  
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Figure 1.6 Phylogenetic tree of FGFR genes 
Representation of the main evolutionary changes on the protein domain 
structure of FGFR. The legend for the protein domains is given in Figure  1.2.  
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comparative modelling studies on the sequence of FGFs and their receptors in C. elegans 
and D.melanogaster indicate that these two species can assume similar conformations 
and make equivalent interactions as those observed in corresponding human structures, 
indicating that the properties driving formation of the ligand-receptor complex are 
conserved through evolution (Nagendra et al. 2001). 
 
1.2.4 FGFR in development and human diseases 
 
1.2.4.1 Role of FGFR during development 
Signalling from FGFs and their receptors plays a significant role both in adult tissue and 
during development in vertebrates. At early stages of embryogenesis, the FGF/FGFR 
system regulates key processes during gastrulation, ensuring correct patterning and 
timing of embryonic differentiation (Dorey and Amaya 2010). Experiments carried out in 
Xenopus and Zebrafish demonstrated that FGF signalling is essential for the 
induction/maintenance of both axial and paraxial mesoderm, which form the notochord, 
and the axial skeleton, skeletal muscles, and dermis, respectively (Amaya et al. 1991, 
Amaya et al. 1993, Griffin et al. 1995). FGF signalling through FGFRs also plays an 
essential role in the coordination of cell movements during gastrulation and neurulation: 
Fgfr1-null and Fgf8-null mouse embryos, for instance, display severe defects in cell 
migration during gastrulation (Deng et al. 1994, Sun et al. 1999, Yamaguchi T. P. et al. 
1994b) and Xenopus embryos expressing a dominant-negative FGFR result in 
failure of blastopore closure (Amaya et al. 1991). The role of FGF signalling in regulating 
embryonic morphogenetic movements is not restricted to vertebrates: in Drosophila, a 
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mutation in the fgfr2 gene results in defects in mesodermal cell migration during 
gastrulation (Beiman et al. 1996, Gisselbrecht et al. 1996).  
In addition to its role during early embryonic development, FGF/FGFR signalling plays a 
fundamental role in skeletogenesis and it is required for the development of several 
organs in the adult, such as the kidney (Bates 2011), prostate (Cotton et al. 2008), limb 
(Cohn et al. 1995, Delezoide et al. 1998), skin (Li C. et al. 2001), inner ear (Wright and 
Mansour 2003), lung (Colvin et al. 2001, Min et al. 1998), brain (Ford-Perriss et al. 2001), 
heart (Lu et al. 2008, Meyers E. N. et al. 1998), ocular lens (Robinson M. L. 2006) and the 
gonadotropin-releasing hormone (GnRH) neuronal system (Gill et al. 2004). Transgenic 
and knockout mouse models for all FGFR isoforms have been generated, covering a wide 
range of diseases affecting each of the organs mentioned above. 
1.2.4.2 FGFR genetic alterations in skeletal disorders  
FGFR1, FGFR2, and FGFR3 are highly expressed in bone primordial and show finely 
regulated spatial and temporal expression patterns throughout bone development, 
suggesting their key roles during this process (Ornitz and Marie 2002). Consistent with 
this, a number of germline mutations have been identified for all FGFRs that give rise to 
a variety of inherited skeletal malformations (Wilkie et al. 1995) (Figure 1.7). All FGFR-
related skeletal disorders can be classified in 2 categories: the chondrodysplasias are 
conditions characterized by defects in long-bone elongation as a result of impaired 
chondrocyte function during endochondral bone formation and include achondroplasia 
syndrome, milder disorder of hypochondroplasia, and neonatal lethal thanatophoric 
dysplasia 2 (TDII) and 1 (TDI); the syndromes belonging to the second class all share a 
common phenotypic feature, craniosynostosis, manifested by premature ossification and 
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fusion of the sutures between the developing flat bones of the skull, due to a defect in 
osteoblast function (Cohen 2006). This class includes syndromes such as Pfeiffer, 
Crouzon, and Jackson-Weiss syndromes. Endochondral and intramembranous 
ossification, regulated by chondrocytes and osteoblasts, respectively, are very intricate 
processes and require involvement of a wide spectrum of molecules, such as growth 
factors, hormones, transcription factors, etc. Although it is clear that proliferation, 
differentiation, and apoptosis of osteoblasts and chondrocytes are dependent on the 
temporal expression and activity of FGFRs (Shimoaka et al. 2002), the precise role of FGF 
signalling in these processes is not entirely clear.  
Summarized below are the most relevant germline mutations identified for all FGFRs that 
give rise to the above-described skeletal disorders:  
Extracellular domain: The majority of the mutations that arise in the ectodomain of 
FGFR2 and FGFR3 in bone development disorders are located in the domain D3 or in the 
linker between D2 and D3 and result in a dominant gain-of-function phenotype (Kannan 
and Givol 2000) (Figure 1.7). A consistent number of these is due to substitution of a 
conserved cysteine residue in D3 (mainly at positions 278 or 342 in FGFR2). The 
subsequent presence of unpaired cysteines prevents formation of stabilizing intrachain 
disulfide bonds within the Ig-like domains and induces the formation of intermolecular 
disulfide bonds, resulting in covalent dimerization of mutant receptor molecules and 
therefore in their constitutive, ligand-independent activation (Cornejo-Roldan et al. 
1999). A similar effect is caused by mutations that involve residues adjacent to Cys in the 
D3 domain, such as Y340H or T341P in FGFR2 (Lajeunie et al. 2006, Nagase et al. 1998). 
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This class of mutation occurs in skeletal disorders classified as ‘receptor dimerization 
syndromes’, which include Pfeiffer, Crouzon, and Jackson-Weiss syndromes.   
Transmembrane domain: The most common mutation on fgfr3 results from either a G-
to-A transition or a G-to-C transversion, changing the codon for Gly380 to Arg in the 
transmembrane domain of FGFR3 (Passos-Bueno et al. 1999). The G380R mutation is 
dominant and causes acondroplasia, the most common form of human genetic dwarfism 
(Rousseau et al. 1994), characterized by defects in long-bone elongation as a result of 
impaired chondrocyte function during endochondral bone formation (Ponseti 1970). 
Interestingly, Monsonego-Ornan et al., showed that G380R substitution results in a 
specific defect in internalization of FGFR3, leading to accumulation of the mutant 
receptor at the plasma membrane and subsequent uncontrolled and prolonged ligand-
dependent receptor activation in chondrocytes (Monsonego-Ornan et al. 2000). 
Substitution of an alanine residue (Ala391Glu) in proximity to the site of the principal 
achondroplasia mutation in fgfr3 causes a entirely different phenotype, Crouzon 
syndrome (Meyers G. A. et al. 1995). This mutation is thought to induce hyperactivation 
of the receptor by stabilizing the dimers through the formation of new hydrogen bonds. A 
number of mutations associated with skeletal pathologies have been identified at the 
junction between the extracellular and transmembrane domain of FGFR2 (S372C and 
Y375C) and FGFR3 (G370C, S371C, Y373C, and G375C) (Adar et al. 2002, Przylepa et al. 
1996) (Figure 1.7). Similar to those in the extracellular domain of FGFR, these mutations 
also result in the creation of Cys residues, forming new intermolecular disulfide bonds, 
suggesting that these residues are not buried in the lipid bilayer of the cell. 
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Kinase domain: A significant number of mutations causing craniosynostosis have been 
identified also in the kinase domain of FGFRs (Figure 1.7). The N549H, N549T, E565G, 
E565A, and K641R substitutions, for example, which map within the kinase hinge, or the 
K659N and R678G, which map into the activation loop of FGFR2, all induce ligand-
independent FGFR2 activation by preventing receptor autoinhibition (Chen H. et al. 
2007). The milder disorder of hypochondroplasia has been shown to be due to the 
substitution of a residue of asparagine (N540) into the tyrosine kinase region of FGFR3 
(Bellus et al. 1996), whereas K650E (Tavormina et al. 1995) and K650M (Tavormina et al. 
1999), which has been shown to cause the strongest constitutive activation of the known 
mutants of FGFR3, cause neonatal lethal thanatophoric dysplasia 2 (TDII) and 1 (TDI), 
respectively. Mutagenesis studies on position 650 and adjacent positions show that the 
K650E mutation mimics the conformational changes normally induced by 
autophosphorylation of Tyr residues within the activation loop (Webster et al. 1996).  
An interesting class of point mutations are those located in homologous positions in all 3 
FGFRs. The P252R in FGFR1, the P253R in FGFR2, and P250R in FGFR3, for example, all 
involve a residue of proline highly conserved within the DII–DIII linker (Bellus et al. 1999). 
The phenotype resulting from each of those mutations, however, is different (Pfeiffer 
syndrome in FGFR1, Apert syndrome in FGFR2, and Muenke syndrome in FGFR3), and this 
reflects different temporal and spatial expression of the specific FGFR mutated 
(Kannan 2000). 
 1.2.4.3 Genetic alterations in FGFR genes in cancer 
All members of the FGFR family have been found to be deregulated in a variety of 
cancers, ranging from solid tumours to haematological malignancies (Wesche et al. 2011). 
 29 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.7 FGFR mutations associated with skeletal disorders  
Schematic diagram showing FGFR1-3 and major sites of mutations. AB: acidic 
box, D1-3: Immunoglobulin-like domain 1-3, TM: transmembrane domain, 
TK: tyrosine kinase domain, A: Apert syndrome, Ach: Achondroplasia, C: 
Crouzon syndrome, CFDH: Craniofacial dysplasia with hypophosphatemia, 
HCH: Hypochondroplasia, J: Jackson-Weiss syndrome, KS: Kallmann 
syndrome, P: Pfeiffer syndrome, TD: Thanatophoric dysplasia (types I and II), 
UC: unclassified disorders.    
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Activating mutations or receptor overexpression induce FGFRs to become constitutively 
active, leading to tumorigenesis and cancer development. However, several other 
mechanisms can contribute to imbalanced FGFR signalling resulting in cancer, including 
SNPs on fgfr genes, overexpression of ligands, and defects in receptor degradation. 
Somatic mutations: Genetic alterations causing sustained activation of FGFRs have been 
found in human cancers (Wesche et al. 2011). Similarly to those associated with skeletal 
disorders, these mutations can have various molecular effects on the protein, from 
enhancing ligand binding to altering ligand specificity, or inducing constitutive 
dimerization of the receptor. Fgfr3, which appears to be one of the most commonly 
mutated oncogenes in human bladder cancer (Cheng et al. 2009), harbours a variety of 
cancer-associated point mutations, both in the extracellular domain and in the kinase 
domain. Interestingly, a number of these mutations are the same as those found to be 
the cause of many of the skeletal disorders previously described (Pandith et al. 2010). For 
instance, S249C and Y373C in the ectodomain, and K650Q/M/N/E in the kinase region of 
FGFR3, are frequently found in bladder cancer and are responsible for the lethal skeletal 
disorder thanatophoric dysplasia (Pandith et al. 2010). Activating mutations in FGFR2 are 
present in about 10% of human endometrial carcinomas (Pollock et al. 2007), and similar 
to those in FGFR3, are frequently identical to those that cause skeletal disorders. These 
include, for example, S252W and P253R, located in the region between D2 and D3, which 
alter FGFR ligand-binding specificity, causing Apert syndrome (Yu K. et al. 2000). Missense 
mutation of fgfr2 gene also occurs in breast cancer, gastric cancer, lung cancer, and 
ovarian cancer. Mutations in the kinase domain of FGFR4 have been identified in 
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childhood sarcoma RMS (Rhabdomyosarcoma) (Taylor J. G. th et al. 2009); most of these 
mutations appear to promote autophosphorylation of the receptor.  
Receptor overexpression: FGFR overexpression resulting in ligand-independent signalling 
may be caused by either gene amplification or aberrant transcriptional regulation of 
FGFRs. The most characterised cancer-related FGFR amplification is that occurring at 
8p11-12, the chromosomal region where fgfr1 is located. This amplicon, which results in 
overexpression of FGFR1, is found in ~10% of human breast cancers and is associated 
with poor prognosis (Gelsi-Boyer et al. 2005, Letessier et al. 2006). FGFR1 is also 
frequently overexpressed in human prostate cancer, where it disrupts the interplay 
between the stroma and epithelium of the prostate (Kwabi-Addo et al. 2004). Gene 
amplification of the fgfr2 gene occurs in diffuse-type gastric cancer (Jang et al. 2001), as 
well as in primary breast cancer (Adnane et al. 1991). In the latter case, the 
overexpressed receptor is subject to C-terminal deletion due to exclusion of the last exon 
from the FGFR2 amplicon. This region includes the residue Y769, which upon ligand-
dependent phosphorylation functions as binding site for PLCγ (Ceridono et al. 2005). The 
result of C-terminal truncation on the FGFR2 amplicon is a receptor that signals in a 
ligand-independent manner (Moffa and Ethier 2007). FGFR3 is overexpressed as a result 
of chromosomal translocation t(4;14) (Kalff and Spencer 2012), which brings FGFR3 under 
the influence of a strong transcriptional enhancer. Approximately 15% to 20% of patients 
with multiple myeloma, a blood cell cancer, harbour this translocation-mediated FGFR3 
overexpression, which is associated with poor prognosis (Chang et al. 2005, Chesi et al. 
1997). 
 32 
 
Ligand availability: Potent aberrant FGF signalling can also result from upregulation of 
FGF expression, which increases ligand availability. Elevated levels of FGFs have been 
found in several human cancers. FGF8 expression, for example, has been shown to be 
upregulated in human breast and prostate cancer (Marsh et al. 1999, Mattila and 
Harkonen 2007), whereas elevated levels of FGF2 are associated with tumour 
vascularisation, consistent with the intimate crosstalk between FGF2 and VEGF signalling 
during angiogenesis (Seghezzi et al. 1998). 
Fusion events: Events of chromosomal translocation can result in FGFR fusion proteins 
with aberrant signalling properties. FGFR fusion proteins are generated by the fusion 
between the tyrosine kinase domain of the receptor and a dimerization domain, leading 
to constitutive dimerization and activation of the tyrosine kinase (Jackson et al. 2010). A 
significant number of FGFR1 fusion proteins have been identified in EMS (8p11 
myeloproliferative syndrome), also called SCLL (stem cell leukaemia lymphoma 
syndrome), a rare myeloproliferative disorder that rapidly progresses into acute 
leukaemia (Wesche et al. 2011). 
Single nuclear polymorphisms: Germline single nuclear polymorphisms (SNPs) have been 
found in both FGFR2 and FGFR4. The G388R SNP is associated with breast and colorectal 
cancer (Bange et al. 2002, Spinola et al. 2005) and  causes a missense mutation in the 
transmembrane domain of FGFR4, leading to a defect in receptor lysosomal degradation 
and a sustained signalling (Wang J. et al. 2008). Furthermore, The SNPs found on FGFR2, 
however, are likely to alter the binding affinity of the receptor with transcription factors, 
inducing FGFR overexpression (Easton et al. 2007). FGFR2 SNPs are associated with an 
increased risk of breast cancer.   
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Impaired FGFR down-regulation: The activity of FGFRs is finely regulated at different 
levels (described in greater detail in Section 1.2.6, Regulation of signalling from FGFR), 
and any defect in the regulatory mechanisms that control FGFR activity can potentially 
lead to imbalanced signalling and result in the development of a malignant phenotype. 
The expression level of the protein Sef, for instance, a feedback inhibitor of FGFR 
signalling (Kovalenko et al. 2003), has been found to be considerably reduced in breast, 
ovary, thyroid, and prostate tumours (Zisman-Rozen et al. 2007). A defective endocytosis 
of FGFRs can also lead to oncogenesis by delaying receptor degradation and resulting in 
prolonged signalling. For instance, the FGFR3, G380R, and K650E mutations found in 
bladder, prostate, testicular cancer, and multiple myeloma (MM), as well as in 
achondroplasia, are thought to increase recycling of mutated receptor, resulting in 
sustained signalling (Cho et al. 2004). A splicing variant of FGFR2 identified in some 
cancer cell lines results from deletion of a region in the CT containing an endocytic motif 
(Cha et al. 2009). This deletion results in inefficient down-regulation of the receptor, 
increased levels of receptor at plasma membrane, and prolonged signalling. 
The critical roles that FGFRs play in multiple steps of tumorigenesis make FGFR an 
attractive target for therapeutic intervention in cancer. A number of therapeutic 
strategies are currently being employed or developed to interfere with FGFR activity, 
including antibodies and small molecule tyrosine kinase inhibitors (Knights and Cook 
2010). 
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1.2.5 Cell signalling via FGFR  
 
1.2.5.1 Receptor trans-phosphorylation 
Ligand-dependent dimerization leads to a conformational change in receptor structure 
that activates the intracellular kinase domain, resulting in trans-autophosphorylation of 
multiple tyrosine residues in the cytoplasmic domain of the receptor (Eswarakumar et al. 
2005). Phosphorylated tyrosine residues function as docking sites for various signalling 
and scaffold proteins, which themselves may also be directly phosphorylated by FGFR, 
leading to activation of various signal transduction pathways. The combination of 
structural biology techniques and chemical quench methodology allows mapping in real 
time the autophosphorylation sites of FGFR, and reveals that this process follows a 
specific dynamic order that reflects activation of a distinct pattern of downstream 
effector proteins (Furdui et al. 2006). This phenomenon is not restricted to the FGFR 
family, but has also been observed for other RTKs, such as the IR (Wei L. et al. 1995) and 
the insulin-like growth factor 1 (IGF-1) receptor (Favelyukis et al. 2001). In the case of 
FGFR1, 7 tyrosine residues distributed throughout the intracellular domain (Y463, Y583, 
Y585, Y653, Y654, Y730, and Y766) have been shown to be subject to 
autophosphorylation following receptor activation (Mohammadi et al. 1996b) (Figure 
1.8). Y653 in the activation loop of the kinase domain is the first residue to be 
phosphorylated (Furdui et al. 2006, Lew et al. 2009). This event has 2 effects: first, it 
enhances 50-to-100 fold the intrinsic catalytic activity of the receptor, resulting in 
autophosphorylation of the other tyrosine residues; second, it triggers recruitment of 
signalling molecules on the intracellular tail of the receptor.   
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FGFR1 FGFR2 FGFR3 FGFR4 
Y463 
Y583/585 
Y653/654 
Y677 
Y730 
Y766 
Y776 
Y466 
Y686/588 
Y656/657 
- 
Y733 
Y724 
Y719 
- 
Y577 
Y647/648 
- 
Y724 
Y760 
Y754 
        - 
- 
Y624/643 
- 
Y719 
Y754 
Y764 
    
 
Figure 1.8 Sites of tyrosine phosphorylation in FGFRs 
The major sites of tyrosine phosphorylation in FGFR1 are shown in the 
figure. The table on the right shows the corresponding tyrosine residues in 
FGFR2, FGFR3 and FGFR4.  
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Subsequently, the residues Y583, Y463, Y766, and then Y585 are phosphorylated. 
Phosphorylation of these residues does not affect the activation state of the receptor, but 
it has been shown to be necessary for the FGFR-mediated mitogenic response 
(Mohammadi et al. 1996b). Y463, for instance, which is the only residue identified thus 
far in the juxtamembrane region of the kinase domain of FGFR1, acts as a binding site for 
the docking molecule Crk, which mediates JNK and ERK1/2 signalling in FGF2-stimulated 
endothelial cells (Larsson et al. 1999) (Figure 1.8). Y766 is instead located in the carboxy 
terminal tail and mediates the binding of PLCγ (Mohammadi et al. 1991), whereas Y583 
and Y585 are situated within the insert region of the kinase subdomains (Figure 1.8). The 
succeeding phosphorylation events occur on Y654, in the activation loop. This further 
enhances receptor catalytic activity and induces tyrosine phosphorylation of the recruited 
signalling proteins (Furdui et al. 2006, Lew et al. 2009). Further, in a recent study, Dudka 
A. et al. identified an additional tyrosine residue (Y677) in the kinase domain of FGFR1 
subject to phosphorylation following receptor activation (Dudka et al. 2010). 
Phosphorylation of Y677 has been shown to be required for recruitment and activation of 
the signal transducers and activators of transcription 3 (STAT3) (Figure 1.8), a 
transcription factor that mediates signalling via the cytokine family of signalling receptors 
(Lim and Cao 2006).     
1.2.5.2 RAS–mitogen-activated protein kinase pathway 
The MAPK pathway is the best characterized pathway downstream of FGFRs and includes 
ERK 1/2, p38 and JNK kinases (Figure 1.9). Each kinase of the MAPK family phosphorylates 
specific serines or threonines of target substrates, promoting downstream critical cellular 
responses, such as cell differentiation and cell proliferation (Turner and Grose 2010). 
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Initiation of the cascade involves the lipid-anchored adaptor protein FGF receptor 
substrate 2 (FRS2) which, through its PTB domain, associates with the juxtamembrane 
region of the inactive receptor in a constitutive, phosphotyrosine-independent manner 
(Gotoh et al. 2004, Ong et al. 2000). In addition to the PTB-mediated binding, FRS2 
constitutively associates to the plasma membrane via a myristoylation modification in its 
N-terminus, which drives the protein in proximity of the receptor (Kouhara et al. 1997). 
Upon activation, FGFR1 can phosphorylate FRS2 on 6 different tyrosines (Ong et al. 2000). 
Once phosphorylated, these tyrosines serve for recognition and assembly of a number of 
signalling and scaffold proteins. Through FRS2, the activated receptor becomes a 
platform for the recognition and recruitment of a specific signalling complex (Ong et al. 
2000). One of the molecules recruited by phosphorylated FRS2 is the SH2-containing 
protein tyrosine phosphatase Shp2 (Gotoh et al. 2004), which is in turn tyrosine 
phosphorylated by the receptor, resulting in the recruitment of the adaptor molecule 
growth factor receptor-bound 2 molecule (GRB2) via its SH2 domain. Additionally, FRS2 
itself contains 4 binding sites for GRB2, which can therefore also be directly recruited by 
FRS2. GRB2 is constitutively associated, via its SH3 domain, with the guanine nucleotide 
exchange factor (GEF) son of sevenless (SOS) (Lowenstein et al. 1992). Translocation of 
the FRS2/GRB2/SOS signalling complex to the proximity of the plasma membrane allows 
SOS to activate H-Ras by GTP exchange, resulting in activation of the downstream RAF 
and MAPK pathways (Eswarakumar et al. 2005) (Figure 1.9).  
The Ras sarcoma (Ras) oncoproteins are members of the family of small guanosine 
triphosphatases (GTPases) and function as GDP/GTP-regulated molecular switches cycling 
between a GDP-bound inactive state and a GTP-bound active state (Vetter and 
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Wittinghofer 2001). The Ras family comprises 3 different groups of highly homologous 
proteins, Harvey-Ras (H-Ras), Kirsten-Ras (K-Ras), and Neuroblastoma-Ras (N-Ras), that 
differ significantly only in their C-terminal 40 amino acids (Hancock 2003). Here, a 
different post-translational modification in each class dictates specific subcellular 
locations to different plasma membrane microdomains. H-Ras, is anchored to the 
cytoplasmic face of the plasma membrane via 2 palmitoylated cysteine residues, Cys181 
and Cys184, and a C-terminal S-farnesyl cysteine carboxymethylester (Roy et al. 2005).  
This localization brings H-Ras in close proximity to the signalling complex, where the 
protein SOS drives the exchange of GDP bound to H-Ras with GTP from the cytosol 
(Schmidt and Hall 2002). 
When in its GTP-bound state, H-RAS can bind to and promote translocation of the Raf 
Murine Sarcoma Viral Oncogene Homolog (Raf) kinase to the plasma membrane (Terai 
2005), where it is fully activated upon additional phosphorylation events (Avruch et al. 
2001). Raf is a serine/threonine kinase and phosphorylates the MAPK/ERK Kinase1 and 2 
(MEK1/2) at 2 serine residues at positions 217 and 221 in the activation loop, resulting in 
activation of MEK1/2 kinase activity (Alessi et al. 1994).  Mammals possess 3 Raf proteins, 
Raf-1, A-Raf, and B-Raf, which present different tissue-specific expression patterns (Storm 
et al. 1990) and target specificity: B-Raf activates predominantly MEK1 and Raf-1 
activates both MEK1 and MEK2, whereas A-Raf is a weak activator (Kolch 2000). The 
direct targets of MEK1/2 phosphorylation are the MAP kinases ERK1 and ERK2. To be fully 
activated, ERK1/2 must be phosphorylated at both a threonine and a tyrosine residue 
(Thr202/Tyr204 for human ERK1 and Thr185/Tyr187 for human ERK2) with the tyrosine 
phosphorylation preceding the threonine phosphorylation (Ferrell and Bhatt 1997). 
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ERK1/2 are proline-neighbouring serine/threonine kinases. Once active, ERK1/2 can 
phosphorylate a number of different cytoplasmic proteins, such as the Ribosomal Protein 
S6 Kinases (RSKs), which upon translocation into the nucleus play a role as transcriptional 
regulators (Chen R. H. et al. 1993), or SOS, initiating negative and positive feedback loops 
acting on the MAPK pathway itself (Kamioka et al. 2010). Alternatively, active ERK1/2 can 
translocate into the nucleus, where they promote phosphorylation of chromatin 
remodelling enzymes as well as transcription factors, such as  c-myc, AP1, and the Ets-like 
gene 1 protein (Elk-1), ultimately inducing cellular responses such as cell differentiation 
or proliferation (Marais et al. 1993) (Figure 1.9). 
A parallel cascade is initiated by the recruitment of the docking molecule Crk to the 
phosphor-tyrosine Y463 on FGFR1 (Larsson et al. 1999). Endothelial cells expressing a 
mutant of FGFR1 in the binding site for Crk (Y463F) show no change in the catalytic 
activity of the receptor, but fail to proliferate due to defective activity of the kinases Jun 
and ERK, demonstrating that Crk is responsible for further propagating mitogenic signals 
by FGF (Larsson et al. 1999). 
1.2.5.3 PI3 kinase-AKT pathway 
Activation of the PI3 kinase/AKT pathway by FGFRs can occur through 3 mechanisms 
(Figure 1.9). First, GRB2, recruited by phosphorylated FRS2, can bind the proline-rich 
region of GRB2-associated binding protein 1 (GAB1) via its C-terminal Sh3 domain (Ong et 
al. 2001). Assembly of the trimeric complex FRS2/GBR2/GAB1 leads to activation of 
phosphatidylinositol-3-kinase kinase (PI3K) via its kinase-regulatory subunit p85, resulting 
in production of phosphatidylinositol 3,4,5-trisphosphate [PI(3,4,5)P3]. This product 
specifically binds the Pleckstrin homology (PH) domain of the serine/threonine protein 
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kinase B (PKB), also known as AKT, regulating its cellular localization and activity (Ong et 
al. 2001). Full activation of AKT is reached when the serine/threonine kinase 
Phosphoinositide-dependent kinase 1 (PKD1) and 2 (PKD2) are also recruited to the 
plasma membrane and phosphorylate the threonine residue-308 in its kinase domain (T-
loop) and the serine residue-473 within the hydrophobic motif (HM) in the CT, 
respectively (Franke 2008). In addition to being controlled by interaction of its regulatory 
p85 subunit with GAB1, the PI3 kinase can also be activated by directly binding to a 
phosphorylated tyrosine residue on FGFR via the p85 subunit (Ryan et al. 1998). Finally, 
activated Ras can also induce translocation of the PI3 kinase catalytic subunit p110 to the 
membrane, consequently promoting its activation (Rodriguez-Viciana et al. 1994). 
Cellular responses activated by the PI3 kinase/AKT pathway range from primarily 
metabolic functions such as glucose transport and glycolysis to cell-cycle progression, 
apoptosis, and cell survival (Franke 2008).  The wide range of biological responses reflects 
the ability of AKT to phosphorylate a wide variety of target proteins, both in the 
cytoplasm and in the nucleus (Figure 1.9). Among the best characterized targets of AKT 
with direct implications on cell survival is the pro-apoptotic BCL2-antagonist of death 
(BAD) protein. Once phosphorylated, BAD is retained in the cytosol, where its pro-
apoptotic activity is effectively neutralized (Zha et al. 1996). Other targets include 
caspase-9 (Cardone et al. 1998) and the X-linked inhibitor of apoptotic proteins (XIAP) 
(Dan et al. 2004), which mediate the AKT-dependent maintenance of mitochondrial 
integrity by keeping cytochrome c and other apoptogenic factors in the mitochondria 
(Kennedy et al. 1999). Key regulators of metabolic functions controlled by AKT include the 
glycogen synthase kinase-3 (GSK-3), which mediates an insulin-mediated increase in 
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glycogen synthesis and suppression of glycogenolysis, (Cross et al. 1995), whereas 
p21Cip1/WAF1 and p27Kip1 are 2 cell-cycle regulator proteins controlled by AKT (Liang et al. 
2002, Rossig et al. 2002, Rossig et al. 2001).  
1.2.5.4 PLCγ/PKC pathway 
The PLCγ pathway involves binding of phospholipase C-gamma (PLCγ) to specific 
phosphotyrosines on activated FGFR1-4 (Ceridono et al. 2005, Mohammadi et al. 1991, 
Vainikka et al. 1994). Recruitment of PLCγ to the membrane is further promoted by 
binding of the PH domain of PLCγ to PI(3,4,5)P3 molecules generated by FGF-dependent 
PI3 kinase activity (Falasca et al. 1998). Following activation, PLCγ induces hydrolysis of 
phosphatidylinositol-4,5-biphosphate [PI(4,5)P2], generating 2 second messengers, 
inositol-1,4,5-triphosphate [I(1,4,5)P3], which promotes the release of intracellular Ca2+, 
and diacylglycerol (DAG). The resulting increase in DAG levels triggers recruitment of 
protein kinases C (PKCs) to the membrane domains, where they undergo conformational 
changes that result in exposure of binding sites to substrates and scaffolding proteins 
(Griner and Kazanietz 2007). In parallel, the increased levels of Ca2+ in the cytoplasm 
further promote the activity of PKCs. Once activated, PKCs can phosphorylate several 
cytoplasmic targets, promoting cellular processes such as cytoskeletal organization, cell 
motility, or cell differentiation (Figure 1.9). 
1.2.5.5 STAT pathway 
A recent study suggested the existence of a novel signalling pathway activated by FGFR 
which involves the activity of the transcription factor STAT3 (Dudka et al. 2010). Although 
generally associated with cytokine signalling, a role for STAT3 has already been described 
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in the signalling cascade activated by EGFR (Alvarez et al. 2006). Similarly, Dudka et al. 
recently showed that STAT3 binds to phosphorylated Tyrosine677 of activated FGFR1, 
resulting in Src-dependent phosphorylation of STAT3 itself on tyrosine residues (Dudka et 
al. 2010). However, the biological effects resulting from FGFR-dependent STAT activation 
remain to be elucidated.   
1.2.5.6 Correlation between FGFR signalling pathways and biological responses 
In the last several years, a considerable effort has been undertaken to define a 
correlation between FGFR-dependent signalling pathways and specific cellular response 
activation. However, analysis of the role of each signalling cascade in a given biological 
outcome reveals that the situation is more complex and no simple correlation can be 
drawn. Some studies, for instance, showed that the FGF-induced ERK1/2 pathways 
mediate cell cycle arrest in chondrocytes (Raucci et al. 2004), while in PC12 cells this is 
required for cell differentiation (Maher 1999), suggesting  that activation of differential 
FGF signalling pathways is cell-type specific. In addition, a number of studies consistently 
suggest that differences in the duration of signalling could dictate the specific cellular 
outcome. Traverse et al., for instance, showed that in PC12 cells, sustained ERK1/2 
activation causes growth arrest and differentiation, while a shorter stimulus induces 
proliferation (Traverse et al. 1992). These and many other observations demonstrate the 
complexity of the FGF response, which is the result of a multidimensional network of 
communication between the large number of components, crosstalk between different 
pathways, and the synergic action of the many mechanisms of regulation and feedback 
loops. 
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Figure 1.9 Intracellular signalling pathways activated by FGFR 
Following ligand binding and receptor dimerization, the intracellular kinase 
domains trans-phosphorylate each other, leading to recruitment of multiple 
signalling and scaffold proteins and activation of several signal transduction 
pathways. The Ras/MAPK pathway involves docking protein FRS2, which 
constitutively binds to FGFR and becomes phosphorylated after FGFR activation. 
Phosphorylated FRS2 recruits a multiprotein complex in the proximity of the 
plasma membrane, comprising Grb2 and SOS, resulting in activation of the 
Ras/MAPK signalling cascade. The PI3 kinase/AKT pathway can be initiated by 
multiple mechanisms, all resulting in activation of the PI3 kinase. Initiation of the 
PLCγ/PKC pathway occurs via recruitment of PLCγ to a phosphotyrosine residue of 
FGFR. PLCγ activity results in release of intracellular calcium and activation of PKC.  
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1.2.6 Regulation of signalling from FGFR 
Considering the critical biological responses regulated by FGFRs, it is not surprising that 
their activity is finely regulated in cells. A number of regulatory mechanisms have been 
described that operate at many levels. These include intrinsic capabilities of the receptor 
to auto-inhibit its own catalytic activity, as well as the action of a number of proteins 
modulating FGF-mediated signalling both in the extracellular space and within the cell. 
1.2.6.1 Extracellular modulators and autoinhibitory mechanisms 
Heparin or HLGAGs are responsible for one of the first mechanisms of modulation of 
FGFR activity. By bridging 2 FGFR monomers together, HLGAGs drive the assembly of an 
active 2:2:2 FGF:FGFR:heparin complex (Schlessinger et al. 2000). In addition, HLGAGs 
have been shown to be important in determining the specificity of FGF/FGFR interaction 
(Guimond and Turnbull 1999, Kan et al. 1999, Pye and Kumar 1998). Finally, by binding 
and retaining FGFs in the extracellular matrix, HLGAGs limit FGF diffusion into interstitial 
spaces, thereby contributing to creating a local reservoir of FGFs, which is necessary for 
generating the strict spatial regulation of FGFR activation within a tissue (Flaumenhaft et 
al. 1990, Gould et al. 1995). Allen et al. investigated how spatio-temporal changes in 
heparan sulphate can promote formation of a ternary complex with FGF and FGFR; they 
found that synthesis of HS is tightly regulated throughout development (Allen and 
Rapraeger 2003). Similar to other RTKs, FGFR activation is intrinsically controlled by 
autoinhibitory mechanisms that keep the receptor in inactive structural conformations. 
As described in Section 1.2.2 (FGFR structure and alternative splicing) a first 
autoinhibitory mechanism is mediated by the D1 domain and the AB in the extracellular 
portion, which at low concentration of ligand intramolecularly interact with the ligand-
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binding site (D2-3) and the HBS on FGFR, respectively (Figure 1.10A). In this state, any 
interaction with ligand and a cofactor is prevented and the receptor is maintained in an 
inactive state (Kalinina et al. 2012, Olsen et al. 2004, Wang F. et al. 1995b). A second 
auto-inhibitory mechanism occurs within the kinase domain of FGFR, which directly 
affects the phosphotyrosine catalytic activity of the receptor. FGFR1, for example, has 
been shown to assume an inactive state when, in the absence of ligand, Arg-661 and Pro-
663 sterically block access of the substrate (Mohammadi et al. 1996a). In contrast, the 
FGFR2 autoinhibitory mechanism is mediated by a network of hydrogen bonds formed by 
the residues E565, N549, and K641, which inhibit the movements of the N-terminal lobe 
towards the C-terminal necessary for kinase activation (Chen H. et al. 2007).  
1.2.6.2 Intracellular modulators and feedback loops 
Multiple mechanisms of regulation are activated by the components of the FGFR 
signalling cascade itself, generating negative and positive feedback loops that shape the 
level of signalling output. A well characterised example of negative feedback loop acting 
in the FGFR pathway is mediated by ERK1/2. This occurs through direct phosphorylation 
of threonine residues on FRS2 by ERK1/2, which result in preventing FRS2 itself from 
being further tyrosine phosphorylated by FGFR (Gotoh 2008). 
Because MAPKs require serine/threonine and tyrosine phosphorylation for full activity, a 
number of dual specificity phosphatases (DSPs) also act as positive or negative regulators 
downstream in the FGFR cascade (Figure 1.10B). MAPK phosphatase-3 (MKP3), also 
known as DSP6, is a well established negative regulator of FGF signalling during 
vertebrate development (Dickinson et al. 2002, Eblaghie et al. 2003). This regulator is 
expressed in response to FGFR activation, as shown in a recent mouse knockout 
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experiment, in which MKP-3-null embryos displayed elevated levels of phospho-ERK in 
limb and several FGFR-associated skeletal dysfunctions (Li C. et al. 2007). This and other 
observations demonstrate that MPK3 is part of a feedback loop which works to set the 
levels of phospho-ERK downstream of the FGFR signalling pathway. In contrast, tyrosine 
phosphatase Shp-2, in addition to its role in the assembly of the complex GRB2/SOS 
following FGFR activation, also functions as a positive regulator of FGF cascade, acting 
upstream of MAPK (Tang et al. 1995). However, the precise molecular mechanism of 
Shp2 action has not yet been described.  
Finally, an important negative feedback loop in the FGF signalling cascade is mediated by 
Sprouty proteins (Figure 1.10B). The regulatory mechanism controlled by Sprouty was 
initially identified in Drosophila (dSpry) for its inhibitory effect on FGF-dependent 
development of thacheal branches (Hacohen et al. 1998). In mammals, 4 Sprouty proteins 
(Sprouty 1–4) have been identified, with Sprouty2 acting similarly to dSpry, regulating 
branching of the mammalian lung (Tefft et al. 1999). Spread1 and Spread2, two members 
of the Sprouty family, have been shown to inhibit FGFR-dependent Ras/MAP-kinase 
activation (Gross et al. 2001, Yusoff et al. 2002). A number of studies also demonstrate an 
inhibitory effect of Spread4 on the FGFR signalling pathway (Sasaki et al. 2001). The mode 
of action of Sprouty proteins in FGF signalling remains elusive, and it appears to strongly 
depend on the cellular context. What is certain is that following FGF stimulation, 
Sprouty1 and 2 undergo tyrosine phosphorylation via a Src-dependent process (Hanafusa 
et al. 2002, Li X. et al. 2004, Mason J. M. et al. 2004, Rubin C. et al. 2003). The 
phosphorylated tyrosine serves as a binding site for SH2 domain-containing proteins, 
such as the adaptor GRB2 and the E3 ubiquitin-protein ligase Cbl. Binding of GRB2 to 
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Sprouty upon FGFR activation has been shown to be sufficient to disengage the docking 
protein from the FRS2/GRB2/SOS signalling complex, resulting in inhibition of the 
signalling (Hanafusa et al. 2002). The role of Cbl in the negative feedback loop mediated 
by Sprouty is not clear. Binding to Cbl in fact has been shown to drive Sprouty 
ubiquitination and subsequent proteasomal degradation (Hall et al. 2003, Mason J. M. et 
al. 2004). One possible explanation is that Sproutys serve as docking proteins rather than 
being a direct substrate for Cbl-mediated ubiquitination. This would bring Cbl in proximity 
to potential targets of ubiquitination and degradation, resulting in a negative effect on 
the signalling cascade (Guy et al. 2009). 
Another mechanism of regulation of FGFR activity is mediated by the transmembrane 
modulator Sef. In mouse and zebrafish, Sef genes together with fgf8 and the sprouty 
genes form a synexpression group, genetic modules in which the expression of different 
genes codifying members of a common pathway is co-regulated (Lin W. et al. 2002, 
Niehrs and Pollet 1999). Sef proteins function as negative modulators of FGFR signalling 
(Furthauer et al. 2002), exerting their inhibitory effects at multiple levels (Figure 1.10B), 
although the precise molecular mechanism of Sef action is still controversial. Some 
studies, for example, show that overexpressing Sef inhibits FGFR1 and FRS2 
phosphorylation (Kovalenko et al. 2003). Other reports, in contrast, demonstrate that Sef 
localizes to the Golgi, where, by binding activated MEK, it inhibits dissociation of the 
MEK/ERK complex, blocking translocation of active ERK into the nucleus (Torii et al. 
2004). Interestingly, ERK can also signal from the Golgi apparatus, where it is responsible, 
for instance, for the mechanism of selection of positive thymocyte, suggesting that the 
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activity of Sec as an FGF signalling inhibitor can be functionally relevant (Daniels et al. 
2006).  
In addition to negative regulators, several molecules that positively modulate signalling 
from FGFR have also been described. Among them, the best characterized are the 
fibronectin- and leucine-rich transmembrane (FLRT) proteins, that mediate cell adhesion 
functions. For all the 3 members (FLRT 1–3) thus far identified in higher vertebrates (Lacy 
et al. 1999), the capability to interact with FGFR1 has been demonstrated (Bottcher et al. 
2004, Haines et al. 2006), while only recently has FLRT2 also been shown to interact with 
FGFR2 (Wei K. et al. 2011). The tissue-specific expression pattern of all FLRTs appears to 
highly correlate with regions of FGFR expression, further supporting the requirement for 
interaction between FGFR and FLRT (Haines et al. 2006). The role of positive modulator of 
FGF-mediated ERK1/2 signalling has been described for both FLRT1 and FLRT3 (Bottcher 
et al. 2004, Wheldon et al. 2010) (Figure 1.10B). However, the precise mechanism of 
action of FLRT remains unclear.  
In addition to FLRT proteins, FGFR signalling can also be modulated by the neural cell 
adhesion molecule (NCAM) (Cavallaro and Christofori 2004) a cell surface glycoprotein 
that mediates important processes in the central nervous system such as intercellular 
adhesion, axonal growth, and cell migration (Hinsby et al. 2004). NCAM-derived peptides 
have been reported to interact with both FGFR1 and FGFR2 (Christensen et al. 2006, 
Kiselyov et al. 2003) and induce specific responses. In the case of FGFR1 for instance, 
NCAM stimulation was reported to induce sustained recycling of receptor to the cell 
surface in a Rab11 and Src-dependent manner and to promote cell migration (Francavilla 
et al. 2009). 
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Figure 1.10 Mechanisms of regulation of FGFR signalling 
A. Conformational opening and activation of FGFR induced by high concentration of 
ligand. Autoinhibitory conformation is held by intramolecular interaction between 
the D1 domain and the D2-D3 region, and between the Acidic box (AB) and the 
heparin binding site (HBS).  B. Diagram depicting the main intracellular factors 
(double red border objects), which either positively or negatively interfere with 
FGFR signalling cascade.  
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Finally, Src proto-oncogene protein tyrosine kinase, which is a key component of the 
signalling pathway by FGFR, has also been implicated as a regulatory factor. Src activity 
and involvement in FGFR cascade is discussed in more detail in Section 1.4, Src family 
kinase. 
 
1.3 Endocytosis and endocytic trafficking 
Endocytosis represents an important mechanism of signal regulation for a wide variety of 
membrane-bound receptors, including all members of the RTKs. Through endocytosis, 
activated receptors undergo regulated internalization and are transferred into the cytosol 
from the cell surface. Thus, by controlling the number of receptors available for activation 
on the plasma membrane, endocytosis actively modulates the desensitization state of 
cells to extracellular signals.   
Once internalized, receptors follow different endocytic routes inside the cells, by which 
they are sorted through predetermined specific cellular compartments up to their final 
destination. Traditionally, endocytic trafficking of RTKs was considered merely a cellular 
strategy to attenuate receptor signalling by sorting the internalized ligand-activated 
receptors into acidic compartments where ligands dissociate and signalling is terminated 
(Beguinot et al. 1984, Stoscheck and Carpenter 1984). However, increasing evidence 
suggests that endocytosis and signal transduction by RTKs are tightly coupled, and that 
trafficking of receptors along the endocytic pathway contributes to spatio-temporal 
regulation of signal transduction (Di Fiore and De Camilli 2001, von Zastrow and Sorkin 
2007).  
 51 
 
Section 1.3.1 below describes the main endocytic routes for internalization of RTKs, with 
particular emphasis on FGFRs, and it illustrates supporting evidence for crosstalk 
between RTKs endocytosis and signalling.  
1.3.1 Pathway of receptor endocytosis 
Generally speaking, endocytosis is the process by which plasma membrane lipids and 
macromolecules embedded within them, as well as extracellular fluids and dissolved 
solutes, are fully internalized into the cell. This is mediated by formation of an endocytic 
vesicle, which is generated by the invagination and subsequent budding of plasma 
membrane. An endocytic vesicle therefore can include not only effector molecules such 
as growth factors and hormones or nutrients, but also toxins and pathogens. Thus, the 
physiological roles of endocytosis vary widely: from removal of membrane-bound 
proteins from the cell surface (as in the case of transmembrane receptors) to the life 
cycle of a number of pathogens, which use endocytosis as mechanism to enter host cells 
(Thorley et al. 2010), to the maintenance of membrane homeostasis within the cell 
(Coupin et al. 1999). In the context of RTKs, a number of endocytic pathways have been 
described; these are defined and classified on the basis of the molecules that mediate 
internalization of cargo proteins.  
1.3.1.1 Clathrin mediated endocytosis 
Clathrin mediated endocytosis (CME) was the first endocytic pathway discovered (Roth 
and Porter 1964), and it remains the best characterized route of entry for RTKs. Through 
CME, receptors are enclosed and transported into vesicles coated with an organized 
network of trimers of clathrin (Figure 1.11A), also known as triskelia. A clathrin triskelion 
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is composed of 3 legs, each comprising one heavy chain and one light chain (Ungewickell 
and Branton 1981). Under specific conditions (Kirchhausen and Harrison 1981), clathrin 
assembles in a network of hexagons and pentagons and forms a ‘cage’ that surrounds the 
vesicle budding from the membrane (Crowther et al. 1976). The protein coat around a 
clathrin-coated vesicle (CCV) is a highly complex structure and, in addition to the clathrin 
triskelion, includes a number of adaptor proteins. These proteins can directly bind to the 
lipid bilayer of the vesicle on one side, whereas on the other, they interact with the 
clathrin cage (McMahon and Boucrot 2011). The entire protein coat, therefore, not only 
provides mechanical strength to the budding vesicle, but also assembles other specific 
molecules necessary for the endocytosis process to occur properly. 
The molecular mechanisms driving the very first steps in the formation of a membrane 
invagination, also called pit, remain unclear. However recent studies have reported that 
the endocytic ‘hot-spots’ on the plasma membrane, enriched in PI(4,5)P2 and where 
clathrin is very likely to be recruited and vesicles to bud, are always marked by the 
presence of a network of 3 interacting proteins: the F-BAR domain-containing protein 
(FCHO), and the scaffold proteins EGFR pathway substrate 15 (Eps15) and Intersectin 
(Henne et al. 2010). Blocking the formation of this network, by depleting the cells of any 
of the 3 components, results in inhibition of clathrin coat recruitment, suggesting that 
these proteins constitute an early module necessary for nascent CCP assembly (Henne et 
al. 2010, Stimpson et al. 2009). Once a membrane invagination has formed, it may either 
become abortive or proceed in the budding process by selecting the specific cargo 
proteins to enclose. Cargo selection is mediated by accessory protein AP2, which is the 
most abundant component of CME machinery after clathrin (Blondeau et al. 2004) (figure 
 53 
 
1.11A). AP2 is recruited to the nucleation module at the plasma membrane via its binding 
sites for PI(4,5)P2. In this respect, AP2 differs from other AP adaptors, such as AP1, AP3, 
or AP4, which have different requirements for membrane binding, and are rather found 
to play a role in CCV formation in secretory or endosomal/lysosomal sorting pathways 
(Nakatsu and Ohno 2003). Recruitment of cargo molecules is then achieved by direct 
interaction between the μ2-subunit and the σ-subunit on AP2 and specific motifs on 
transmembrane receptors (Collins et al. 2002, Kelly et al. 2008, Sorkin 2004). The μ2-
subunit recognizes tyrosine-based motifs of the form YXXΦ (where Φ is an amino acid 
with a bulky, hydrophobic side chain and X is any amino acid), whereas the σ2-subunit, 
with an additional contribution from the α-subunit, engages the [DE]XXXL[LI] dileucine 
signals on cargo proteins (Bonifacino and Traub 2003). The binding site on the μ2-subunit 
is occluded in steady-state conditions, and phosphorylation of residue Thr156 by adaptor-
associated kinase 1 (AAK1) is required to ‘open’ the cargo binding site and induce full 
binding capacity of AP2 to the cargo molecule (Ricotta et al. 2002). AP2 also interacts 
with several other accessory proteins via its α and β appendages. These proteins can 
either interact with specific cargoes and mediate indirect binding of cargos with AP2 
(Traub 2009) or function as membrane curvature effectors, as in the case of Epsin (Ford 
et al. 2002, Ford et al. 2001). Upon cargo selection, clathrin triskelia are recruited to the 
plasma membrane via interactions with both AP2 and other adaptor proteins. The β2-
subunit of AP2 interacts with clathrin via a LΦXΦ[DE] motif (also called ‘clathrin box’) 
(Dell'Angelica et al. 1998), inducing clathrin polymerization at the plasma membrane and 
assembly of the ‘cage’ around the forming vesicle (Brodsky et al. 2001). In addition, 
clathrin polymerisation also seems to stabilize a curvature of the membrane, as the 
coated pit invaginates (Hinrichsen et al. 2006). A number of BAR-domain containing 
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proteins, such as amphiphysin or endophilin, are then recruited to the area where the 
curvature of the vesicle neck is forming. Through their BAR domains, these proteins are 
thought to deform the plasma membrane and to help form the neck (Mim and Unger 
2012). Additionally, through an SH3 domain, they bind to the proline-rich region of the 
GTPase Dynamin, recruiting the enzyme around the vesicle neck (Ferguson et al. 2009). 
Although the precise mechanism is not clear, Dynamin oligomerization around the vesicle 
neck appears to induce GTP hydrolysis (Figure 1.11A), ultimately resulting in membrane 
fission and release of the vesicle into the cytoplasm (Bashkirov et al. 2008). Once the 
vesicle is formed, the clathrin coat and the adaptor protein layer are removed. 
Disassembling of the clathrin lattice back to single triskelions is mediated by ATPase heat 
shock cognate 70 (HSC70) and its cofactor auxilin/GAK (Barouch et al. 1997, Ungewickell 
et al. 1995). This uncoating allows the formed vesicle to fuse with the target endosome, 
where the cargo is delivered, and the coating components are released and reused for 
the next event of vesicle formation (Figure 1.11A). Among the receptors internalized 
through CME, some are endocytosed constitutively regardless of ligand binding. The best 
studied of these is Transferrin receptor (TfR), whose trafficking mostly occurs through 
CME (Jing et al. 1990). On the contrary, many receptors enter cells through CME in a 
stimulation-dependent manner, including RTKs, such as EGFR or FGFR, and G protein-
coupled receptors (GPCRs). 
Once internalised, newly formed vesicles fuse with one another or with pre-existing 
organelles; this is known as sorting/early endosome (SE or EE) (Hsu and Prekeris 2010) 
(Figure 1.11B). The reduced pH of this compartment induces dissociation of many ligand-
receptor complexes, followed by recycling of the receptor component back to the plasma 
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membrane. Receptor recycling can occur either directly (rapid recycling) (Deneka, M., 
2003) or indirectly (slow recycling) via recycling endosomes (REs) (Grant and Donaldson 
2009), generally located in proximity to the nucleus, and referred to as the perinuclear 
recycling compartment (Figure 1.11B). Many cargoes are not recycled, but instead are 
sorted to late endosomes (LE) and ultimately to lysosomes for degradation. Others are 
delivered to the trans-Golgi network (TGN) via a retrograde transport (Bonifacino and 
Hurley 2008) (Figure 1.11B). 
Endosomal sorting and vesicular trafficking are regulated by several proteins and lipids. 
Rab proteins, for instance, are a family of small GTPases that coordinate membrane 
trafficking by mediating vesicle fusion (Chavrier and Goud 1999), motility (Hammer and 
Wu 2002), and by recruiting the cargoes (Elizabeth Smythe 2002), as well as specific 
tethering factors. The functional specificity of each Rab member is conferred by its 
specific subcellular localization. For this reason different populations of endosomes have 
been identified according to the presence of a specific Rab member. Protein Rab5 for 
example is localized to the early endosomal compartments, where it mediates both EE 
fusion and motility (Gorvel et al. 1991, Nielsen et al. 1999), whereas Rab4 and Rab11 
associate with both the rapid and slower recycling compartments, respectively (Ullrich O. 
et al. 1996, Van Der Sluijs et al. 1991).  
1.3.1.2 The early endosomal compartment  
The EEs appear as a pleomorphic compartment composed of morphologically, chemically 
and functionally distinct sub-domains, including thin tubular structures and large vesicles 
(Gruenberg 2001). As mentioned earlier, the main function of EEs is the sorting of 
endocytic cargoes to their specific intracellular destination. This is accomplished through 
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the action of an elaborate machinery comprising several endocytic regulatory and 
effector proteins. The GTPase Rab5 lies at the centre of this machinery and is the most 
extensively studied Rab member of the early endosomal compartment (Barbieri et al. 
1996, Gorvel et al. 1991). Rab5 regulates a wide range of endocytic processes: it is 
involved in the formation of clathrin-coated vesicles (McLauchlan et al. 1998), in 
subsequent fusion of these vesicles with EEs, in the homotypic endosome-endosome 
fusion (Gorvel et al. 1991) and in the motility of EEs on microtubule tracks (Nielsen et al. 
1999). In order to regulate all these processes, Rab5 interacts with several effector 
proteins on specific domains of the early endosomal compartment where they carry out 
their specialized endocytic function (Christoforidis et al. 1999, Grosshans et al. 2006). One 
such effector protein, EEA1, was identified as a key component of the endocytic 
machinery for docking and fusion of EEs (Christoforidis et al. 1999), and is a widely used 
marker for EE due to its specific localization to this compartment. Interestingly, while 
Rab5 is equally distributed between CCVs and early endosomes, the localization of EEA1 
is only restricted to the membranes of the EE (Rubino et al. 2000). This observation 
suggested that the Rab5 effector EEA1 specifies the target compartment in the process of 
fusion between CCV and EE, thus providing directionality to the vesicular transport from 
the plasma membrane towards the EE (Rubino et al. 2000). 
APPL1 and APPL2 (Adaptor protein containing PH domain, PTB domain and Leucine zipper 
motif) are other two Rab5 effectors that specifically associate with a distinct 
subpopulation of Rab5-positive EEs (Miaczynska et al. 2004). Rather than having a role in 
endosomal transport, APPL proteins have been shown to be important in signalling 
(Miaczynska et al. 2004, Rashid et al. 2009). This observation suggests that the EE is not 
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only a transitional compartment, but it can actively play a role in signal transduction. The 
role of endocytic organelles in signal propagation is discussed in greater detail in Section 
1.3.3, Crosstalk between RTK endocytosis and signalling. 
1.3.1.3 Clathrin-independent endocytosis  
A number of RTKs, as well as other cargo molecules, can also be internalized by endocytic 
pathways independent of clathrin. Thus far, a relatively high number of clathrin-
independent endocytosis (CIE) pathways have been identified. However, less is known 
about these, and more importantly, the studies that have focused on these alternative 
routes of entry rely primarily on inhibition of CME as their study methodology, and 
therefore could not exclude all the indirect effects that inhibition of one pathway can 
have on another pathway. One of the best-defined alternative pathways is endocytosis 
via caveolae. Caveolae appear at the electron microscope as plasma membrane 
invaginations of 50±80 nm in diameter.  
Caveolae composition is cell-type dependent (Parton et al. 1997, Rothberg et al. 1992, 
Stan et al. 1997), but they are always enriched in cholesterol, sphingolipids (Simons and 
Toomre 2000) and caveolin1 (Rothberg et al. 1992). Each one of these components is 
essential for the formation and the stability of caveolae: in their absence caveolae 
formation is prevented (Fra et al. 1995, Rothberg et al. 1992). Caveolin1 constitutes the 
protein coat, with 100–200 molecules per caveola in HeLa cells (Pelkmans 2005) (Figure 
1.11A).  
In addition to caveolin1, caveolae have been shown to contain dynamin (Henley et al. 
1998, Oh et al. 1998), which, similar to its role in CME, is recruited to the neck of caveolar 
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invaginations, where it mediates scission of the vesicle from the plasma membrane (De 
Camilli et al. 1995) (Figure 1.11A). Many other aspects of caveolar endocytosis remain to 
be established, such as the exact role of caveolin1 in the endocytic process, or the 
involvement of other accessory proteins. Once internalized, caveolar vesicles fuse and 
transfer their cargo to larger tubular membrane organelles. These organelles, once 
thought to be independent compartments distinct from endosomes and known as 
caveosomes (Pelkmans et al. 2001), have recently been shown to correspond to late 
endosomal compartments (Hayer et al. 2010). From here, the internalized cargoes are 
sorted either to the ER, the Golgi complex, or to other compartments (Figure 1.11B).  
Cargoes that can be internalized through caveolae include cholera toxin (Montesano et 
al. 1982), folic acid (Rothberg et al. 1990), serum albumin (Schnitzer and Oh 1994), 
glycosphingolipid Lactosyl Ceramide (LacCer) (Puri et al. 2001), and Simian Virus 40 
(Pelkmans et al. 2002).  
The observation that inhibiting both CME and endocytosis via caveolae does not block 
internalization of several cargoes suggests that other ways of entry that are both clathrin- 
and caveolin1-independent exist. However, their functional roles and the molecules 
involved in these pathways remain elusive. In the context of RTKs, mechanisms of 
internalization involving large volumes of membrane, such as the circular dorsal ruffles 
(CDRs) or the large protrusions formed during macropinocytosis, have been proposed to 
mediate ligand-induced endocytosis (Abella et al. 2010, Schmees et al. 2012) (Figure 
1.11A).  
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Figure 1.11 Endocytosis and endocytic trafficking of RTKs 
A. Major endocytic routes for the entry of RTKs into cells. The diagram shows the 
main functional attributes known for each pathway.  B. RTKs internalized through 
CME are trafficked into the early endosomes and then sorted to late endocytic 
compartments for degradation (lysosomes). Alternatively, cargoes can be recycled 
back to the cell surface via either a fast or a slow recycling pathway. Cargoes 
internalized through caveolar endocytosis are trafficked into an intermediate 
compartment, where they are sorted either to Golgi or to the endoplasmic 
reticulum. Alternatively, caveolin1-coated vesicles can deliver their content into 
early endosomes, sorting cargoes to the canonical endocytic pathway.  
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1.3.2 Endocytosis of FGFRs 
Although the signalling pathways activated by FGFRs have been extensively studied, little 
is known about the endocytic route mediating their internalization, and the studies to 
date that have focused on this issue have reached rather controversial conclusions. The 
first study on FGFR endocytosis dates back on 1996, when Glaizes et al. found that basic 
FGF, or FGF2, localizes in caveolae structures in BHK cells (Gleizes et al. 1996). This first 
observation was further supported by the presence of a putative caveolin-binding motif 
in the cytoplasmic domain of all members of the FGFR family (Couet et al. 1997). Several 
years later, Marchese et al. examined the effect of stimulation of epithelial cells with 
keratinocyte growth factor (KGF) or FGF7 (Marchese et al. 1998). KGF specifically binds 
and activates KGF receptor (KGFR) or FGFR2-IIIb, one of the two alternative splicing 
products from FGFR2 mRNA specifically expressed in epithelial tissues (Miki et al. 1991, 
Miki et al. 1992). By using immunogold electron microscopy on NIH 3T3 cells, Marchese 
et al. observed localization of KGF inside endocytic pits, which these authors speculate to 
be clathrin-coated structures. A clathrin and caveolae-independent pathway was also 
proposed for endocytosis of FGFRs. Upon inhibition of endocytosis from both coated pits 
and caveolae through the endocytic uptake of FGF1 was still occurring, indicative of an 
alternative route for the internalization of FGFR (Citores et al. 2001). Similarly, Reilly et al. 
show that uptake of FGFR1 was independent of both caveolae and coated pits (Reilly et 
al. 2004). Finally, a recent study extensively investigated the mechanism of internalization 
of both FGFR1 and FGFR3, and demonstrated that after depletion of cells for clathrin, or 
by expressing a dominant-negative mutant of dynamin, FGFR3 uptake was only partially 
inhibited, whereas endocytosis of FGFR1 was almost completely blocked (Haugsten et al. 
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2011). Thus, previous reports about FGFR endocytosis appear to be quite controversial, 
and it appears that no firm conclusion can be drawn. However, it is possible that the 
discrepancy is the result of employment by each of the groups mentioned above of 
different combinations of FGF ligands/FGFR isoforms, or the use of a different cellular 
platform for analysis of FGFR endocytosis. As a matter of fact, each FGF ligand, as well as 
each FGFR and the specific combination of the two, has been shown to activate specific 
intracellular pathways, to physiologically target specific cell types, and to promote its 
own specific cellular response. It would not be surprising, therefore, that different FGFRs 
employ different endocytic routes, or that 2 cell lines use different endocytic pathways to 
internalize the same FGFR. 
Following internalization, FGFR appears to follow the canonical intracellular route, being 
mainly targeted to lysosomes for degradation (Haugsten et al. 2005). However, several 
reports showed that this process is more complex, and that similar to the internalization 
pathway, the intracellular fate of FGFR can be receptor/ligand-isoform specific. 
Supporting evidence emerges from Belleudi et al., who showed that both FGF7 and 
FGF10 bind to FGFR2-IIIb in epithelial cells, but while FGF7 mainly targets the receptor to 
lysosomal compartments where the receptor is degraded, FGF10 mostly promotes 
receptor recycling (Belleudi et al. 2007). FGFR4 also seems to follow either the 
degradation or the recycling pathway, and the deciding factor between the 2 fates 
depends on the presence of targeting signals in the cytoplasmic domain of the receptor 
(Citores et al. 2001). Finally, a comparative study between the 4 members of FGFR family 
stimulated with the same FGF1 ligand revealed that each of them is targeted to 
lysosomes or to recycling compartments to different extents, and that the molecular 
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event that controls this sorting is receptor ubiquitination (Haugsten et al. 2005). In fact, 
while FGFR1-3 are efficiently ubiquitinated and targeted to lysosomes for degradation, 
FGFR4 is poorly ubiquitinated and found mostly in the recycling route. A study also 
described a role for Src kinase and RhoB in the activation and transport of FGFR from the 
plasma membrane (Sandilands et al. 2007). The role of Src in FGFR signalling and 
endocytosis is described in more detail in Section 1.4, Src family kinase. 
 
1.3.3 Crosstalk between endocytosis and RTK signalling 
As mentioned above, it is increasingly clear that signal transduction by RTKs can be 
sustained and modulated by endocytosis and that, conversely, receptor signalling can 
regulate the endocytic machinery. The first regulatory effect that endocytosis might have 
on receptor signalling is through control of the pool of receptors on the cell surface 
available for interaction with plasma membrane effector/docking molecules. Most of the 
molecules forming the signalling platforms during the initial events of RTK activation are 
required to be targeted to the proximity of the plasma membrane. Thus, physically 
removing receptors from these compartments could have profound effects on the 
magnitude of signalling. Despite this, many receptors have been demonstrated to remain 
active and continue to signal along the endocytic pathway (Jiang and Sorkin 2002, Li H. S. 
et al. 2005, Sorkin and Von Zastrow 2002). A well known example is that of EGFR, which 
has been demonstrated to remain associated with the signalling complex GRB2/Shc/SOS 
in endosomes and to signal from this location through H-Ras (Jiang and Sorkin 2002). 
Endosomes, therefore, that traditionally were considered as mere transitional 
compartments, are now thought to function as important signalling platforms where 
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receptor signalling originated from the plasma membrane is sustained and where new, 
unique signals are generated (Miaczynska and Zerial 2002, Miaczynska and Bar-Sagi 
2010). Two of the most well characterised examples of specific endosomal signal 
propagation are those mediated by MP1/p14/p18 and APPLs. MP1/p14/p18 is a scaffold 
protein complex that specifically localizes to the membranes of the late endosomes via 
the myristoyl and palmitoyl groups of the component p18 (Magee and Cygler 2011). By 
binding and targeting MEK1 and ERK1 to the late endosomal membranes, the 
MP1/p14/p18 complex enhances MEK1-dependent activation of ERK1 in response to EFG 
(Schaeffer et al. 1998). Notably, this ERK1 signal propagation depends strictly on 
localisation of the MP1/p14/p18 complex on late endosomes, as a mislocalised plasma 
membrane resident complex does not enhance ERK1 activation (Teis et al. 2002). 
Similarly, the adaptor proteins APPL, which specifically localizes to a subpopulation of 
Rab5-positive endosomes (Miaczynska et al. 2004), have been shown to play a role in 
signal transduction events initiated at the plasma membrane. In response to extracellular 
stimuli, such as EGF stimulation, APPL proteins translocate from the EE to the nucleus, 
where they regulate the expression of different genes (Miaczynska et al. 2004). Similarly, 
APPLs have been shown to interact with and regulate the activity of the kinase Akt upon 
growth factor stimulation (Schenck et al. 2008). Importantly, APPLs function in regulating 
both Akt activity and the mitogenic response has been demonstrated to be dependent on 
their endosomal localization (Schenck et al. 2008) and their binding to Rab5 (Miaczynska 
et al. 2004). 
If receptors are still able to signal from endosomes, the localization of internalized 
receptors in specific endocytic compartments can be critical to their ability to interact 
 64 
 
with membrane-associated signalling/adaptor molecules. In this context, trafficking of 
activated receptors can also spatially modulate the signalling response by placing the 
receptor in the appropriate cellular district, where it interacts with the resident 
molecules.  
Finally, endocytosis plays a role in receptor signalling by sorting the internalized receptor 
to different cellular destinations, resulting in different effects on signalling: targeting the 
receptor to lysosomal compartments results in attenuation of signalling, by means of 
protein degradation; on the contrary, sorting the receptor to the recycling routes leads to 
a ‘re-sensitization’ of the cell to external ligands, by replenishing the cell surface with 
ligand-free receptor available for activation (Scita and Di Fiore 2010). In this context, it 
has been proposed that the route of entry for some receptors might be critical to 
determining a different endocytic pathway and, consequently, a different signalling 
output (Scita and Di Fiore 2010). EGFR, for example, has been found to be mainly 
targeted to degradation when it internalizes through CIE, whereas it significantly recycles 
back to cell surface when it enters through CME. The ultimate signalling output from 
EGFR appears to be determined by the integration of these 2 pathways (Sigismund et al. 
2008).   
Ubiquitination plays a particularly important role in regulating RTK trafficking. A number 
of RTKs have been shown to be ubiquitinated upon activation at the plasma membrane, 
resulting in targeting the receptor into internal vesicles of the MVB and their degradation 
in lysosomes (Levkowitz et al. 1998). Mutations that uncouple RTKs from ubiquitination 
have oncogenic properties, resulting in a sustained mitogenic signal as a result of reduced 
receptor degradation (Abella and Park 2009). Interestingly, ubiquitination has also been 
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suggested to regulate other steps of receptor endocytosis. c-Cbl, for instance, the E3 
ubiquitin-conjugating enzyme required for ligand-dependent ubiquitination of EGFR 
(Levkowitz et al. 1998, Waterman and Yarden 2001), has been proposed to control EGFR 
internalisation into CCVs by interacting with CIN85 (Cbl-interacting protein) and the BAR-
containing protein endophilins (Soubeyran et al. 2002), which induces membrane 
curvature during pit formation. Further, in Drosophila melanogaster, c-Cbl appears to be 
important in concentrating the RTKs in specific subcellular compartments during border 
cell migration (Jekely et al. 2005). 
The role of endocytosis as temporal and spatial regulator of RTK signalling is further 
supported by the identification of a wide variety of diseases, including cancer, associated 
with defects in endocytic machinery (Bache et al. 2004, Parachoniak and Park 2012) 
(Table 1.2). As described above, a significant number of these defects prevent RTKs from 
being efficiently ubiquitinated and downregulated. Up to 20% of breast cancers, for 
example, overexpress the EGFR/HER2 hetorodimer, which contrary to the homodimer 
EGFR/EGFR, is unable to be targeted by c-Cbl, resulting in impaired lysosomal 
degradation of EGFR, sustained recycling, and enhanced signalling (Muthuswamy et al. 
1999). Although involvement of Cbl in endocytosis of FGFR has not been clearly 
elucidated (Wong et al. 2002), defects in FGFR ubiquitination have been implicated in 
some forms of skeletal disease. Mutations that prevent FGFR3 Cbl-mediated 
ubiquitination, resulting in inhibition of lysosomal degradation and amplification of 
receptor signalling, have been identified in patients with Achondroplasia (ACH) and 
related Chondrodysplasias (Cho et al. 2004). Other examples of components of the 
endocytic machinery implicated in cell tumorigenesis are the proteins Eps15 and 
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Protein Function in receptor 
endocytosis 
Human cancer Reference 
c-Cbl Ubiquitilation of  ligand-activated 
RTKs 
Point mutations, insertions 
and deletions in acute 
myeloid leukaemia 
(Abbas et al. 2008, 
Dikic and Giordano 
2003, Peschard and 
Park 2003, Shtiegman 
and Yarden 2003) 
Eps15 Scaffolding protein for clathrin 
and receptor recruitment. 
 
fusion in  acute myeloid 
leukaemia 
(Floyd and De Camilli 
1998, So et al. 2003) 
Endophilin-2 membrane curvature inducing 
protein during vesicle formation 
fusion in  acute myeloid 
leukaemia 
(Floyd and De Camilli 
1998, Habermann 
2004, Liu H. et al. 
2004) 
Sprouty Competes with RTKs for Cbl 
binding 
Downregulation in breast 
and prostate cancers. 
(Lo et al. 2006) 
Hip1 Interacts with AP-2, 
clathrin and phosphoinositides 
fusion in   Chronic 
Myelomonocytic Leukemia 
(Ross et al. 1998) 
Clathrin heavy 
chain  
Coat protein fusion in  inflammatory 
myofibroblastic tumour  
and large B-cell lymphoma 
(Bridge et al. 2001) 
Caveolin1 Coat protein Deregulated in multiple 
cancer types;  
Amplification in aggressive 
breast carcinomas 
(Shatz and Liscovitch 
2008) 
Rabaptin-5 Effector of Rab5 required for 
endosomal fusion 
Myelomonocytic leukaemia (Magnusson et al. 
2001) 
Tsg101 Part of ESCRT1 machinery, sorts 
ubiquitinated proteins 
from endosomes to lysosomes 
Aberrant transcripts found 
in different cancers 
(Babst et al. 2000, 
Gruenberg and 
Stenmark 2004, Li L. 
and Cohen 1996) 
Cortactin Drives actin polimerization and 
binds dynamin 
Amplification and 
overexpression in breast 
carcinoma and in  head 
and neck squamous cell 
carcinoma 
(Buday and 
Downward 2007) 
Table 1.2 Components of endocytic machinery aberrantly expressed in human 
cancers 
Data adapted from (Bache et al. 2004, Mosesson et al. 2008).  
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Endophilin-2. In some forms of human myeloid leukaemia, chromosomal translocations 
on chromosome 11q23 often result in fusion proteins comprising the N-terminal domain 
of ALL1/HRX and either Eps15 or Endophilin-2 (Floyd and De Camilli 1998). Finally, 
isoforms of FGFR2-IIIb with deletions in the cytoplasmic domain have been found in some 
human cancers and have been demonstrated to have impaired ligand-induced 
internalisation, reduced degradation, and sustained receptor activation (Cha et al. 2009). 
 
1.4 Src family kinase 
The Src family of protein tyrosine kinases (SFKs) is a family of non-RTKs that play an 
important role in regulating signals from a multitude of cell surface receptors. By coupling 
intracellular signalling machinery with membrane-bound receptors, SFKs control cellular 
processes, including cell adhesion, migration, cell cycle, survival, and differentiation. The 
SFK family includes 9 members, divided into 2 groups according to their tissue expression 
patterns: Src, Fyn, and Yes are expressed in a broad range of tissues, while Fgr, Lyn, Hck, 
Lck, Blk, and Yrc elicit a limited expression range (Courtneidge 2002). All members of the 
SFK family share a conserved molecular architecture, consisting of 6 distinct domains:  an 
Src homology domain 4 (SH4), which is always myristoylated and under specific 
conditions palmitoylated (Koegl et al. 1994, Resh 1999) and drives the kinase association 
with membranes (Pellman et al. 1985); a unique domain, specific for each Src family 
protein; an SH3 and an SH2 domain, which control the range of Src binding partners; a 
kinase domain (SH1); and a C-terminal autoinhibitory region (Cooper and King 1986). 
Dissection of the molecular organization of Src kinases has revealed that they switch 
between close inactive and open active conformations. This process is driven by 
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phosphorylation events on 2 tyrosine residues, Tyr416 and Tyr530 in human c-Src, 
located within the activation loop and the C-terminal regulatory region, respectively. C-
terminal Src kinase (CSK)-mediated phosphorylation of Tyr 530 induces Src to be locked in 
a close auto-inhibited conformation held by interaction between the SH2 domain and the 
phosphotyrosine residue (Yamaguchi H. and Hendrickson 1996). Disruption of this 
interaction either by dephosphorylation of Tyr530 or binding of the SH3 and SH2 domains 
to Src protein partners, converts Src to an open conformation, which results in 
autophosphorylation of Tyr416 and in full kinase activity (Tatosyan and Mizenina 2000).  
1.4.1 c-Src 
The c-Src (cellular-Src) oncogene encodes for a 60-kDa cellular protein with tyrosine 
kinase activity originally identified (Stehelin et al. 1977) for its similarity with the 
transforming oncoprotein (v-Scr) of the tumour-inducing retrovirus RSV (Rous sarcoma 
virus) (Brugge and Erikson 1977, Purchio et al. 1978). The main difference between c-Src 
and v-Src, is that the latter harbours a truncation of the carboxy-terminal tail (Takeya and 
Hanafusa 1983), which results in high kinase activity and transforming potential (Iba et al. 
1984, Tanaka and Fujita 1986). This, in fact, is the region that contains autoinhibitory 
Tyr530, whose absence in v-Src constitutively locks the kinase in the active conformation.   
Subcellular localization of c-Src is a crucial determinant for its activation. c-Src has been 
found to associate to cellular membranes, including plasma membrane (Willingham et al. 
1979), nuclear membrane (David-Pfeuty and Nouvian-Dooghe 1990) and endosomal 
membrane (Kaplan K. B. et al. 1992). As mentioned above, c-Src targeting to cellular 
membranes is mediated by the N-terminal domain, where post-translational myristilation 
(Kaplan J. M. et al. 1988) plus a 6 basic amino acid region are required for c-Src binding to 
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lipid bilayers (Sigal et al. 1994). In addition to the bound-membrane component, a pool of 
c-Src has also been detected in the cytoplasm (Willingham et al. 1979). However, while 
plasma-membrane-associated c-Src is thought to participate in signal transduction events 
via growth factor receptors or to mediate cell adhesion in the focal adhesion complexes, 
the role of c-Src at the other cellular locations has not yet been clarified. The pleotropic 
role that c-Src plays in cells explains the well documented role of the kinase in the 
development and progression of tumours. The kinase activity of c-Src is often found to be 
elevated in human colon (Cartwright et al. 1989) and breast cancers (Verbeek et al. 
1996), as an effect of various molecular mechanisms, such as mutations and 
dephosphorylation of Tyr530. In highly metastatic colon carcinoma, for instance, a c-Src 
mutation has been identified (Irby et al. 1999) that results in truncation of the C-terminal 
region responsible for the autoinhibitory mechanism. This mutated form of c-Src still 
contains (and ends with) the Tyr530 residue, but it lacks the adjacent amino acids 
necessary for intramolecular binding to the SH2 domain, causing the kinase to be 
constitutively active and resulting in elevated kinase activity (Cantley and Songyang 
1994). 
1.4.2 Src and RTKs 
Involvement of Src kinases in the signalling of RTKs has been extensively demonstrated. 
The first evidence came from a study on PDGF-stimulated NIH3T3 fibroblasts which 
revealed that PDGFR is able to directly interact with Src, Yes, and Fyn, consequently 
inducing their phosphorylation and activation (Kypta et al. 1990, Mori et al. 1993). 
Similarly, a number of studies also described the implication of Src in signalling activated 
by EGFR. Src has been shown to potentiate EGF-induced cell proliferation (Luttrell et al. 
 70 
 
1988) and tumorigenesis (Maa et al. 1995) by binding to EGFR and inducing receptor 
autophosphorylation. The direct interaction between the 2 kinases appears to be 
mediated by 3 auto-phosphorylated tyrosine residues on EGFR which serve as binding 
sites for Src SH2 domain (Lombardo C. R. et al. 1995). Interestingly, a crosstalk between 
Src and EGFR has also been implicated in EGFR endocytosis and trafficking. Fibroblasts 
overexpressing Src elicit an increased rate of internalization of EGFR when compared to 
endogenously Src expressing control cells, while no effect can be detected on receptor 
recycling rate (Ware et al. 1997). The molecular mechanism underlying the Src effect on 
EGFR endocytosis is thought to involve events of phosphorylation on clathrin heavy chain 
(CHC) (Wilde et al. 1999). According to the model proposed, activated EGFR causes 
activation of Src, which in turn phosphorylates CHC, inducing clathrin redistribution at the 
cell surface. Recruitment of new clathrin would result in enhanced uptake of activated 
EGFR from the plasma membrane (Wilde et al. 1999). Other groups have implicated 
dynamin in Src-dependent regulation of EGFR endocytosis. Ahn et al., for instance, 
showed that Src-mediated phosphorylation of dynamin at Tyr597 promotes its GTPase 
activity, and can consequently result in enhanced endocytosis of EGFR (Ahn et al. 2002). 
Src is also one of the key downstream effectors in the signalling cascade from FGFR, and 
it has been implicated as a crucial FGFR regulatory factor. Evidence for the involvement of 
Src in FGFR signalling began to emerge in 1994 from the work from Zhan et al., who 
described direct interaction between FGFR1 and the kinase in vitro (Zhan et al. 1994). The 
interplay between FGFR and Src was further confirmed by a number of other studies 
which implicated Src in different FGFR-induced cellular responses, such as neurite 
outgrowth (Kremer et al. 1991), cell migration or cell shape change (Liu J. et al. 1999), and 
 71 
 
mesoderm induction during Xenopus development (Weinstein et al. 1998). To date, the 
exact role of Src in the signalling cascade of FGFR has not been entirely elucidated, but 
several recent reports describe potential physiological substrates for FGFR-mediated Src 
activity. Li et al. showed that Src is recruited to active FGFR via the adaptor protein FRS2, 
and that upon recruitment and activation, Src phosphorylates the signalling negative 
regulator Sprouty2, which in turn attenuates FGFR signalling via the ERK1/2 pathway (Li 
et al. 2004). This is the first clear evidence that Src plays a role in a mechanism of 
regulation of FGFR signalling. In addition to this negative effect, Src has also been 
proposed to positively regulate the signalling from FGFR. Sandilands et al., found that in 
FGF2-stimulated fibroblasts, active Src colocalises with activated FGFR at the plasma 
membrane and that, in the absence of the kinase, only a small pool of active FGFR is 
targeted at the cell surface (Sandilands et al. 2007). Further, Src inhibition was also 
shown to affect FGFR downstream signalling output, including both the Akt and the 
ERK1/2 pathways. These observations suggest that Src may regulate the transport of 
activated FGFR to and from the plasma membrane, consequently affecting the 
downstream signalling cascade induced by the receptor. Recently, a study employed 
ultrahigh resolution mass spectrometry techniques to identify Src kinase substrates 
involved in the signalling pathway from FGFR. By combining stable isotope labelling by 
amino acids in cell culture (SILAC) assay with chemical inhibition of Src activity, this study 
identified a consistent number of new kinases and adaptor proteins phosphorylated by 
Src in response to FGFR activation (Cunningham et al. 2010). One of the Src targets 
identified in this work is the scaffold protein Eps8, already implicated in the trafficking of 
EGFR (Di Fiore and Scita 2002). The physiological function and role of Eps8 in the context 
of RTKs is described in more detail in Section 1.5, Eps8. 
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Consistent with the key role that Src plays in the FGFR signalling cascade, it is not 
surprising that Src is increasingly emerging as a very attractive target for therapy against 
FGFR-associated malignant disorders, such as stem cell leukaemia-lymphoma syndrome 
(SCLL) (Ren et al. 2011). In this context, multiple classes of inhibitors selectively affecting 
Src activity have been developed, such as the combined src/abl inhibitor dasatinib, which 
however, did not yield significant effects in a phase II trial (Herold et al. 2011), or the 
inhibitor bosutinib, which, on the contrary, showed evidence of activity in a phase II trial 
(Campone et al. 2012). 
 
1.5 Eps8 
EGFR pathway substrate 8 (Eps8) is a ubiquitously expressed protein of 97 KDa originally 
discovered in a screening for targets of EGFR-mediated phosphorylation (Fazioli et al. 
1993). The structural organization of Eps8, as predicted by analysis of the primary 
sequence, comprises a phosphotyrosine binding protein (PTB) domain at the N-terminus, 
followed by an SH3 domain and a sterile α motive-pointed (SAM-PNT) domain (Di Fiore 
and Scita 2002) (Figure 1.12A). The PTB domain is thought to mediate interaction of Eps8 
with signalling/scaffolding proteins, even though no binding partner for this domain of 
Eps8 has yet been identified. Similarly, the SAM-PNT domain has been proposed to be 
involved in protein-protein interaction and in the formation of Eps8 homo- and hetero-
oligomers (Di Fiore and Scita 2002). A region of 27 residues within this domain, known as 
the ‘effector region’, has been shown to mediate Eps8 binding to SOS-1, resulting in 
activation of the signalling complex Eps8/Abi1/SOS1, and to mediate direct interaction of 
Eps8 with F-actin, driving Eps8 localization to sites of actin remodelling (Scita et al. 2001). 
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The SH3 domain of Eps8 has been studied extensively and the resolved crystal structure 
revealed that Eps8-SH3 may represent the prototype of a novel family of SH3 modules. 
While a canonical SH3 domain, in fact, structurally adopts a well-characterized 
monomeric β-barrel conformation (Yu H. et al. 1992), Eps8-SH3 appears to assume a 
dimeric configuration, in which the 2 interacting β-barrels share some polypeptide chains 
(Kishan et al. 1997). Interestingly, further analysis of SH3 binding affinity revealed that, 
even if Eps8-SH3 exists in dimeric and monomeric configuration in equilibrium (Kishan et 
al. 1997), only the monomeric form is available to protein interaction (Mongiovi et al. 
1999). Thus, it has been proposed that the dimer may represent a temporary inactive 
state that prevents Eps8 from interacting with signalling binding partners (Di Fiore and 
Scita 2002). Another peculiarity of the SH3 domain of Eps8 is its ability to interact with a 
PXXDY consensus sequence, instead of the canonical XPXXP (Mongiovi et al. 1999). A 
number of Eps8 interaction partners have been identified which display the PXXDY 
consensus.          
1.5.1 Eps8 and RTKs 
As mentioned in Section 1.5, Eps8 was originally identified as a substrate of the kinase 
activity of active EGFR. Its involvement in signalling from RTKs was further confirmed by 
the observation that Eps8 overexpression in different cell lines enhances EGF-mediated 
mitogenic responsiveness (Fazioli et al. 1993) and that alteration of eps8 activity could 
result in EGFR-associated malignant phenotypes (Matoskova et al. 1995). Clear 
elucidation of the role of Eps8 and its physiological substrates in the EGFR signalling 
pathway was described in Scita et al., in which Eps8 was described as coordination of 
EGFR-mediated signals along the Ras/PI3K/Rac cascade (Scita et al. 1999). In the model 
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proposed by Scita and illustrated in Figure 1.12B, Eps8 is part of a signalling complex 
together with the Rac-specific GEF SOS-1 and the scaffold protein E3b1/Abi1, which forms 
upon EGFR-mediated Ras activation at the plasma membrane. The Eps8/Abi1/SOS-1 
ternary complex is targeted via the effector region of the SAM-PNT domain of Eps8 to F-
actin sites (Innocenti et al. 2002, Scita et al. 2001), where SOS-1 serves as an activating 
GEF for the GTPase Rac, ultimately resulting in actin polymerization. The signalling 
complex requires the presence of each of the 3 components to be functional, and Eps8 
depleted cells show no Rac-mediated actin remodelling response (Scita et al. 1999). 
A role for Eps8 in endocytosis of EGFR has also been described (Figure 1.12B). Eps8 has 
been shown to bind to the GAP protein RN-tre, resulting in a negative effect on EGFR 
internalisation (Lanzetti et al. 2000). Although the exact molecular mechanisms are not 
yet known, the inhibitory effect on EGFR endocytosis seems to involve the GTPase Rab5, 
already implicated in the process of receptor internalisation (Bucci et al. 1992). According 
to the model proposed, when it is sequestered in the complex with Eps8, RN-tre is not 
able to function as activating GAP for Rab5, resulting in inhibition of receptor endocytosis 
and sustained receptor signalling at the plasma membrane (Lanzetti et al. 2000). 
Interestingly, Eps8 has been found to associate with internalised EGFR, while no 
interaction has been detected with the plasma-membrane pool of the receptor (Burke et 
al. 2001), further implicating Eps8 in EGFR trafficking regulation.  
The fact that Eps8 participates in both Rac and Rab5 signalling depending on the complex 
it associates with (Eps8/Abi1 and Eps8/RN-tre, respectively), suggests that it can function 
as coordinator of the 2 alternative pathways. This consideration is further supported by 
the observation that Abi1 and RN-tre compete for the interaction with Eps8, diverting 
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Eps8 function from actin to endocytosis regulation, and vice-versa (Figure 1.12B). Further 
supporting evidence for involvement of Eps8 in receptor endocytosis is from the recent 
Taylor et al. By using a live-cell total internal reflection fluorescence (TIRF) microscopy 
based assay, this group examined the recruitment dynamics of a list of endocytic proteins 
in the process of CCV scission (Taylor M. J. et al. 2011). Eps8 was identified among the 
proteins recruited during the scission events and showed a pattern of recruitment similar 
to that of dynamin (Taylor M. J. et al. 2011).      
Evidence of a role for Eps8 in the signalling pathway from FGFR is also beginning to 
emerge. As already mentioned, Cunningham et al. recently showed that Eps8 is 
phosphorylated at different tyrosine residues in a Src-dependent manner upon FGF 
stimulation (Cunningham et al. 2010). These phosphorylated tyrosine residues on Eps8 
may be important for mediating the recruitment and activation of key signalling effectors 
in the FGFR pathway, suggesting that the role of Eps8 as coordinator of signalling events 
could be conserved across different RTKs.  
1.5.2 Eps8 and cancer 
The first observation of a mitogenic effect for eps8 came from studies on fibroblast and 
hematopoietic cells which showed increased mitogenic response to EGF upon eps8 
overexpression (Fazioli et al. 1993). To date, eps8 has been found to be upregulated in a 
variety of tumours, including colon and oral tumours (Chu et al. 2012, Maa et al. 2007), 
and it correlates with migration and invasiveness of different cancer cell lines such as 
cervical cancer- or oral squamous cell carcinoma (OSCC)-derived cell lines (Chen Y. J. et al. 
2008, Yap et al. 2009). Additionally, tyrosine phosphorylation of eps8 has been observed  
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Figure 1.12 Domain organization of Eps8 and its role as coordinator of signals 
downstream of EGFR 
A. Structural organization of Eps8 comprises a PTB domain, followed by an SH3 
domain, and a SAM-PNT domain. The latter contains the binding site for the 
interaction with Sos1, whereas the EGFR binding region is located upstream and 
is indicated with blue bars. B. Eps8 can associate with two signalling complexes 
(Eps8/Abi1 or Eps8/RN-tre) and participate in either Rac or Rab5 signalling, 
regulating actin remodelling or EGFR endocytosis, respectively.    
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to occur constitutively in some human tumours, suggesting that pTyr-eps8 may represent 
a useful marker for detecting tumour cell lines (Matoskova et al. 1995). 
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1.6 Thesis aims 
 
FGFRs regulate fundamental processes in the cell, including proliferation, differentiation 
and angiogenesis, and their activity must be accurately regulated to prevent uncontrolled 
sustained signalling. Endocytosis and trafficking of FGFRs can modulate initiation and 
propagation of signals and defects in these 2 processes, which are implicated in a variety 
of skeletal disorders as well as malignancies. Thus, it is extremely important to 
understand the mechanisms of FGFR endocytosis and trafficking and the impact they 
have on the receptor signalling response. Recent proteomic studies have identified Eps8 
as a potential coordinator of the interplay between FGFR signalling and trafficking. 
However, the exact role of eps8 in the context of FGFR remains unknown.  
This thesis aims to: 
- examine the dynamics of receptor recruitment and clustering at the cell surface prior to 
internalization  
- identify the endocytic pathway for endocytosis of FGFR2 
- investigate trafficking of FGFR through the endocytic system 
- establish the role of Src and eps8 in regulation of FGFR trafficking and signalling  
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CHAPTER 2 
MATERIALS AND METHODS 
 
2.1 Buffers and Solutions 
2.1.1 Bacterial culture 
 Luria Bertani broth (LB): 10 g/l bacto-tryptone, 5 g/l yeast extract, 10 mM NaCl, pH 
7.4 
 Ampicillin plates: LB + 15 g/l bacto-agar, 100 μg/ml ampicilin 
 Kanamycin plates: LB + 15 g/l bacto-agar, 50 μg/ml kanamycin 
2.1.2 Mammalian cell culture 
 Dulbecco’s Modified Eagle Medium: pre-made (Invitrogen) and supplemented 
with 4.5 g/l L-glutamine (Invitrogen) 
 Roswell Park Memorial Institute Medium: pre-made (Invitrogen) 
 Foetal Bovine Serum: purchased as frozen (Labtech International) 
 Penicillin-Streptomycin solution (100x): pre-made (Invitrogen) 
 0.05% Trypsin-EDTA solution: pre-made (Invitrogen) 
2.1.3 Protein manipulation 
 Triton X-100 lysis buffer: 50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1% Triton X-100 
(w/v), 1 mM Na3VO4, 50 mM NaF, 25 mM β-glycerophosphate supplemented with 
1 tablet of complete mini protease inhibitors cocktail (Roche) per 10 ml of buffer 
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 SDS sample buffer (5x): 250 mM TrisHCl pH 6.8, 10% SDS (w/v), 30% Glycerol 
(w/v), 5% β-mercaptoethanol (w/v), 0.02% bromophenol blue (w/v) 
 Tris-Glycine running buffer: 25 mM Tris, 0.2 M glycine, 0.2% SDS (w/v) 
 MOPS running buffer (20X): pre-made (Invitrogen) 
 Western blot transfer buffer: 25 mM Tris, 0.2 M glycine, 10% methanol (v/v) 
 Phosphate Buffered Saline Tween (PBST): PBS,  0.05% Tween 20 (v/v) 
 Immunoblot blocking buffer: pre-made buffer (LI-COR Biosciences) in PBST 
2.1.4 Immunofluorescence 
 Fixation solution: 4% paraformaldehyde (w/v) in Tris Buffered Saline (TBS) pH 7.4 
 Washing buffer: Phosphate Buffered Saline (PBS) 
 Glycine wash solution: 100 mM glycine in TBS 
 Permeabilization solution: 20 mM glycine and 0.1% saponin (w/v) in TBS 
 Blocking solution: 10% FCS and 0.1% saponin (w/v) in TBS 
2.1.5 Live cell imaging 
 Cell Imaging Media (CIM):  Hanks Balanced Salt Solution (HBSS) (SIGMA) and 10 
mM Hepes, pH 7.4 
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2.2 Reagents and Antibodies  
All primary and secondary antibodies used are listed in Table 2.1. 
Antibody Species Manufacturer Working dilution 
Rab11 RP Invitrogen 1:200 (IF) 
EEA1 (clone 1G11) MM Abcam 1:200 (IF) 
Caveolin1 RP BD Biosciences 1:1000 (IB) 
α-adaptin 1/2 (clone M-300) RP Santa Cruz 1:1000 (IB) 
α-tubulin MM SIGMA 1:10000 (IB) 
Clathrin heavy chain (TD.1) MM Santa Cruz 1:1000 (IB) 
Dynamin2 (C-18)  GP Santa Cruz 1:1000 (IB) 
ERK1 (clone K-23) RP Santa Cruz 1:1000 (IB) 
pERK 1/2 (clone E-4) MM Santa Cruz 1:1000 (IB) 
AKT (clone 40D4) MM Cell Signalling 1:1000 (IB) 
pAKT (Thr 308) RP Cell Signalling 1:1000 (IB) 
Eps8 (clone M-238) RP Santa Cruz 1:1000 (IB) 
myc (clone 9E10) MM Roche 1:500 (IP) 1:1000 (IB) 
Mouse IgG IRDye800CW GP LI-COR 1:5000 (IB) 
Rabbit IgG IRDye680CW GP LI-COR 1:5000 (IB) 
Mouse IgG IRDye800CW GP LI-COR 1:15000 (IB) 
Rabbit IgG IRDye680CW GP LI-COR 1:15000 (IB) 
Table 2.1 List of all primary and secondary antibodies used in this study, including 
their working dilutions, species and manufacturer. RP: Rabbit Polyclonal. MM: 
Mouse Monoclonal. GP: Goat Policlonal. IF: Immunofluorescence. IB: 
Immunoblotting.  
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FGF2 was in-house prepared (by Susan Brewer). EGF was purchased from Sigma. Heparin 
and Dynasore were purchased from Sigma. SU5402 was purchased from Calbiochem. 
Dasatinib was purchased from Sellek Chemicals. 4-12% NuPAGE Novex Bis-Tris gels used 
for SDS-PAGE were purchased from Invitrogen. 
siRNA oligos targeting α-adaptin (sequence AAGAGCAUGUGCACGCUGGCCA), caveolin1 
(SmartPool l-003467) and Eps8 (SmartPool L-017905) and Non-silencing control (NSC) 
oligoes, were purchased from Dharmacon. All siRNAs were resuspended in RNase-free 
water (Thermo Scientific) to 20 μM and stored at -20°C. 
 
2.3 Plasmids 
The construct encoding C-terminally GFP-tagged FGFR2IIIc (FGFR2-GFP) was a gift from J. 
Ladbury (The University of Texas, Houston, TX). EGFP-tagged EGFR was a gift from A. 
Sorkin (University of Pittsburgh, Pittsburgh, PA). N-terminal myc-tagged full-length 
mNbr1 was made by Gateway cloning (Invitrogen) according to manufacturer's 
instructions. EGFP-tagged BAIAPL2L-GFP, IRSp53 and IRTKS were gifts from R. Insall 
(Beatson Institute for Cancer Research, Glasgow, UK). Constitutively active Src was 
provided by Margaret Frame (Edinburgh Cancer Research UK Centre). DsRed tagged 
clathrin light chain A (clathrin-dsRed) was a gift from T. Kirchhausen (Harvard Medical 
School, Boston, MA). Caveolin 1-mRFP was a gift from A. Helenius (ETH Institut of 
Biochemistry, Zurich, Switzerland). Eps8-mCherry was a gift from Giorgio Scita (IFOM 
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University of Milan, Milan, Italy). 
 
2.4 Cell biology techniques 
2.4.1 Preparation of (heat shock) competent bacterial cells   
E. coli DH5α strain was used to propagate plasmids. A single colony was inoculated in 2 
ml of LB-medium and grown over night at 37°C while shaking at 250 rpm. The following 
morning 500 ml of LB-medium were inoculated with 1 ml of saturated overnight culture, 
and grown to an OD600 nm = 0.5. Cells were transferred in 2 pre-chilled sterile 250 ml 
centrifuge tubes and cooled on ice for 20 min, before being pelleted by centrifugation at 
5000 rpm for 10 min at 4°C. The supernatant was removed and the pellet resuspended in 
10 ml ice-cold MgCl2-CaCl2 solution by gentle vortexing. Cells were centrifuged at 2500 
rpm for 5 min at 4°C, the supernatant was discarded and the pellet resuspended in 10 ml 
of ice-cold 0.1 M CaCl2 by gentle vortexing. Cells were then directly used for 
transformation or dispensed into 50 µl aliquots and stored at -80°C until use. 
2.4.2 Heat shock transformation of competent bacterial cells  
~1µg of pre-purified plasmid was added directly to 50 µl of DH5α E.coli thawed, 
competent cells. After incubation on ice for 30 min, cells were heat-shocked in a 42°C 
water bath for 45 seconds and then transferred back to ice for a further 2 min. Cells were 
resuspended in 1 ml of LB-medium (without antibiotic) and incubated for 1 hr at 37°C in 
order to assist cell recovery. 100-150 µl of the resulting culture was spread on LB plates 
(with appropriate antibiotic added) and grown overnight at 37°C. About 12-16 hr later 
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two colonies per plasmid were picked and processed for the purification and isolation 
steps.   
2.4.3 Mammalian cell lines and cell culture 
Eps8 shRNA and control shRNA HeLa cells were a gift from Giorgio Scita (IFOM University 
of Milan, Milan, Italy). LNCap cells were a gift from Hing Leung (Beatson Institute, 
Glasgow, UK). HeLa cells were propagated in Dulbecco’s Modified Eagle Medium (DMEM) 
supplemented with 10% foetal bovine serum (FBS), penicillin and streptavidin (100X) and 
4.5 g/l L-glutamine in a 5% CO2 atmosphere at 37°C. Cells were split into fresh media at a 
dilution of 1:16 when they reached ~90% confluency. LNCaP cells were propagated in 
Roswell Park Memorial Institute (RPMI) medium supplemented with 10% foetal bovine 
serum (FBS), penicillin and streptavidin (100X) in a 5% CO2 atmosphere at 37°C. Cells 
were split into fresh media at a dilution of 1:8 when they reached ~80% confluency.   
2.4.4 Transfection 
All DNA and siRNA transfections were performed by using Lipofectamine2000 
transfection reagent (Invitrogen) according to the manufacturer’s protocol. DNA 
transfection was performed when cells had reached 90% confluency. After transfection, 
cells were incubated for 24 hr, then split 1:2 and incubated for further 24 hr to allow 
efficient expression of recombinant proteins. Before each experiment, cells were starved 
for 30 min in serum-free DMEM (unless otherwise stated). For siRNA transfection, cell 
were allowed to reach 50% confluency. At this stage a first round of transfection was 
performed, following the manufacturer’s protocol, and a second one after 24 hr, when 
cells had reached a high confluency. After 3-4 hr cells were split 1:2 and incubated for 
further 24 hr to allow efficient gene silencing.  
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2.4.5 Stimulations and inhibitions 
For the FGFR2 studies, cells were stimulated with 20 µg/ml heparin and 50 ng/ml FGF2 
for the indicated amounts of time. In preliminary experiments using different 
concentrations of FGF2 (1 to 100 ng/ml) 50ng/ml was shown to be the optimal 
concentration to be used in further experiments. For the inhibition assays cells were 
either treated with 25 µM SU5402 for 5 min, 80 µM Dynasore for 30 min or 50 nM 
Dasatinib for 30 min or treated as above in the absence of drug (control) before FGF2 
stimulation. To block the stimulation and receptor internalization, cells were rinsed twice 
with cold PBS and kept on ice before the fixation/lysis. For the EGFR studies, cells were 
stimulated with 50 ng/ml EGF for 30 min.   
2.4.6 Immunochemistry 
Cells grown on coverslips were fixed in 4% paraformaldehyde in TBS for 10 min, washed 
in TBS/100mM glycine and permeabilized with TBS/0.1% saponin/20mM glycine. After 
blocking with TBS/0.1% saponin/10% FCS, cells were incubated with primary antibodies, 
then washed and incubated with secondary antibodies. After staining, the coverslips 
were mounted in Hydromount (National Diagnostic) and imaged in confocal microscopy 
by using either the Nikon A1R or the Zeiss LSM710 system (see section 2.6). Each 
experiment was repeated a minimum of 3 times and an image that represented the 
phenotype of most of the cells was selected and prepared by using NIS-Elements Imaging 
Software version 3.2 (Nikon). 
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2.5 Molecular biology techniques 
2.5.1 Plasmid DNA purification and isolation  
5 ml LB media supplemented with appropriate selection antibiotics were inoculated with 
a single bacterial colony and grown overnight at 37°C on a shaker. Cells were centrifuged 
at 6,000 rpm for 15 min. Plasmid DNA was isolated using the QIAGEN Plasmid Maxi Kit, 
which is based on a modified alkaline lysis procedure, followed by binding of plasmid DNA 
to anion-exchange resins at low-salt and pH conditions. The DNA pellet was washed once 
with Isopropanol and once with 70% ethanol and dissolved in 300 µl of autoclaved H20. 
2.5.2 Cell lysis and measure of protein concentration 
Confluent cultures of HeLa cells were rinsed twice in cold PBS and lysed in Triton X-100 
lysis buffer supplemented with complete mini protease inhibitors cocktail (Roche). Cell 
lysates were removed from the bottom of the flasks/plates by using a scraper and 
centrifuged (14,000 g for 20 min at 4°C) to clear the protein phase from the rest of the 
cellular components. The whole procedure was performed at 4°C. For protein 
concentration measurement, bovine serum albumin (BSA) standards were prepared at 
concentration of 2.5, 5, 10, 15, 20 and 25 μg/ml in dH2O in order to obtain a standard 
curve for measurements. The concentration of protein samples was determined by 
Coomassie (Bradford) protein assay (Thermo Scientific) on a range of dilutions from the 
cleared protein lysates. For the analysis of the whole cell lysates, SDS sample buffer was 
added to the lysates and the sample boiled for 10 min at 95°C. If not immediately used 
for SDS PAGE analysis, boiled lysates were stored at -20°C. 
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2.5.3 Immunoprecipitation, SDS PAGE and immunoblotting 
Immunoprecipitation was carried out by incubating the cleared lysates with dynabeads 
(Invitrogen) crosslinked with anti-myc antibody at 4°C overnight. Beads were then 
collected by short centrifugation (2.500 g for 3 min at 4°C), washed 5 times in lysis buffer, 
resuspended in SDS sample buffer and boiled for 10 min at 95°C. Boiled extracts were 
resolved by a 4-12% NuPAGE Bis-Tris SDS gel in MOPS buffer and transferred to 
Immobilon PVDF-FL membrane (Millipore) at 4°C using Immunoblot transfer buffer at 100 
V for 1:15 hr. The membrane was blocked in methanol and then incubated overnight at 
4°C with primary antibody diluted in blocking buffer. After washing in PBST, the 
membrane was incubated with secondary antibody for 1 hr at room temperature 
followed by washing and detected using an Odyssey infrared imaging system (LI-COR). 
Quantification by densitometric scanning of Western blots was performed using Odyssey 
Application Software version 3.0 (Li-COR). Since the primary antibodies used in this 
analysis detected both the 42 kDa and 44 kDa form of ERK/pERK, two bands were 
visualized and captured. The p44 phosphoERK levels were calculated by normalizing, for 
each point of the timecourse, the relative optical density value of the p44 phosphoERKs 
band to the corresponding total p44 ERK value. 
 
2.6 Microscopy techniques 
2.6.1 Laser Scanning Confocal Microscopy (LSCM), Epi-fluorescence Microscopy (E-FM) 
and Super-resolution microscopy  
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Confocal laser and Epifluorescence microscopy were performed with an inverted 
microscope (Eclipse Ti, Nikon A1R) at 37°C using a 60X 1.45NA oil-immersion objective 
and Andor iXon 885 EMCCD camera. GFP constructs were excited with an Argon-Ion 457-
514 nm laser, mRFP and dsRed constructs with a Green Diode 561 nm laser. Confocal 
microscopy was also performed with a Zeiss LSM 710 confocal microscope with a 40X 
1.3NA oil-immersion objective and a Transmission-Photomultiplier LSM T-PMT. 
Epifluorescence microscopy was also performed by using a Nikon TE300 Inverted Epi-
fluorescence microscope using an 60X 1.40NA oil-immersion objective and a cooled 
CCD camera (Hamamatsu C4742-98-12WRB). All images were prepared with NIS-
Elements Imaging Software version 3.2 (Nikon). Super-resolution imaging was performed 
on a gSTED system (Leica) and image stacks were deconvolved using Huygens linked 
within the Leica software.   
2.6.2 Total Internal Reflection Fluorescence Microscopy (TIR-FM)  
TIRF microscopy was performed with the system described above as well as with an 
inverted microscope (IX81, Olympus) using a 60X 1.49NA oil-immersion objective and a 
12-bit CCD camera (ORCA-R2 C10600, Hamamatsu). GFP constructs were excited with a 
491-50 Diode type laser, dsRed constructs with a 561-50 DPSS type laser. Images were 
analyzed and prepared with Xcellence Advanced Live Cell Imaging System version 1.1 
(Olympus).  
 
2.7 Miscellaneous techniques 
2.7.1 Receptor trafficking assay 
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Cells were transfected with FGFR2-GFP or EGFR-GFP and 24 hr before the experiment 
were plated into 35-mm glass-bottomed dishes (MatTek Corporation). On the day of the 
experiment, cells were starved for 30 min and, where indicated, treated with trafficking 
inhibitors. Media was then removed and cells were washed twice with phosphate-
buffered saline (PBS), and incubated in prewarmed (37°C) cell imaging media (CIM). Cells 
were placed on the microscope stage, inside a temperature control chamber (37°C), and 
stimulated by addition of ligand. Real-time analysis of receptor trafficking was performed 
by imaging cells once every 5 min, immediately following stimulation. For the 
quantification analysis, FGFR2-GFP intensity in the plasma membrane associated region 
of the cells was calculated for each frame of the time-lapses (1 frame/5 min). From each 
time point, a background value was subtracted, corresponding to the cytosolic 
fluorescence intensity before the stimulation with FGF2 (time = 0 min). In order to define 
the plasma membrane associated region, cells were treated with a red membrane stain 
(DiI, Invitrogen) for 5 min before the analysis. For the EGFR trafficking assays, the total 
cellular EGFR-GFP intensity was measured at each time point to quantify receptor 
degradation, whereas the number of intracellular endosomes positive for EGFR was 
analyzed at each time point to quantify receptor endocytosis. Data analysis was 
performed using NIS-Elements Imaging Software version 3.2 (Nikon). 
2.7.2 Transferrin and cholera toxin B uptake assay 
For siRNA studies, cells were transfected with FGFR2-GFP and either α-adaptin siRNA or 
caveolin1 siRNA and plated into 35-mm glass-bottomed dishes (MatTek Corporation). 
Following starvation for 30 min, cells were incubated for 30 min either with Alexa-Fluor-
546–transferrin (Invitrogen) or with Alexa-Fluor-555-cholera toxin B (Invitrogen) at 37°C 
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and 5% CO2. For the Dynasore studies, cells transfected with FGFR2-GFP and plated into 
35-mm glass-bottomed dishes were treated with Dynasore following 30 min starvation. 
Cells were then incubated for 30 min in Alexa-Fluor-546–transferrin at 37°C and 5% CO2.  
For the FGF2-dependent uptake assay, cells were incubated for 30 min with ligand and 
Alexa-Fluor-546–transferrin at 37°C and 5% CO2.  
Following treatments, cells were acid washed  twice to remove transferrin/cholera toxin 
B still bound at the cell surface, then fixed in 4% paraformaldehyde (PFA) and analyzed. 
All images were acquired by using a Nikon TE300 Inverted Epi-fluorescence microscope 
using an 60X 1.40NA oil-immersion objective and a cooled CCD camera (Hamamatsu 
C4742-98-12WRB). 
 For quantification of transferrin and cholera toxin uptake, cells randomly located on the 
coverslips were scanned at fixed intensity settings below pixel-saturation, and the total 
cellular intensity was determined. Data analysis was performed using ImageJ (National 
Institutes of Health, NIH). For the triple colocalization, HeLa cells were incubated with 
Alexa-Fluor-633-transferrin (Invitrogen) for 5 min, in order to mark the early endosomes. 
Cells were then rinsed, fixed and analyzed via confocal microscopy. 
2.7.3 Colocalization of FGFR2/EGFR with clathrin and caveolin1 
HeLa cells cotransfected with GFP tagged receptors (FGFR2 or EGFR) and either clathrin-
dsRed or caveolin1-mRFP were plated into 35-mm glass-bottomed dishes. On the day of 
the experiment, cells were starved for 30 min in serum-free media, stimulated with the 
corresponding ligand for 30 min, then rinsed twice in PBS, fixed in 4% PFA and analyzed in 
TIRFM. For the quantitative analysis, each spot of FGFR2, EGFR, clathrin and caveolin1 
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was identified and a circle was drawn around it. Spots were identified as colocalizing 
when the majority of the fluorescence intensity of the pixels within the circular regions 
fitted in both the channels. To exclude the possibility that the colocalization was the 
result of random alignment of receptor spots with clathrin/caveolin spots, a negative 
control was also included for each experiment. As a control for random colocalization 100 
regions that did not contain receptor clusters were analyzed for the presence of 
clathrin/caveolin. Data analysis was performed using NIS-Elements Imaging Software 
version 3.2 (Nikon). 
2.7.4 Analysis of recruitment of FGFR2 and clathrin   
HeLa cells co-expressing FGFR2-GFP and clathrin-dsRed and plated into 35-mm glass-
bottomed dishes, were starved for 30 min in serum-free media and then imaged in 
simultaneous two-colour TIRF microscopy at 37°C (1 frame/30 sec) following receptor 
stimulation. For the quantification, each timelapse was analyzed backward for the 
appearance of FGFR2 and Clathrin at colocalizing spot and the percentage of clathrin 
clusters forming at pre-existing FGFR2 spots, of FGFR2 spots recruited at pre-formed 
Clathrin clusters or FGFR2 and Clathrin clustering simultaneously at the plasma 
membrane were normalized for cell surface area. Data analysis was performed using 
Xcellence Advanced Live Cell Imaging System version 1.1 (Olympus). 
2.7.5 Analysis of redistribution of clathrin to cell surface   
LNCaP cells expressing clathrin-dsRed and HeLa cells coexpressing FGFR2-GFP and 
clathrin-dsRed were plated into 35-mm glass-bottomed dishes. 30 min before the 
experiment, cells were starved in serum-free media and treated, where indicated, with 
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the trafficking inhibitors or with Eps8 siRNA. Cells were then rinsed in PBS, incubated in 
prewarmed (37°C) cell imaging media and  analyzed in TIRF microscopy before and 30 
min after stimulation with ligand. The number of clathrin spots was calculated for each 
condition and normalized for cell surface area. Data analysis was performed using 
Xcellence Advanced Live Cell Imaging System version 1.1 (Olympus). 
2.7.6 Analysis of endocytic events at plasma membrane 
HeLa cells cotransfected with FGFR2-GFP and clathrin-dsRed were starved in serum free 
media for 30 min, then rinsed in PBS, incubated in prewarmed (37°C) cell imaging media 
and imaged in live-cell TIRF microscopy at 37 °C for 2 min (1frame/200msec) before and 
30 min after ligand addition. The number of clathrin spots disappearing from the TIRF 
field was calculated and normalized for cell surface area. Data analysis was performed 
using Xcellence Advanced Live Cell Imaging System version 1.1 (Olympus). 
2.7.8 Time dependent colocalization of FGFR2 with Eps8 
HeLa cells transiently transfected with FGFR2-GFP and Eps8-mCherry and plated into 35-
mm glass-bottomed dishes were starved for 30 min in serum-free media, then rinsed 
twice in PBS and fixed in 4% PFA, or treated as above upon incubation with ligand for 
either 10 or 30 min. After fixation, cells were imaged in confocal microscopy using the 
Nikon A1R system (see section 2.6). Colocalization between FGFR and Eps8 was assessed 
by identifying every spot and drawing a circle around it. Two spots were identified as 
colocalizing when the majority of the fluorescence intensity of the pixels within a circle 
fitted in both the green and red channels. Data analysis was performed using NIS-
Elements Imaging Software version 3.2 (Nikon). 
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2.7.9 Colocalization of FGFR2 with makers for endocytic compartment 
Eps8 shRNA and control shRNA HeLa cells transiently transfected with FGFR2-GFP were 
stimulated with FGF2 for 30 min  following 30 min of serum-free media starvation. Cell 
were then immunostained with anti-EEA1 and anti-Rab11 antibodies (in order to mark 
the early endosomal and the perinuclear recycling compartment, respectively) and 
imaged in confocal microscopy. For lysosomal staining, cells were incubated with 75 nM 
LysoTracker Red (Molecular Probes) for 30 min and immediately imaged in imaging media 
at room temperature. Data analysis was performed using NIS-Elements Imaging Software 
version 3.2 (Nikon). 
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CHAPTER 3 
RESULTS 
 
3.1 Identification of a model system and expression of functional GFP-
tagged FGFR2 
The transcripts of three out of the five fibroblast growth factor receptors (FGFR1-3) are 
subjected to an alternative splicing event that uses either exon 8 or exon 9 to encode the 
second half of the D3 domain (Figure 1.5). The two splice variants generated by this event 
(IgIIIb and IgIIIc) display different ligand-binding specificities and a specific cell-lineage 
pattern of expression. This study uses FGFR2IIIc as a model for analysis of FGFR 
endocytosis and trafficking. This splice variant of FGFR2 is specifically expressed in 
mesenchymal cells, both during early organogenesis and in adulthood (Orr-Urtreger et al. 
1993). To investigate in real-time the endocytic dynamics of receptors in mammalian 
cells, an ectopically overexpressed C-terminal GFP-tagged form of FGFR2IIIc (herein 
referred to as FGFR2-GFP) was employed. The functionality of this fusion protein was 
previously validated in a published report from John Ladbury’s group (Schuller et al. 
2008), which showed that the GFP-fused receptor is kinase active and that tagging does 
not interfere with receptor functionality.  
In living cells, to follow the dynamics of transiently overexpressed FGFR2-GFP, 
identification of an adequate cell model was a critical step. Two different cell lines were 
screened as potential cellular platforms for the cell imaging studies, HEK-293T cells 
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(epithelial cells from embryonic kidney) and HeLa cells (human cervical cancer cells). Both 
these cell lines have been shown to express very low levels of endogenous FGFR2 (Ahmed 
et al. 2008), an important criterion to follow to avoid any interference that the 
endogenous FGFR2 could have with the ectopically transfected counterpart. Preliminary 
analysis of FGFR2-GFP expression level in HEK-293 and HeLa cells (Figure 3.1) revealed 
that both cell lines express a sufficient quantity of transfected proteins, allowing for high-
quality microscopy analysis. Further, both HEK-293T and HeLa cells expressing FGFR2-GFP 
and imaged in confocal microscopy in the absence of ligand show plasma membrane 
localisation of the fusion protein (Figure 3.1, left panels), confirming the correct targeting 
of FGFR2-GFP.   
The b isoform of FGFR2 has the ability to bind multiple ligands of the FGFs family (see 
Table 1.1). Among these ligands, FGF1 and FGF2 have been shown to interact with very 
high affinity with FGFR2IIIc (Miki et al. 1992) and to efficiently induce receptor-mediated 
signalling and biological responses (Mehta et al. 2001, Singh et al. 2012). Consistent with 
these observations, FGFR2-GFP expressing HEK-293T and HeLa cells were incubated with 
FGF2 ligand and imaged in confocal microscopy. As shown in Figure 3.1 (right panels), 
ligand stimulation for 15 minutes induces receptor internalisation from the plasma 
membrane and redistribution into intracellular endocytic compartments. Notably, in 
ligand-stimulated HeLa cells (lower right panel), the receptor specifically appears to be 
targeted to perinuclear regions, suggesting that FGFR2 might be trafficked through a 
canonical endosomal route by which it is sorted either to degradative or late recycling 
perinuclear compartments. These observations demonstrate that FGFR2 efficiently  
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Figure 3.1. Cellular localisation of FGFR2-GFP in HEK-293T and HeLa 
cells 
HEK-293T and HeLa cells transfected with FGFR2-GFP fusion protein 
were incubated for 15 minutes in the absence (left panels) or presence 
(right panels) of FGF2 ligand, fixed and imaged in confocal microscopy. 
In non-stimulation conditions, both cell lines show a predominant 
membrane localisation of FGFR2. On the contrary, upon ligand 
stimulation, receptor redistributes from the plasma to intracellular peri-
nuclear compartments. Scale bars = 10 µm.   
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responds to FGF2 stimulation and provide further confirmation of the functionality of the 
FGFR2-GFP fusion protein. 
Finally, to assess whether the cellular localisation and behaviour of FGFR2-GFP reflects 
that of an endogenous receptor, this study examined the dynamic of internalisation of 
endogenous FGFR1 in HEK293 cells. As shown in Figure 3.2, localisation of the 
endogenous receptor is comparable to that of ectopically transfected FGFR2-GFP, both 
before and after FGF2 stimulation, further validating this system for use in live-cell 
imaging studies.   
3.1.1 Conclusion  
Preliminary characterisation of a model system suitable for studying FGFR2 trafficking by 
live-cell imaging resulted in identification of two cell lines, HeLa and HEK-293T. Both 
these cell lines express very low levels of endogenously expressed FGFR2 (Ahmed at al. 
2008), which makes them a suitable cell platform for studying, in real-time, the endocytic 
dynamics of an ectopically transfected C-terminal GFP-fused FGFR2. Expression level 
analysis of the fusion protein in both cell lines showed a level of receptor sufficient to 
allow live-cell imaging studies and revealed that the GFP tag does not affect either ligand 
binding or receptor activation and its subsequent internalisation. In conclusion, GFP-
tagged FGFR2 has been successfully validated, and both HeLa and HEK293T cells appear 
to be suitable model systems for studying trafficking of the receptor in living cells. 
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Figure 3.2. Cellular localisation of endogenous FGFR1 in HEK-293T cells 
HEK-293T cells were incubated for 15 minutes in the absence (left panels) 
or presence (right panels) of FGF2 ligand, fixed and immunostained for 
FGFR1. Confocal microscopy analysis of the cells shows that, similar to 
overexpressed FGFR2-GFP fusion protein, endogenous receptor localises at 
the cell surface in absence of ligand, whereas it is targeted to peri-nuclear 
endocytic compartments upon FGF2 stimulation. Scale bars = 10 µm.   
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3.2 Establishment of live-cell imaging assays to study FGFR  
Having identified an appropriate cell model for studying the endocytic dynamics of 
FGFR2, the next step was to establish living-cell–based assay systems to investigate, in 
real time, the basic aspects of receptor trafficking, including receptor dynamics at the cell 
surface, internalisation, and endocytic trafficking. 
As extensively described in the Introduction, ligand-mediated FGFR activation promotes 
regulated receptor endocytosis from the cell surface and subsequent trafficking into the 
cell. Several aspects of FGFR endocytosis and trafficking have been studied by several 
groups, but the conclusions reached appear to be quite contradictory. Further, all 
previous reports regarding endocytosis and the trafficking route of FGFR employed fixed, 
cell-based techniques and limited their analysis to antibody-labelling methods. In the 
present study, practical and efficient tools were developed to visualize in real-time the 
entire sequence of stages of trafficking of FGFR2, by combining advanced optical 
microscopy technique with fluorescent tagged proteins expressing cells. The live-cell 
imaging assays used in this study are described in the next section; their contribution lies 
in allowing visualization of spatial and temporal endocytic dynamics of the receptor 
within a live biological context.    
3.2.1 Confocal live-cell imaging of FGFR trafficking 
Confocal microscopy is an optical imaging technique that allows visualization deep within 
living cells or tissues and, more importantly, the collection of high-resolution optical slices 
of the object, from which three-dimensional representation of the sample can be 
created. The principle of a confocal microscope, as well as its major advantage over a 
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conventional microscope, is the use of a spatial filtering strategy to remove out-of-focus 
light from the image (Figure 3.3A). The presence of suitably positioned pinholes allows 
only the light from the focal plane to reach the detector, resulting in sharply defined 
images. Other key advantages of confocal over conventional microscopes include: higher 
level of sensitivity, due to the ability to capture images over time via highly sensitive light 
detectors; reduced invasiveness, due to reduction of light-scattering artefacts; 
employment of high-power laser illumination; and digital 3-D reconstructions of the 
sample.  
Confocal microscopy is extensively used in cell biology and, in combination with 
development of fluorescent fusion proteins, it has become a very effective tool in the 
study of dynamic processes in living cells, such as actin remodelling and receptor 
trafficking. To monitor in real-time the dynamics of activated FGFR2 trafficking, time-
lapse confocal imaging of FGFR2-GFP expressing HeLa cells, was performed (Figure 3.4A). 
The flat morphology, wide cytoplasmic area, and ease of culture make HeLas a preferred 
cell line for live-cell imaging experiments over HEK-293T cells. To create a biological 
system that retains physiological conditions, cells were kept at 37°C while on the stage of 
the microscope and imaged repeatedly at deﬁned time points (1 frame/minute) 
immediately upon addition of FGF2 ligand. Figure 3.4A shows still frames captured from a 
confocal time-lapse of live FGFR2-GFP expressing HeLa cells stimulated with FGF2. In the 
absence of ligand stimulation (time 0), FGFR2 exclusively localises at the cell surface and 
no vesicle is detectable within the cell. A few small FGFR2-containing vesicles begin to 
appear from the inner surface of the plasma membrane at a very early time point, 
typically beginning 5 minutes after FGF2 addition (magnification), demonstrating that the  
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Figure 3.3. Advanced optical microscopy techniques used in this study 
A. By employing spatial filtering techniques (pinholes), a confocal microscope 
allows only the light from the “in-focus” focal plane to reach the detector, 
removing any out-of-focus light emitted by the sample. This results in collection of 
high-resolution optical slices of the specimen.  B. In epifluorescence microscopy, 
the incident light hits the coverslip/sample interface with a zero degree angle 
against the vertical axis (dashed line) and is entirely refracted into the medium, 
resulting in excitement of all parts of the specimen simultaneously.  C. When the 
refractive index of the sample (n2) is less than that of the coverslip (n1) and the 
angle of incidence of light (θ) is wider than the critical angle (θc = 63.95° in the case 
of glass/water interface), the excitation beam is entirely reflected. Complete 
internal reflection generates an evanescent wave into the sample that extends 
only a few hundred nanometres, exciting fluorophores within a restricted 
specimen region immediately adjacent to the coverslip/sample interface. 
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process of ligand-mediated receptor activation occurs rapidly, within few minutes. This is 
consistent with similar studies on the kinetics of internalisation of EGFR, another 
important member of the RTK family, which is observed to undergo internalisation 
already at 5 minutes following ligand incubation (Schmidt-Glenewinkel et al. 2009). As 
FGF2 stimulation time increases, vesicles pinch off from the plasma membrane and are 
released into peripheral cytoplasmic regions, which correspond to early endosomal 
compartments (as clearly demonstrated later in this chapter). Finally, at late time points 
following ligand stimulation, FGFR2 is nearly undetectable at the cell surface, as its 
localisation shifts toward perinuclear compartments. The dynamic of internalisation of 
FGFR2 was subsequently quantified from the imaging data (Figure 3.4B). The sum of the 
pixel intensity value of FGFR2-GFP within the plasma membrane associated region of the 
cells was calculated for each frame of the time-lapses and plotted against time of 
incubation with FGF (quantification procedures are explained in more detail in the 
Methods, Section 2.7.1 Receptor trafficking assay). Consistent with the imaging data, the 
resulting plot reveals an initial latent phase of 5–7 minutes, in which the FGFR2-GFP 
fluorescent signal remains associated with the plasma membrane region. This 
corresponds to the phase during which the receptor recognizes and associates with the 
ligand and vesicles begin to form. With time, fluorescence signals decrease due to 
receptor internalisation, and reaches minimum value at 30 minutes, when the entire pool 
of surface-bound receptors is internalised and redistributed within intracellular 
compartments.    
The kinase activity of FGFR seems to play a key role in receptor internalisation. This is 
demonstrated, for example, by the observation that mutant receptors with inactive  
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Figure 3.4. Live-cell confocal microscopy analysis of FGFR2 trafficking 
A. Selected frames from a confocal time-lapse of live HeLa cells expressing FGFR2-GFP 
and stimulated with FGF2. Prior to ligand stimulation (0 min FGF2), FGFR2 
predominantly localises at the cell surface. Following FGF2 addition, the first receptor-
containing vesicles begin to form and to invaginate from the plasma membrane (5 
minutes, magnification). At late time points after ligand stimulation, FGFR2 is 
redistributed away from the cell periphery and targeted to peri-nuclear 
compartments. Scale bars = 10 µm.  B. The time-lapse experiment shown in (A) was 
performed in 14 cells and the FGFR2-GFP pixel intensity within the plasma membrane 
(PM) region was calculated (as described in Methods) for each time point and plotted 
as a function of time. A photo-bleaching control curve was obtained from cells 
expressing FGFR2-GFP and imaged without FGF2 stimulation (mean ± SEM). 
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kinase, such as the FGFR1 K514A mutant, are unable to internalise properly (Sorokin et al. 
1994). To confirm that the kinase activity of FGFR2 is required for receptor internalisation 
to occur, FGFR2-GFP expressing HeLa cells were treated with the SU5402 compound and 
receptor trafficking was assessed using the above-described live-cell imaging assay. 
SU5402 is a potent inhibitor of FGFR kinase activity, with an IC50 value of 0.03 µM for 
FGFR1, and exerts its function by occupying the adenine binding site of ATP with the 
indolin-2-one core (Mohammadi et al. 1997). As shown in Figure 3.5, following treatment 
with SU5402 inhibitor, the presence of ligand does not alter localisation of FGFR2, which 
remains associated with the plasma membrane even after 30 minutes of stimulation, 
demonstrating that kinase activity of FGFR2 is necessary for receptor internalisation. 
3.2.2 Total internal reflection fluorescence live-cell imaging of FGFR2 dynamics at 
plasma membrane   
Total internal reflection fluorescence (TIRF) microscopy is a widely used mode of 
fluorescence light microscopy. Developed by Daniel Axelrod at the University of Michigan 
in the early 1980s, TIRF is a powerful method for visualizing processes within membranes 
of living cells. TIRF employs an evanescent wave generated at the interface between two 
transparent media with different refractive indices, when the incident light travels at an 
angle greater than the critical angle and undergoes total reflection (Figure 3.3C). The 
evanescent wave exponentially decays with distance to the interface, extending only a 
few hundred nanometres into the sample, resulting in excitation of fluorophores in 
proximity to the coverslip. This generates images both with high signal-to-noise ratio, as 
fluorophores in the rest of the cell are not excited, and high axial resolution (on the order  
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Figure 3.5. FGFR2 kinase activity is required for receptor internalisation 
A. HeLa cells transiently transfected with FGFR2-GFP and incubated for 5 minutes in 
the presence (lower panels) or absence (control, upper panels) of SU5402 and imaged 
in confocal microscopy for 30 minutes. The first (left panels) and the last frame (right 
panels) of the time-lapse are shown, corresponding to the situations before and after 
FGF2 treatment, respectively. While in control cells activated FGFR2 undergoes 
efficient internalisation from the plasma membrane, treatment with the inhibitor of 
FGFR kinase activity entirely prevents receptor internalisation. Scale bars = 10 µm.  B. 
The experiment in A was performed in 8 cells and the FGFR2-GFP intensity in the PM 
region of the cells was quantified (as described in Methods) for each frame of the 
time-lapses and plotted as a function of time (mean ± SEM). 
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of 100 nanometres), allowing direct, time-resolved visualization of membrane-associated 
processes such as endocytosis, cytoskeletal dynamics, and cell adhesion. In this study, 
TIRF microscopy was employed to monitor dynamic processes involving FGFR2 at the 
plasma membrane, such as clustering of activated receptor or colocalisation with plasma 
membrane endocytic markers, as well as to visualize individual endocytic events 
occurring at the cell surface.  
A preliminary analysis of the dynamics of activated FGFR at the plasma membrane was 
performed by imaging in TIRF microscopy FGFR2-GFP expressing HeLa cells before and 
after stimulation with FGF2. As depicted in Figure 3.6 (lower panels), in the absence of 
ligand, FGFR2-associated fluorescence appears uniformly diffuse over the cell surface, 
whereas upon stimulation for 15 minutes, the receptor appears to be redistributed into 
spots. This suggests that ligand-mediated activation of FGFR2 induces receptor clustering 
at the cell surface, a phenomenon already described for many other membrane-bound 
receptors and thought to correlate with the activation state of the receptor itself (Care 
and Soula 2011, Nagy et al. 1999).  
The same cells were also simultaneously imaged in epifluorescence microscopy. This is 
the most conventional and common fluorescence set-up, so called because it employs an 
episcopic light to illuminate the sample and because it excites all parts of the specimen 
simultaneously (Figure 3.3B). Consistent with the TIRF data, cells imaged in 
epifluorescence prior to stimulation showed diffuse FGFR-associated fluorescence at the 
plasma membrane, which after FGF addition assumed a heterogeneous punctuate 
distribution (Figure 3.6, upper panels). 
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Figure 3.6. Clustering of active FGFR2 at plasma membrane 
Live-cell epifluorescence (upper panels) and TIRF (lower panels) imaging of 
FGFR2-GFP expressing HeLa cells before and after FGF2 stimulation. In 
absence of ligand, FGFR2 localises at the cell surface, where it appears 
uniformly distributed. The presence of FGF2 induces heterogeneous 
redistribution of receptor into punctuate spots on the plasma membrane, 
suggesting that multiple active FGFR2 form clusters in response to ligand 
stimulation. Scale bars = 10 µm.     
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3.2.3 Conclusion 
The combination of advanced optical microscopy techniques with the use of fluorescent 
fusion proteins has proven to be a powerful tool for the study in real-time the dynamics 
of FGFR2 endocytosis and trafficking within a live biological context. Ligand-dependent 
internalisation and intracellular trafficking of FGFR2 were investigated using confocal 
microscopy, allowing high-resolution, time-resolved optical imaging. Ligand stimulation 
was shown to induce rapid internalisation of FGFR2, preceded by a latency period of 7 
minutes, at which time the receptor recognises and associates with ligand, and 
endocytosis begins. The first receptor-containing vesicles form at 5 minutes after FGF2 
addition, and at 15–20 minutes FGFR2-GFP fluorescence is homogeneously distributed 
between plasma membrane and intracellular compartments. At late time points after 
ligand stimulation, the entire pool of surface-bound receptor is internalised and targeted 
to perinuclear compartments. 
The first key step in the pathway initiated by FGFR includes trans-phosphorylation events 
mediated by the kinase domain of the receptor. Here, kinase activity of FGFR2 was 
demonstrated to play a critical role in receptor internalisation, since SU5402, a potent 
inhibitor of FGFR kinase activity, completely prevented FGF2-dependent internalisation. 
Finally, live-cell TIRF microscopy was employed to investigate the dynamics of activated 
receptor at the plasma membrane. Ligand stimulation was shown to induce redistribution 
of FGFR2-GFP into heterogeneous punctuate spots, suggesting that, similar to other 
members of the RTK family (Abulrob et al. 2010), FGFR2 clusters at the plasma membrane 
in response to ligand stimulation.  
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By altering receptor density at the cell surface, this process may have profound effects on 
the activation state of FGFR2. For example, it may contribute to initiation of the 
intracellular signalling cascade by concentrating active receptors within specific 
membrane domains enriched in signalling molecules. Or it could strengthen receptor 
activation by physically recruiting multiple receptors together and enabling them to 
trans-phosphorylate and activate each other.       
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3.3 Pathway for internalisation of FGFR2 
Similar to other members of RTK family, following ligand binding and receptor activation, 
FGFRs undergo regulated endocytosis from the plasma membrane. Multiple pathways 
have been implicated in the internalisation of FGFRs, including both clathrin-mediated 
and caveolar endocytosis. Additionally, few investigators have observed involvement of 
pathways that proceed independently of clathrin and caveolins. Thus, identification of 
the route of entry for FGFRs into the cell remains controversial. One aim of this study is to 
document the endocytic pathway(s) by which FGFR2 is internalised and trafficked during 
the early phases of receptor activation.   
3.3.1 FGFR2 is internalised through dynamin-dependent endocytosis 
The literature has described an increasing variety of pathways that mediate the uptake of 
transmembrane receptors; they differ in the protein machinery involved, the cargo 
protein selected, and the intracellular route chosen. The best characterised route of entry 
for RTKs is clathrin-mediated endocytosis (CME). Through CME, several receptors 
(including epidermal growth factor receptor and transferrin receptor), along with their 
ligands, are packaged and transported into clathrin-coated vesicles (CCVs). A network of 
specific adaptor and accessory proteins coordinates formation of this class of vesicles, 
including the GTPase dynamin, which mediates the scission of the vesicles from the 
plasma membrane and their release into the cytoplasm. A number of pathways that 
proceed independently of clathrin have also been described. Among these, endocytosis 
via caveolae seem to impart a major contribution to the internalisation process for 
several RTKs. Even though most aspects of endocytosis via caveolae remain poorly 
understood, dynamin has also been implicated as a membrane scission protein in 
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caveolar endocytosis (Henley et al. 1998). The observation that not all receptor 
endocytosis is blocked by overexpressing a GTPase-inactive form of dynamin2 or by using 
a small-molecule inhibitor of dynamin GTPases, revealed the existence of other pathways 
implicated in RTK endocytosis that are dynamin- (and therefore clathrin- and caveolin-) 
independent. These include processes such as micropinocytosis or the Arf6 and 
GEEC/CLIC-dependent pathways (Mayor and Pagano 2007).  
Both the size of the vesicles and the dynamic of formation from the plasma membrane 
observed in the FGFR2 trafficking assays (Figures 3.4-3.6), suggest that FGFR2 can be 
trafficked via a canonical pathway of endocytosis. To unequivocally identify the path of 
entry for FGFR2, first the involvement of dynamin activity in this process was assessed. A 
recently developed small-molecule inhibitor of dynamin GTPases (Dynasore) (Macia et al. 
2006) was used to block any dynamin-dependent mechanism of endocytosis in HeLa cells, 
and the effect on FGFR2 trafficking was then investigated. To pre-emptively verify the 
activity of Dynasore in the cell system, its effect on the uptake of transferrin was 
examined. Transferrin, along with its receptor, enters cells constitutively by clathrin-
mediated endocytosis, a process which is, therefore, entirely dependent on dynamin 
activity. Fluorescently labelled (red) transferrin was incubated with HeLa cells at 37°C and 
allowed to internalise for 15 minutes in the presence or absence (control) of Dynasore. 
Cells were then acid-washed twice to remove transferrin still bound at the cell surface, 
and transferrin uptake was measured. While in control cells transferrin undergoes 
efficient endocytosis and traffics to perinuclear compartments, incubation with Dynasore 
completely blocks uptake and subsequent intracellular accumulation of the ligand (Figure 
3.7A). By measuring the integrated intensity of internalised transferrin inside 25–30 cells, 
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the inhibitory effect of Dynasore on transferrin was quantified, revealing a significant 
reduction (ca 50%) of internalisation (Figure 3.7B). 
After validating its efficacy in HeLa cells, Dynasore treatment was used in combination 
with the previously described trafficking assay to investigate the role of dynamin in 
internalisation of FGFR2. HeLa cells transiently expressing FGFR2-GFP were incubated in 
the presence or absence (control) of Dynasore for 30 minutes, then imaged in live-cell 
confocal microscopy for an additional 30 minutes upon FGF2 stimulation. The first and 
the last frames from a selected time-lapse are shown in Figure 3.8A. In control cells, 
FGFR2 efficiently undergoes ligand-dependent endocytosis from the plasma membrane 
(upper panels). However, when dynamin activity is inhibited, FGFR2 internalisation is 
entirely blocked and receptor redistribution away from the cell surface does not occur 
(lower panels). Interestingly, the endocytosis process seems to initiate properly upon 
ligand addition, as shown by formation of FGFR2-containing vesicles that invaginate from 
the plasma membrane (high-magnification images). Although closer analysis is necessary 
for confirmation, the forming vesicles seem to fail to leave the plasma membrane and, 
even upon longer stimulation times (30 minutes FGF2), they still appear localised at the 
cell periphery, consistent with a defect in the vesicle scission event due to inhibition of 
GTPase dynamin activity. Quantification analysis confirms that impairment of dynamin 
activity significantly reduces FGFR2 endocytosis, as clearly shown by the flat kinetic curve 
observed in the Dynasore treatment condition (Figure 3.8B). Thus, these results 
demonstrate that active FGFR2 enters cells via a dynamin-dependent pathway.  
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Figure 3.8. FGFR2 is internalized through dynamin dependent endocytosis 
A. HeLa cells transiently transfected with FGFR2-GFP and incubated for 30 minutes in the 
presence (lower panels) or absence (control, upper panels) of Dynasore and imaged in 
confocal microscopy for 30 minutes. Three frames of a selected time-lapse are shown, 
corresponding to conditions before, and 15 and 30 minutes after FGF2 treatment. While 
in control cells activated FGFR2 undergoes efficient internalisation from the plasma 
membrane, treatment with the dynamin inhibitor entirely blocks receptor endocytosis. 
Scale bars = 10 µm.  B. The experiment in A was performed in 14 cells and the FGFR2-GFP 
intensity in the PM region of the cells was quantified (as described in Methods) for each 
frame of the time-lapses and plotted as a function of time (mean ± SEM). 
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3.3.2 FGFR2 is internalised through clathrin-dependent endocytosis 
Having established the involvement of dynamin in the internalisation of FGFR2, the next 
step was to further focus the analysis and identify the specific pathway that mediates 
endocytosis of FGFR2. As mentioned above, GTPase dynamin has been implicated as a 
mediator of vesicle scission events in multiple endocytosis pathways. Among these, the 
best-characterised are CME and entry via caveolae. To assess whether activated FGFR2 
enters cells through clathrin or caveolae (or both), each of the endocytosis pathways was 
selectively inhibited via a small interference RNA (siRNA)-based strategy, and the effect 
on FGFR2 internalisation was examined. Selective blocking of CME was obtained by 
employing a synthetic siRNA sequence specific to α-adaptin (Motley et al. 2003), a key 
component of the clathrin-mediated endocytosis machinery. To demonstrate the 
effectiveness of α-adaptin siRNA treatment in inhibiting the CME process, the effect on 
uptake of transferrin, which is a specific marker of clathrin-mediated endocytosis 
(Hanover et al. 1984), was evaluated. As depicted in Figure 3.9A, HeLa cells with down-
regulated α-adaptin expression show low levels of intracellular transferrin when 
compared to scrambled siRNA (control) treated cells, confirming that α-adaptin siRNA 
treatment results in potent inhibition of CME. Quantification analysis of transferrin 
fluorescence intensity reveals a statistically significant reduction (88%) of transferrin 
internalisation in α-adaptin siRNA treated cells (Figure 3.9B). Selective inhibition of 
caveolar endocytosis was instead obtained by using a siRNA against caveolin1 (Li W. et al. 
2012), which has been shown to be essential for caveolae formation (Rothberg et al. 
1992). Similar to the effect observed in α-adaptin siRNA treated cells, HeLa cells 
transfected with caveolin1 siRNA showed a significantly reduced uptake of cholera toxin  
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Figure 3.9. Silencing α-adaptin subunit of AP2 complex or caveolin1 expression leads to 
significant reduction of transferrin or cholera toxin B uptake, respectively 
A, C. HeLa cells treated with either alpha-adaptin or caveolin1 siRNA were incubated 
respectively with fluorescent-tagged transferrin or cholera toxin B, then fixed and analyzed 
in epifluorescence microscopy. siRNA-mediated downregulation of alpha-adaptin 
expression clearly prevents transferrin uptake and redistribution to intracellular peri-
nuclear compartments (A). Similarly, silencing of caveolin1 gene results in inhibition of 
cholera toxin B internalization (C). Scale bars = 10 µm.  B, D.  The experiments in A and C 
were performed in 24 and 14 cells, respectively, and transferrin/cholera toxin B 
fluorescence intensity was quantified (mean ± SEM) (*, p < 0.05; **, p < 0.01; ***, p < 
0.001).  E. Western blot analysis of lysates from HeLa cells treated with either alpha-
adaptin or caveolin1 siRNA and probed with anti alpha-adaptin or anti-caveolin1 antibody.  
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B sub-unit (CTxB), a conventional marker of caveolar endocytosis (Pelkmans et al. 2001), 
demonstrating that downregulation of caveolin1 is an effective strategy to inhibit 
caveolar endocytosis (Figures 3.9C and 3.9D). Finally, although both siRNA sequences 
employed in this work have been validated in published studies (Li W. et al. 2012, Motley 
et al. 2003, Rappoport and Simon 2008), western blot analysis confirmed potent and 
selective silencing of both α-adaptin and caveolin1 expression by the respective siRNAs, 
with no effect on negative control proteins (Figure 3.9E).  
These inhibitory strategies were used in live-cell imaging studies to identify the 
endocytosis pathway for FGFR2. HeLa cells expressing FGFR2-GFP and treated either with 
α-adaptin or caveolin1 siRNA were imaged in confocal microscopy for 30 minutes upon 
stimulation with FGF2. In addition, a scrambled siRNA, targeting a nonsense sequence, 
was used as negative control, to discount any indirect effects on FGFR2 trafficking that 
may result from the siRNA delivery method. As shown in Figure 3.10A, in control 
condition, the receptor undergoes internalisation from the plasma membrane and 
eventually traffics to perinuclear compartments (upper panels), demonstrating that 
scrambled siRNA exhibited no suppressive effect on receptor trafficking. Conversely, α-
adaptin siRNA treatment entirely prevented receptor endocytosis, and active FGFR2 
remained associated with the cell surface even 30 minutes following FGF2 treatment 
(lower panels). This is further confirmed by quantification analysis of receptor 
internalisation (Figure 3.10B), which shows that approximately 80% of the total pool of 
FGFR2 is still localised at the plasma membrane 30 minutes after ligand stimulation, and 
by the flat kinetic for FGFR2 uptake in α-adaptin siRNA treated cells in comparison with 
scrambled siRNA (control) treatment cells. In contrast, downregulation of caveolin1  
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Figure 3.10. Active FGFR2 enters cells through clathrin-mediated endocytosis 
A. HeLa cells co-transfected with FGFR2-GFP and alpha-adaptin siRNA (or 
scrambled siRNA as control) were imaged in confocal microscopy for 30 minutes 
following stimulation with FGF2. The first (left panels) and the last frame (right 
panels) of selected time-lapses are shown, corresponding to conditions before 
and after FGF2 treatment. Silencing alpha-adaptin expression potently blocks 
FGFR2 endocytosis and consequent redistribution of receptor away from the cell 
periphery. Scale bars = 10 µm.  B. The experiment in A was performed in 13 cells 
and FGFR2-GFP intensity in the PM region of the cells was quantified (as described 
in Methods) for each frame of the time-lapses and plotted as a function of time 
(mean ± SEM). 
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Figure 3.11. FGFR2 endocytosis does not occur via caveolae 
A. HeLa cells co-transfected with FGFR2-GFP and caveolin1 siRNA (or scrambled siRNA as 
control) were imaged in confocal microscopy for 30 minutes following stimulation with 
FGF2. The first (left panels) and the last frame (right panels) of selected time-lapses are 
shown, corresponding to conditions before and after FGF2 treatment. Downregulating 
of caveolin1 expression has no effect on FGFR2 endocytosis, even at longer stimulation 
times, demonstrating that FGFR2 is not internalised through caveolae. Scale bars = 
10 µm.  B. The experiment in A was performed in 11 cells and FGFR2-GFP intensity in the 
PM region of the cells was quantified (as described in Methods) for each frame of the 
time-lapses and plotted as a function of time (mean ± SEM). 
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expression had no effect on FGFR2 endocytosis (Figure 3.11A) and the kinetic curves for 
FGFR2 internalisation were similar in absence (control) or presence of caveolin1 (Figure 
3.11B). Taken together, these results show that activated FGFR2 enters cells via CME, but 
not through caveolae.  
3.3.3 Active FGFR2 colocalises with clathrin at the plasma membrane but not with 
caveolin1  
In Section 3.2.2, TIRF live-cell imaging to examine FGFR2 dynamics at the plasma 
membrane showed FGFR2 to form clusters at the plasma membrane in response to ligand 
stimulation just prior to internalisation. This process is conserved across many different 
RTKs and ensures that multiple ligand-receptor complexes are concentrated in the same 
coated pits at the cell surface, and ultimately enclosed and transported into the same 
coated vesicle. Having demonstrated that endocytosis of FGFR2 proceeds via clathrin, it 
can be speculated that receptor clustering on the  cell surface specifically occurs at sites 
of CME (and conversely not at caveolae membrane domains). To verify this, colocalisation 
of activated FGFR2 with known markers for each of these two endocytic pathways was 
studied. Clathrin and caveolin1, which constitute the vesicle coat proteins, respectively, in 
clathrin-mediated and caveolar endocytosis (Pearse 1976, Rothberg et al. 1992), have 
been extensively employed as specific markers for these two internalisation pathways 
(Damm et al. 2005, Engqvist-Goldstein et al. 2001). To further validate use of the two 
proteins as markers for CME and entry via caveolae, their distribution at the plasma 
membrane, along with activated EGFR was investigated by employing dual-colour TIRF 
microscopy. The uptake of EGFR has been widely studied and it often provides a model 
for the analysis of receptor-mediated endocytosis. Despite controversial findings about 
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the specific route of entry, recent works performed in live-cell systems confirmed that 
EGFR enters cells via clathrin-coated pits, whereas caveolae seem not to be involved in 
this process (Kazazic et al. 2006, Rappoport and Simon 2009). Consistent with these 
observations, when HeLa cells co-expressing EGFR-GFP and either clathrin-dsRed or 
caveolin1-mRFP fusion proteins were stimulated with 100 ng/ml EGF for 15 minutes, 
striking colocalisation of activated receptor with clathrin was observed, while no 
colocalisation with caveolin1 was found (Figure 3.12). This result confirms that activated 
EGFR clusters at the plasma membrane only at sites of clathrin-mediated endocytosis 
(marked by the presence of clathrin), and not at sites of caveolar endocytosis (marked by 
caveolin1), further validating the use of these two proteins as markers for the respective 
endocytosis pathways.  
Similar to the EGFR studies, a series of colocalisation analyses were performed between 
active FGFR2 and either clathrin or caveolin1 to investigate the distribution of FGFR2 at 
the plasma membrane at sites of clathrin-mediated and caveolar endocytosis, 
respectively. HeLa cells co-transfected with FGFR2-GFP and clathrin-dsRed or caveolin1-
mRFP fusion proteins were stimulated with FGF2 for 15 minutes at 37°C to allow ligand 
binding and receptor clustering. Cells were then fixed and imaged in TIRF microscopy. An 
image that represents the phenotype of most of the cells was selected and is represented 
in Figure 3.13. A high degree of colocalisation (yellow) is detectable between active 
FGFR2 and clathrin (Figure 3.13A, upper panels), further confirming the potential for 
clathrin-mediated endocytosis of FGFR2. Despite the significant overlap, a fraction of 
clathrin can be detected that does not colocalise with FGFR2, consistent with the 
involvement of clathrin in endocytosis of a variety of other surface receptors. Conversely,  
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Figure 3.12. Activated EGFR colocalizes with clathrin at the plasma membrane but 
not with caveolin1 
A. HeLa cells co-expressing EGFR-GFP and either clathrin-dsRed (upper panels) or 
caveolin1-mRFP (lower panels), were incubated with EGF for 30 minutes at 37°C, 
then fixed and analysed in dual-colour TIRF microscopy. Overlap of EGFR and 
clathrin/caveolin1 appears in yellow (merge). High-magnification of selected regions 
from the cells shows clear colocalisation of EGFR with clathrin but not with 
caveolin1. Scale bars = 5 µm.  B. Quantification of colocalisation was performed by 
analyzing the overlapping of clathrin/cavolin1 and EGFR spots. A control of random 
colocalisation is also shown (mean ± SEM, n = 12 cells) (*, p < 0.05; **, p < 0.01; ***, 
p < 0.001).   
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every single FGFR2 spot seems to overlap with clathrin, further suggesting that CME is the 
only route of entry for FGFR2. This conclusion is confirmed by the absence of any overlap 
between active FGFR2 and caveolin1 at the plasma membrane (lower panels), 
demonstrating that caveolae are not involved in internalisation of FGFR2.   
Quantitative analysis of colocalisation was also performed. Each FGFR, clathrin and 
caveolin1 spot was identified and a circle drawn around it. Two spots were identified as 
colocalising when most of the fluorescence intensity within the circular regions fit in both 
the red and green channels. Analysis of 25 cells revealed that there was 55% 
colocalisation of FGFR2 with clathrin, whereas colocalization with caveolin1 resulted in 
less than 11%. For each experiment, a control of random colocalization was also 
determined by analyzing a number of circular regions that did not contain FGFR2. As 
depicted in the graph in Figure 3.13B, this value was statistically indistinguishable from 
the colocalisation value calculated between FGFR2 and caveolin1. Taken together, these 
data demonstrate that, upon ligand-mediated activation, FGFR2 colocalises with clathrin 
at the plasma membrane but not with caveolin1, further confirming that FGFR2 is 
internalised through clathrin-mediated endocytosis. 
3.3.4 Activated FGFR clusters at sites of pre-formed, clathrin-coated pits 
CME machinery concentrates receptors, together with other adaptor and accessory 
proteins, at specific domains of the plasma membrane. These are sites where clathrin 
polymerises and where membrane invaginates, eventually generating a vesicle. Even  
 
 
 124 
 
 
 
 
 
 
 
 
 
Figure 3.13. Activated FGFR2 colocalises with clathrin at the plasma membrane but 
not with caveolin1 
A. HeLa cells co-expressing FGFR2-GFP and either clathrin-dsRed (upper panels) or 
caveolin1-mRFP (lower panels), were incubated with FGF2 for 30 minutes, then fixed 
and analysed in dual-colour TIRF microscopy. High-magnification of selected regions 
from the cells shows overlay of green and red channels in yellow (merge), revealing 
that active FGFR2 colocalises with clathrin at the cell surface but not with caveolin1. 
Scale bars = 5 µm.  B. Quantification of colocalisation was performed by analyzing the 
overlapping of clathrin/cavolin1 and FGFR2 spots. A control of random colocalisation is 
also shown (mean ± SEM, n = 12 cells) (*, p < 0.05; **, p < 0.01; ***, p < 0.001).   
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though the different stages of clathrin-mediated endocytosis have been extensively 
described, the exact order of recruitment of different proteins at the sites of CCV 
formation remains unclear. The striking colocalisation between FGFR2 and clathrin 
described in Subsection 3.3.3 can be explained by three non-mutually exclusive 
hypotheses: (1) the receptor can be recruited to sites of pre-formed clathrin at the 
plasma membrane; (2) CCPs can form where the receptor had previously clustered; and 
(3) clathrin and FGFR2 can be recruited simultaneously. To determine which of the three 
hypotheses best describes the dynamics of recruitment of FGFR2 and clathrin at sites of 
CME, HeLa cells co-expressing clathrin-dsRed and FGFR2-GFP were imaged in dual-colour 
TIRF microscopy upon FGF2 stimulation. The appearance of FGFR2 spots on the TIRF field 
relative to the appearance of a colocalising clathrin spot (or vice versa) was analyzed. As 
shown in Figure 3.14A, in most of the events analyzed, FGFR2 clusters were observed to 
form at sites of pre-existing clathrin. Clathrin was almost always found to sit on the 
plasma membrane at sites where the receptor would subsequently be recruited (Figure 
3.14 A and B). A very small percentage (12%) of FGFR spots was also observed to appear 
simultaneously with clathrin. However, this could be due to the low time-resolution of 
the time-lapses, 1 frame/30 sec: the recruitment of clathrin and receptor at sites of CME 
might be separated by only a few seconds, seeming simultaneous when watched with a 
frame rate of 1 frame/30 sec. Interestingly, similar recruitment dynamics have also been 
observed for EGFR (Rappoport and Simon 2009), suggesting that recruitment to pre-
existing CCPs could be a conserved mechanism across RTKs. 
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3.3.5 Conclusions         
The results presented in this chapter show that FGFR2 is internalised through clathrin-
mediated endocytosis. The first evidence of this came from analysis of the involvement of 
GTPase dynamin in the process of FGFR2 endocytosis. Treatment with the potent 
dynamin inhibitor Dynasore completely prevented receptor internalisation from the 
plasma membrane upon ligand stimulation, demonstrating that FGFR2 endocytosis 
occurs through a dynamin-dependent pathway. Two of the best characterized 
endocytosis pathways that are dynamin-dependent include clathrin-mediated and 
caveolar endocytosis. To assess whether activated FGFR2 enters cells through clathrin or 
caveolae, each of these endocytosis pathways was selectively inhibited by employing an 
RNAi-based approach. Silencing the expression of α-adaptin, a key component of CME 
machinery, resulted in impaired FGFR2 endocytosis. Conversely, silencing of caveolin1, 
the coat protein required for caveolar endocytosis, showed no effect on FGFR2 
internalisation. In addition, by employing TIRF microscopy, active FGFR2 was shown to 
colocalise with clathrin at the cell surface, but not with caveolin1. This indicates that in 
response to ligand stimulation, the receptor forms clusters at the plasma membrane, 
specifically at sites of clathrin-mediated endocytosis, and not at caveolae membrane 
domains, further confirming that that FGFR2 enters cells through clathrin-mediated 
endocytosis and not through caveolae. Finally, the dynamics of recruitment of FGFR2 and 
clathrin at sites of CME was investigated and shown to be similar to that already 
described for other RTK family members: activated receptor accumulates at spots of 
clathrin that already existed prior to FGF stimulation.    
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3.4 FGFR signalling promotes CME through Src and Eps8 
Internalisation and intracellular trafficking of RTKs through CME depend on their 
concentration in clathrin-coated pits on the plasma membranes. Therefore, the 
abundance of available clathrin on the cell surface is an important determinant for 
regulation of endocytosis. This assumption is further supported by a number of recent 
studies that directly associate activation of RTKs with an increase in plasma membrane 
clathrin-coated pits with a subsequent effect on receptor endocytosis. Wilde et al., for 
instance, showed that activated EGFR causes redistribution of clathrin to the cell 
periphery and, consequently, promotes EGFR uptake (Wilde et al. 1999). Similarly, nerve 
growth factor (NGF) has been demonstrated to signal through its receptor (Trk) to induce 
an increase of clathrin at the plasma membrane and promote clathrin-mediated 
endocytosis (Beattie et al. 2000). Even though the exact role of this process in the context 
of RTK has not yet been clarified, it may represent an important regulatory process by 
which receptors can control the pool of clathrin on the plasma membrane available for 
endocytosis, therefore modulating internalisation of receptors themselves. One of the 
goals of this project is to investigate whether a similar regulatory mechanism also 
controls endocytosis of FGFRs and to identify the effectors involved in this regulatory 
process. 
3.4.1 FGFR2 activation induces recruitment of clathrin at the cell surface and promotes 
CME   
To assess whether FGFR stimulation also caused clathrin redistribution, HeLa cells 
expressing FGFR2-GFP and clathrin-dsRed were imaged in TIRF microscopy before and 30 
minutes after FGF2 stimulation. As depicted in Figure 3.15A, after FGF2 treatment there 
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was a marked increase in clathrin puncta at the plasma membrane. This increase was 
quantified in 30 cells (from 3 different experiments): for each cell imaged, a line was 
manually drawn around the external cell perimeter and the number of clathrin spots per 
surface area was calculated. In FGF2 treated cells, the average number of puncta per 
surface area was 203% of the non-treated control cells, a statistically significant result (p 
= 0.001) (Figure 3.15B). These observations demonstrated that FGF2 stimulation 
promotes recruitment of new clathrin at the plasma membrane.  
To assess whether FGF2 signals through its receptor FGFR2 to induce this clathrin 
redistribution, cells were pre-treated with FGFR kinase inhibitor SU5402 and clathrin 
puncta were quantified before and after FGF2 stimulation, as described above. 
Quantification analysis is shown in Figure 3.15B and demonstrates that when receptor 
kinase activity is impaired, ligand stimulation fails to induce clathrin redistribution at the 
cell surface, indicating that FGF2 binds and activates FGFR2 to promote recruitment of 
new clathrin at the plasma membrane. Interestingly, the steady-state level of clathrin in 
non-stimulated cells does not appear to be altered by SU5402 treatment, suggesting that 
basal FGFR2 signalling does not regulate CME. 
The next step was to define the biological role of the increase of plasma membrane 
clathrin-coated pits induced upon FGF2 stimulation. One possible scenario is that this 
new pool of clathrin is recruited from the cytoplasm to the cell surface to be employed in 
receptor endocytosis. To verify this, HeLa cells cotransfected with FGFR2-GFP and 
clathrin-dsRed were imaged in live-cell TIRF microscopy at a rate of 5 frames/second for 
120 seconds before and 30 minutes after ligand addition. The density of endocytic events 
before and after FGF2 stimulation was quantified by counting the number of clathrin 
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spots disappearing from the TIRF field during each 120-second time-lapse. The analysis 
clearly showed a significant increment in the density of endocytosis events after FGF2 
treatment (Figure 3.16A), confirming that the clathrin-coated pits recruited at the cell 
surface following ligand stimulation were actively involved in clathrin-mediated 
trafficking.  
To further confirm this, the effect of FGF2 treatment on endocytosis of transferrin, a 
specific validated marker of clathrin-mediated endocytosis (Hanover et al. 1984), was 
examined. Unexpectedly, FGF2 stimulation did not result in an increase in transferrin 
uptake (Figure 3.16B), suggesting that the increased clathrin puncta undergoing 
endocytosis upon FGFR2 activation may represent a cargo-specific population of clathrin-
coated pits.  
Finally, to exclude that this effect was cell-line specific or due to overexpression 
conditions in our model system, similar studies were performed in cells endogenously 
expressing FGFR2, specifically LNCaps (Carstens et al. 1997). Even in the absence of 
expression of GFP-tagged FGFR2, FGF2 stimulation resulted in a similar increase in plasma 
membrane clathrin spot number (Figure 3.17).  
Thus, these data demonstrated that, similar to other members of the RTK family, 
activated FGFR2 promotes recruitment of new clathrin at the plasma membrane, which in 
turn is required for CME.   
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Figure 3.15. Activated FGFR2 signals through Src to promote an increase of CCPs at 
the plasma membrane 
HeLa cells transiently transfected with FGFR2-GFP and clathrin-dsRed, and pre-
incubated in the presence (or absence) of SU5402 or dasatinib were imaged in TIRF 
microscopy before and 30 minutes after ligand stimulation.  A. Incubation with FGF2 
induces a significant increase in the number of clathrin puncta at the plasma 
membrane. Scale bars = 5 µm.  B. Quantification analysis of clathrin spot number 
normalised to cell surface area for the conditions described above reveals that the 
FGFR2-dependent increase of clathrin at the plasma membrane is Src-dependent and 
requires the kinase activity of the receptor (mean ± SEM; n = 30 cells for each 
condition in (B) (*, p < 0.05; **, p < 0.01; ***, p < 0.001).   
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Figure 3.16. FGF2 treatment promotes clathrin-mediated endocytosis but does not 
result in an increase in transferrin uptake  
A. HeLa cells co-expressing FGFR2-GFP and clathrin-dsRed were imaged in live-cell TIRF 
microscopy at 37°C for 2 minutes (5 frame/sec) before and 30 minutes after FGF2 
stimulation. The experiment was performed in 24 cells and the total number of clathrin 
spots disappearing from the TIRF field was calculated, revealing a significant increment 
in the density of endocytosis events upon FGF2 addition.  B. FGFR2-GFP expressing HeLa 
cells were incubated with transferrin-AlexaFluor546 and either stimulated with FGF2 or 
non-stimulated (control). The experiment in A was performed in 49 cells and transferrin 
fluorescence intensity was quantified (as described in Methods), showing that FGF2 
stimulation does not induce an increase in transferrin uptake (mean ± SEM) (*, p < 0.05; 
**, p < 0.01; ***, p < 0.001)   
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3.4.2 FGF-dependent increase in CME is mediated by Src and Eps8    
After demonstrating that FGFR2 signalling has a direct effect upon endocytic machinery 
by inducing clathrin redistribution, the involvement of effector molecules with a role in 
this regulatory feedback was investigated. The protein kinase Src is one of the candidate 
molecules having specific function in this mechanism of regulation. Wilde et al. in fact 
identified Src as responsible for regulating the cellular distribution of clathrin upon EGFR 
activation (Wilde et al. 1999). In addition, recently, Src has clearly emerged as one of the 
key downstream effectors in the FGFR signalling cascade, with implications for its role as 
a regulatory factor in FGFR trafficking. To investigate the role of Src in FGFR-dependent 
redistribution of clathrin, HeLa cells co-expressing FGFR2-GFP and clathrin-dsRed were 
treated with the Src family kinase (SFK) inhibitor Dasatinib and imaged in TIRF microscopy 
before and 30 minutes after FGF2 stimulation. Quantification analysis of clathrin puncta 
(Figure 3.15B) revealed that Dasatinib treatment significantly inhibits the increment in 
clathrin spots number upon FGFR2 stimulation, demonstrating that SFKs play a role in this 
process. Interestingly, Dasatinib treatment did not cause complete inhibition of clathrin 
recruitment, and a partial increase in plasma membrane clathrin-coated pits (around 
30%) could still be observed. However, this result is consistent with the presence of 
alternative pathways downstream of FGFR2 that bypass Src involvement; thus, FGFR2 
appears to signal through both Src-dependent and Src-independent pathways to regulate 
plasma membrane distribution of clathrin. Further, the basal level of clathrin puncta in 
non-stimulated conditions does not appear to be altered by Dasatinib treatment, 
suggesting that Src activity is not required for constitutive endocytosis. 
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As discussed in Section 1.4.2, active Src plays a key role in regulating FGFR2 transport to 
and from the plasma membrane (Sandilands et al. 2007). In characterizing targets for Src 
kinase with a role in the regulation of FGFR signalling and trafficking, Cunningham et al. 
recently identified a set of putative proteins (Cunningham et al. 2010). Among these, the 
multifunctional scaffold protein Eps8 was particularly interesting, since it has been shown 
to participate in CME (Taylor et al. 2011), in EGFR trafficking and signalling (Lanzetti et al. 
2000), and in actin dynamics (Provenzano et al. 1998). Consistent with these observations 
and to further investigate the mutual relation between FGFR and Src, a series of TIRF 
studies was performed to assess whether Eps8, along with Src, was also responsible for 
regulating the distribution of clathrin upon FGFR2 activation. HeLa cells expressing 
FGFR2-GFP and clathrin-dsRed were treated with siRNA targeting Eps8, and the effect on 
FGF-dependent clathrin redistribution at the cell surface was examined. As depicted in 
Figure 3.18A, Eps8 silencing entirely prevented the increase in clathrin puncta at the 
plasma membrane upon FGFR activation. Importantly, the siRNA sequences used in this 
study were already employed and validated in the literature (Disanza et al. 2006). In 
addition, western blot analysis confirmed potent silencing of Eps8 expression without 
affecting the levels of negative control protein, tubulin (Figure 3.18B). Therefore, the 
recruitment of new clathrin at the plasma membrane is promoted by activated FGFR2 
signalling though Src and Eps8.  
Finally, to further confirm the role of Eps8 in CME, a series of biochemical studies were 
performed. Coimmunoprecipitation analyses revealed that Eps8 interacts with clathrin 
heavy chain, α-adaptin and dynamin2, all members of the endocytosis machinery 
(Doherty and McMahon 2009) (Figure 3.19A). Interestingly, similar results were also  
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Figure 3.19. Eps8 interacts with AP2, clathrin and dynamin. 
A. Cellular extracts from HeLa cells transiently overexpressing myc-Eps8 
(where indicated) were immunoprecipitated with anti-myc antibody, 
resolved by SDS-PAGE and analysed by immunoblotting for the levels of 
specified proteins.  B. Cellular extracts from HEK283T cells transiently 
transfected with myc-Eps8 (where indicated) were  stimulated or not with 
FGF2, immunoprecipitated with anti-myc antibody, resolved by SDS-PAGE 
and analysed by immunoblotting for the levels of specified proteins.  
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obtained in HEK293, the cell line used to originally identify the connection between FGFR, 
Src and Eps8 (Cunningham et al. 2010) (Figure 3.19B). These findings demonstrate that 
Eps8 is incorporated into an endocytic machinery together with other key proteins, 
further confirming its role during the early phases of FGFR2 trafficking.   
3.4.3 Conclusions 
In this chapter, a novel mechanism of regulation of FGFRs trafficking was described. Using 
high-resolution TIRF microscopy, FGF2 was shown to signal through FGFR2 regulation of 
clathrin redistribution at the cell surface. As shown in Figure 3.15, FGF stimulation is 
sufficient to induce an increase in CCPs at the plasma membrane, and this process 
appears to be dependent on FGFR2 kinase activity. Since a similar phenomenon was 
observed for other members of RTKs, including EGFR (Wilde et al. 1999), Trk (Beattie et 
al. 2000), and IR (Corvera 1990), this may represent a mechanism conserved within the 
RTK family. 
Clathrin exists as a heterogeneous population when in association with the plasma 
membrane: a small portion is actively involved in formation of clathrin-coated vesicles; 
the vast majority of clathrin, however, constitutes a static pool which is not immediately 
involved in CME (Rappoport et al. 2006). It is possible that the new clathrin recruited at 
the cell surface following FGFR2 activation may constitute the ‘dynamic’ pool. In such 
case, FGF-dependent activation of FGFR2 would result in an incremental CME process, 
generating a mechanism for regulating receptor trafficking. This hypothesis was validated 
by looking at the density of endocytosis events occurring at the cell surface upon FGF2 
stimulation. As illustrated in Figure 3.16A, FGFR2 activation increases not only the 
number of CCPs at the plasma membrane, but also the number of CME events, 
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demonstrating that downstream FGFR signalling has a direct effect on endocytosis 
machinery. Interestingly though, FGFR2 activation had no effects on transferrin uptake 
(Figure 3.17B), suggesting that the CCPs recruited upon FGFR2 activation may represent a 
cargo-specific population. Although further investigation is needed, these observations 
may imply that the route of entry for activated RTKs is a cargo-specific pathway, which 
would be an entirely new scenario in the context of receptor-mediated, clathrin-
mediated endocytosis. The results set forth in this chapter also show involvement of Src 
protein kinase in FGFR-dependent peripheral accumulation of clathrin. This finding is not 
surprising, as Src activity has already been implicated in the regulation of cellular 
distribution of clathrin upon activation of other growth factor receptors, such as EGFR.  In 
line with these observations, and given the key role that Src plays in the FGFR signalling 
pathway, inhibition of Src kinase activity was shown to prevent increase in CCP number 
following FGFR2 activation (Figure 3.15B).  
In a recent proteomic study (Cunningham et al. 2010), the scaffold protein Eps8 was 
identified as a target of Src kinase activity in response to FGFR2 activation. In the present 
study it was shown that Eps8, along with Src, plays a role in the FGFR2-dependent 
redistribution of CCPs at the cell surface, as downregulation of Eps8 expression by siRNA 
inhibits the increment of clathrin puncta at the plasma membrane (Figure 3.18). 
Furthermore, FGFR2 signalling through Src to Eps8 was shown to regulate distribution of 
CCPs at the plasma membrane and consequently to promote clathrin-mediated 
endocytosis. Finally, Eps8 was shown to interact with the CME machinery (Figure 3.19), 
further supporting its role in the early phases of FGFR2 endocytosis.  
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At present, the molecular mechanism by which Src and Eps8 mediate clathrin 
redistribution is not clear. As mentioned in the Introduction, Eps8 in the context of RTKs 
functions as scaffold protein for a number of signalling molecules, coordinating different 
signalling cascades. It would be interesting to determine whether regulation of clathrin 
redistribution observed upon FGFR2 activation also depends on additional signalling and 
adaptor molecules recruited by phosphorylated Eps8. In particular Rab5, whose function 
has already been associated with Eps8 (Lanzetti et al. 2000) is an interesting candidate, as 
it has been implicated in regulation of CME machinery (Bucci et al. 1992), and in the 
FGFR2 signal transduction pathway (Vecchione et al. 2007). 
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3.5 Regulation of FGFR2 trafficking and signalling through Src and Eps8 
As described in detail in Section 1.4.2, Src and RTKs, the non-receptor tyrosine kinase Src 
is one of the main effectors downstream of FGFR, and it has been implicated as a key 
regulatory factor with both positive and negative roles in activation and termination of 
FGFR signalling. In addition, the first line of evidence suggesting a role for Src in the 
regulation of FGFR trafficking recently came from Sandilands et al., in which the kinase 
was shown to also control the transport of FGFR to and from the plasma membrane 
(Sandilands et al. 2007). In such a scenario, it may be speculated that Src-dependent 
regulation of receptor trafficking can in turn affect downstream signalling output, and 
that Src may be a key intermediate that operates at the crossroads of signalling and 
trafficking of FGFRs. In this chapter, the involvement of Src activity in the regulation of 
endocytosis and trafficking of FGFR2 is further investigated, providing new supporting 
evidence for reciprocal crosstalk between FGFR2 signalling and trafficking. Further, given 
identification of Eps8 as a target of Src-mediated phosphorylation in the FGFR signalling 
cascade (Cunningham et al. 2010) and its function in clathrin-mediated endocytosis of 
FGFR2, the potential role of Eps8 in regulating FGFR2 signalling and the early phases of 
endocytic receptor trafficking was also investigated. 
3.5.1 Src kinase activity regulates early endocytic trafficking of FGFR2 
The data described in Section 3.4 suggest a role for Src in the early phases of FGFR2 
clathrin-mediated endocytosis. To further validate this observation, the effect of Src 
kinase activity inhibition on internalisation and trafficking of activated FGFR2 was studied. 
Chemical inhibition of Src activity was obtained using the selective Src family kinase (SFK) 
inhibitor Dasatinib (Lombardo L. J. et al. 2004), which has been previously shown to block 
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Src-mediated FGFR signalling and trafficking processes (Sandilands at al. 2007). In the 
presence of ligand, cells treated with the SFK inhibitor showed impaired receptor 
internalisation: following 30 minutes of stimulation, over 75% of the total amount of 
receptor was not endocytosed and still localised at the plasma membrane (Figure 3.20A 
and B). Src inhibition also affected the intracellular trafficking of FGFR2: higher 
magnifications of cells incubated with ligand for 30 minutes show that in Dasatinib 
treatment condition, the pool of internalised FGFR2 atypically and statically localises in 
peripheral compartments rather than in perinuclear regions, suggesting a role for Src in 
regulating early endocytic trafficking of activated FGFR2 (Figure 3.20A). To confirm these 
results, super-resolution confocal microscopy studies were also performed, providing 
detail at a resolution smaller than 50 nm. As shown in Figure 3.20C, super-resolution 
imaging of activated FGFR2-GFP in Dasatinib-treated cells revealed the clear presence of 
FGFR2-positive puncta localised in a peripheral endocytic compartment, confirming the 
role of Src in early endocytic trafficking of FGFR2. 
3.5.2 Role of Eps8 on endocytic trafficking of FGFR2  
Given the established role of Eps8 as a Src-dependent effector in FGFR signalling 
(Cunningham et al. 2010) and its importance in regulating redistribution of clathrin at the 
plasma membrane upon FGFR2 activation, the next step was to elucidate the role of this 
scaffold protein in FGFR2 trafficking. To do so, we monitored the effect of knocking down 
Eps8 gene expression on FGFR2 internalisation by using the established receptor 
trafficking assay. A new cell line with stable Eps8 shRNA expression was employed in 
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these studies. Although this Eps8 knock-down cell line was already validated in the 
literature (Disanza et al. 2006), western blot analysis was performed, confirming potent 
and selective silencing of Eps8 expression (Figure 3.21C). When FGFR2-GFP expressing 
Eps8 shRNA were stimulated with FGF2 ligand for 30 minutes, significant attenuation of 
receptor internalisation and trafficking toward perinuclear regions was observed (Figure 
3.21A). Interestingly, similar to Src inhibitor treated cells, FGFR2 containing vesicles that 
did not leave thecell periphery were also observed upon ligand stimulation (Figure 
3.21A). Further, quantification analysis of FGFR2 internalisation revealed that the effect 
of Eps8 silencing was not evident during the earliest phases of receptor trafficking, 
suggesting a potential role for Eps8 in regulating FGFR2 sorting through early endocytic 
compartments rather than the process of internalisation itself (Figure 3.21B). Thus, 
inhibition of Src and downregulation of Eps8 expression produce similar effects on FGFR2  
Figure 3.20. Src kinase activity is required for FGFR2 trafficking 
A. HeLa cells transiently transfected with FGFR2-GFP and incubated for 30 minutes in the 
presence (lower panels) or absence (control, upper panels) of SFK inhibitor dasatinib 
were imaged in confocal microscopy for 30 minutes following FGF2 stimulation. The first 
(left panels) and last frame (right panels) of the time-lapse are shown, corresponding to 
conditions before and after FGF2 treatment, respectively. While in control cells activated 
FGFR2 undergoes efficient internalisation from the plasma membrane, dasatinib 
treatment prevents receptor endocytosis and trafficking toward peri-nuclear 
compartments. Higher magnifications of dasatinib-treated cells show that when Src 
activity is impaired, activated FGFR2 atypically and statically localises in the peripheral 
compartment rather than in peri-nuclear regions. Scale bars = 10 µm.  B. The experiment 
in A was performed in 10 cells and FGFR2-GFP intensity in the PM region of the cells was 
quantified (as described in Methods) for each frame of the time-lapses and plotted as a 
function of time (mean ± SEM).  C. Analysis of dasatinib-treated cells in super-resolution 
confocal microscopy reveals the presence of FGFR2-positive puncta localised in a 
peripheral endocytic compartment. Scale bars = 4 µm.  
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trafficking, further confirming a connection between Src kinase activity and Eps8 in the 
context of FGFR2 endocytosis.    
Once established that Eps8 plays a role in regulating FGFR2 trafficking within a peripheral 
endocytic compartment, subcellular localisation of Eps8 action on the endocytic 
trafficking of FGFR2 was investigated. HeLa cells co-expressing FGFR2-GFP and Eps8-
mCherry were imaged in dual-colour confocal microscopy at various times upon FGF2 
stimulation. As shown in Figure 3.22A, in the absence of ligand, both Eps8 and FGFR2 
localise in proximity to the plasma membrane. Interestingly, Eps8 staining revealed 
punctate structures, suggesting that Eps8 is associated with (or resides inside) peripheral 
vesicles. Colocalisation between Eps8 and FGFR2 at the cell periphery is maintained, 
although to a lesser extent, upon stimulation with FGF2 for 10 minutes (Figure 3.22B), 
when the first receptor-containing vesicles begin to form. However, following ligand 
incubation for longer periods (e.g. 30 minutes), FGFR2 redistributes away from the cell 
Figure 3.21. Silencing of Eps8 impairs FGFR2 trafficking 
A. Eps8 knock-down HeLa cells (Eps8 shRNA) transiently transfected with FGFR2-GFP 
were imaged in confocal microscopy for 30 minutes following FGF2 stimulation. The first 
(left panels) and the last frame (right panels) of the time-lapse are shown, 
corresponding to conditions before and after FGF2 treatment, respectively. Similarly to 
dasatinib treatment, the absence of Eps8 prevents receptor internalisation and its 
trafficking toward peri-nuclear compartments. Higher magnifications of Eps8 knock-
down cells show atypical peripheral localisation of FGFR-containing vesicles, suggesting 
a role for Eps8 in early endocytic trafficking of FGFR2. Scale bars = 10 µm.  B. The 
experiment in A was performed in 8 cells, and FGFR2-GFP intensity in the PM region of 
the cells was quantified (as described in Methods) for each frame of the time-lapses and 
plotted as a function of time (mean ± SEM).  C. Cellular extracts from Eps8 knock down 
(shRNA) or control vector (control) HeLa cells were resolved by SDS-PAGE and analysed 
by immunoblotting with anti-Eps8 antibody (blot representative of 3 experiments). 
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periphery, trafficking toward perinuclear compartments, and colocalisation with Eps8 in 
peripheral vesicles is lost. Notably, when Eps8 is imaged with EEA1, a validated marker 
for early endosomes (Stenmark et al. 1996), clear colocalisation is observed (Figure 
3.22C), suggesting that Eps8 localisation is restricted to the early endosomal system.  
To further confirm early endosomal localisation of Eps8 action, a series of triple-labelling 
experiments was performed between activated FGFR2, following 10 minutes FGF2 
stimulation, Eps8, and an early endosomal marker (transferrin upon 5 minutes 
incubation). As shown in Figure 3.22D, triple colocalisation revealed the presence of a 
region of overlap (in white) between the three proteins. Taken together, these data 
confirm that Eps8 specifically resides in the early endocytic compartments and that 
activated FGFR2 transits through this compartment during early phases of receptor 
trafficking, to be ultimately sorted toward perinuclear regions. This observation is 
consistent with findings from Burke et al. on EGFR endocytosis, where Eps8 was found to 
associate with internalised EGFR only at early time-point stimulation (10 minutes) (Burke 
et al. 2001 and unpublished data); this corresponds to the time at which EGFR 
accumulates in early endosomes.  
Finally, to further validate the connection between Src kinase activity and Eps8 function 
within the peripheral endocytic system, colocalisation between the two proteins was 
studied. The result, depicted in Figure 3.23, revealed a striking overlap of Eps8 with 
constitutively active Src, specifically at the cell periphery, confirming evidence of 
localisation of Src/Eps8 action within the peripheral endocytic compartment. 
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 Figure 3.22. Localisation of Eps8 action on FGFR2 trafficking is restricted to the early 
endosomal system 
A. HeLa cells transfected with FGFR2-GFP and Eps8-mCherry were stimulated with 
FGF2 for either 10 or 30 minutes, or non-stimulated, then fixed and imaged in confocal 
microscopy. During the early stages of activation (up to 10min FGF2 stimulation), 
FGFR2 localises in peripheral compartments, where it colocalises with Eps8. Upon 
ligand incubation for longer periods (30 minutes), FGFR2 redistributes away from the 
cell periphery, while Eps8 localisation remains restricted to peripheral compartments, 
just beneath the plasma membrane. Scale bars = 10 µm B. Quantification analysis of 
colocalisation between FGFR2 and Eps8, showing significant overlap only during early 
phases of receptor activation, when both proteins localise in early endocytic 
compartments (mean ± SEM, *, p < 0.05; **, p < 0.01; ***, p < 0.001, n = 14 cells).  C. 
Eps8-GFP expressing HeLa cells were fixed and immunostained for EEA1 and analysed 
in confocal microscopy. Scale bars = 10 µm.  D. HeLa cells co-expressing FGFR2-GFP 
and Eps8-mCherry were stimulated with FGF2 10 minutes. Upon incubation with 
transferrin-AF633 during the latter 5 minutes of stimulation, cells were rinsed, fixed, 
and imaged in confocal microscopy. Higher-magnification images of selected regions 
from the cells show colocalisation (in white) of FGFR2, Eps8 and 5-min internalised 
transferrin, demonstrating that during the early phases of receptor trafficking, 
activated FGFR2 transits through the early endocytic compartments, where Eps8 
specifically resides. Scale bars = 5 µm.  
 
 
Figure 3.23. Colocalisation between Eps8 and active Src 
HeLa cells co-expressing Eps8-mCherry and constitutive active Src (SrcCA) were fixed 
and immunostained for active Src (phospho416Src antibody), then analysed in confocal 
microscopy. Higher-magnification regions show clear colocalisation between active Src 
and Eps8 (in yellow). Scale bars = 5 µm. 
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3.5.3 Role of Eps8 in trafficking FGFR2 out of early endocytic system 
Results illustrated thus far indicate that Eps8 may be important in regulating early phases 
of FGFR2 trafficking following endocytosis. A clear indication that Eps8 is important in  
ensuring correct transit of FGFR2 out of the early endocytic system came from a series of 
immunofluorescence analyses performed on the previously described Eps8 shRNA cell 
line. In these studies, the differential fate of activated FGFR2 in the presence or absenc 
eof Eps8 was investigated by analysing colocalisation of activated receptor with validated 
markers of the endocytic pathway (Figure 3.24). Consistent with the live-cell imaging 
investigations described earlier in this study, in scrambled shRNA (control) cells, upon 
stimulation with FGF2 ligand for 30 minutes, activated FGFR2 was found to accumulate to 
an intracellular region adjacent to the nucleus. Thus, analysis of colocalisation between 
activated FGFR2 and EEA1 revealed a very low extent of overlap (Figure 3.24A and B), 
confirming that following stimulation for 30 minutes, the internalised receptor is 
trafficked away from the early endocytic compartments. However, in the absence of Eps8 
expression, the extent of colocalisation between FGFR2 and EEA1 significantly increases, 
demonstrating that Eps8 plays a critical role in sorting the receptor out of the early 
endocytic system.  
As described in Section 1.3, Endocytosis and endocytic trafficking, the canonical endocytic 
pathway enables transport of RTKs from early endosomal compartments toward 
lysosomes for degradation and/or the recycling pathway. Thus, on the basis of the 
observations described above, it is possible that the role of Eps8 is to regulate the exit of 
FGFR2 from the peripheral early endosomes toward these late compartments. To confirm 
this hypothesis, localisation of activated FGFR2 was studied in relation to specific markers 
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for perinuclear recycling (Rab 11, Ullrich O. et al. 1996) and lysosomal degradative 
compartments (Lysotracker). As depicted in Figure 3.24 C–F, in control cells 30 minutes 
post stimulation, FGFR2 was found to accumulate in both the recycling and the 
degradative compartment, as demonstrated by the high degree of colocalisation with 
Rab11 and Lysotracker, respectively. This indicates that, similar to other members of the 
RTK family such as EGFR, activated FGFR2, upon transiting through the endosomal 
system, is either recycled back to the plasma membrane or sorted for degradation. 
However, in Eps8 knock-down cells, the extent of accumulation of activated receptor with 
both Rab11 and Lysotracker-positive compartments appears significantly reduced. This 
observation is consistent with the previously observed accumulation of receptor in early 
endosomal compartments in Eps8 knock-down condition. Thus, taken together, these 
findings demonstrate that Eps8 is required for trafficking activated FGFR2 out of the 
peripheral early endosomes and toward the degradative and perinuclear recycling 
compartments.   
3.5.4 Role of Eps8 in FGFR2 signalling  
As discussed in greater detail in Section 1.3.3, receptor endocytosis and signalling are 
tightly linked processes and they can profoundly influence each other. Thus, in light of 
the findings thus far, it is possible that Eps8, by controlling the early endocytic trafficking 
of FGFR2, can also influence the signalling activated downstream of the receptor. To 
investigate this issue, the output profile of FGFR2 signalling was analyzed upon FGF2 
stimulation in the presence or absence of Eps8. Because activated FGFR2 signals through 
the RAS-MAPK pathway (Eswarakumar et al. 2005), phosphorylated ERK1/2 were used as 
indicators of duration and intensity of signalling activated downstream of the receptor. 
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As shown in Figure 3.25A, in control cells FGF2 stimulation promotes rapid appearance of 
the p44 form of activated ERK (ERK1), which was maximally induced at 5 minutes. In this 
condition, however, stimulation with FGF2 had no effect on the p42 form of ERK (ERK2), 
whose basal level was unchanged over time. In fact non-transfected HeLa cells subjected 
to overnight serum starvation show a basal level of expression of the p42 form of ERK 
(Figure 3.25C). When Eps8 expression was silenced, significant effects on pERK activation 
were observed. In fact, as depicted in Figure 3.25A and B, in Eps8 knock-down cells the 
FGF2-dependent amplification of the p44 form of ERK during early-phase activation was 
diminished. This observation suggests that Eps8 is important for FGFR2-dependent 
activation of the RAS-MAPK pathway during early phases of receptor endocytosis, 
probably via a feedback mechanism generated by the primary role of Eps8 in regulating 
transit of activated receptor through the early endocytic system. This finding also suggest 
that FGFR2 remains active upon endocytosis and continues to signal along  
Figure 3.24. Eps8 is required for sorting activated FGFR2 out of peripheral early 
endosomes and toward degradative and peri-nuclear recycling compartments   
Eps8 knock down (Eps8 shRNA) and vector control HeLa cells transiently transfected with 
FGFR2-GFP were stimulated with FGF2 for 30 minutes and immunostained for EEA1 (A) or 
Rab11 (C), or treated with LysoTracker-Red (E). Then, cells were fixed and analysed in 
confocal microscopy. Higher-magnification images of selected cell regions show that in 
absence of Eps8, active FGFR2 is retained in early endosomal compartments (EEA1-
positive) and is prevented from sorting to both peri-nuclear recycling (Rab11-positive) and 
lysosomal degradative (LysoTracker-positive) compartments. Scale bars = 5 µm. (B, D, F) 
Colocalisation of active FGFR2 with EEA1, Rab11 or LysoTracker was quantified in control 
cells as 0.19 ± 0.02, 0.57 ± 0.04, and 0.74 ± 0.01, respectively, and in Eps8 knock down 
cells as 0.36 ± 0.04, 0.24 ± 0.05, and 0.18 ± 0.01, respectively (Pearson’s coefficient, 
mean ± SEM, *, p < 0.05; **, p < 0.01; ***, p < 0.001, n = 18 cells).   
 
 154 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.25. Eps8 regulates RAS-MAPK signalling pathway downstream of FGFR2  
A. Eps8 knock down (Eps8 shRNA) and vector control HeLa cells transiently expressing 
FGFR2-GFP were lysed following stimulation with FGF2 for the indicated times. Cellular 
extracts were resolved by SDS-PAGE and analysed by immunoblotting for levels of specified 
proteins. The time-course of Erk1/2 phosphorylation in response to FGF2 shows significant 
attenuation of p44 ERK (ERK1) level at 5 minutes FGF2 stimulation in Eps8 knock down cells.  
B. Quantification analysis by densitometric scanning of western blots of p44 pERK level 
following FGF2 stimulation in Eps8 knock down (black) and vector control (gray) HeLa cells 
(mean ± SEM, *, p < 0.05; **, p < 0.01; ***, p < 0.001, n = 5 experiments).  C. Non transfected 
HeLa cells were starved overnight in serum free media and lysed following stimulation with 
FGF2 for the indicated times. Cellular extracts where resolved by SDSPAGE and analysed by 
immunoblotting for the levels of specified proteins. 
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the endocytic pathway, similar to observations for other members of the RTK family, such 
as EGFR (Jiang and Sorkin 2002). Finally, the presence of a lower amplitude of signalling 
output which remains unaffected even in the absence of Eps8 indicates that activated 
FGFR2 can also signal through the RAS-MAPK pathway in an Eps8-independent manner. 
3.5.5 Conclusions 
The evidence presented in this chapter establishes Src kinase as a key regulator of early 
endocytic trafficking of FGFR2. Live-cell imaging studies revealed that functional Src 
activity is required for correct endocytosis of FGFR2 and its consequent trafficking toward 
perinuclear compartments. In fact, cells treated with the Src-family inhibitor Dasatinib 
showed impaired receptor internalisation as well as a clear defect in the redistribution of 
internalised receptor away from the cell periphery. Super-resolution imaging studies in 
Dasatinib-treated cells confirmed the importance of Src activity in ensuring regular 
endocytic trafficking of FGFR2, as demonstrated by the clear accumulation of receptor-
containing vesicles in peripheral endocytic compartments upon 30 minutes’ FGF2 
stimulation. 
The results presented in this chapter also demonstrate a role for the multifunctional 
scaffold protein Eps8 in FGFR2 trafficking. Involvement of Eps8 in the context of FGFR2 
was already demonstrated by Cunningham et al., where the adaptor protein was 
characterized as target of Src-mediated phosphorylation in the FGFR signalling cascade 
(Cunningham et al. 2010). In the present study, clear evidence of the key role of Eps8 in 
regulating FGFR2 endocytosis came from real-time analysis of FGFR2 trafficking in KDEps8 
cells. Similar to the result obtained in Dasatinib-treated cells, the absence of Eps8 led to 
impaired receptor trafficking and accumulation of FGFR2-positive puncta in a peripheral 
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endocytic compartment. The observation that silencing of Eps8 protein phenocopies the 
effect of Src kinase activity inhibition on FGFR2 trafficking further confirms the 
mechanistic link between FGFR2 activation, Src activity, and Eps8 function, specifically 
localised in an early endocytic compartment.  
The precise role of Eps8 in regulating FGFR2 trafficking was also characterized by a series 
of colocalisation studies. The results show that Eps8 is required for trafficking the 
activated receptor out of early endosomal systems and toward degradative and the 
perinuclear recycling compartments. In fact, in the absence of the adaptor protein, the 
transit of activated receptor through the EEA1-positive compartments is blocked and 
FGFR2 accumulates at the cell periphery and is prevented from being trafficked to late 
lysosomal and recycling compartments.   
Finally, the findings shown here provide new insight into the crosstalk between trafficking 
and signalling of FGFR2. Biochemical studies revealed that depletion of Eps8 severely 
inhibits the ability of FGFR2 to activate the RAS-MAPK pathway in its early phases, 
suggesting a role for Eps8 in regulating and also signalling downstream FGFR2. Whether 
this is an indirect consequence of Eps8-dependent regulation on receptor trafficking or a 
direct effect of Eps8 on downstream signalling output remains to be verified. In 
conclusion, these findings demonstrate that Src acts through Eps8 to regulate 
endocytosis and early endocytic trafficking of FGFR2, and that Eps8 functions as a key 
coordinator in the interplay between FGFR2 trafficking and signalling. 
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CHAPTER 4  
DISCUSSION 
 
RTKs undergo rapid and controlled internalisation from the cell surface in response to 
ligand binding (Le Roy and Wrana 2005, von Zastrow and Sorkin 2007). Endocytosis and 
trafficking of receptors along the endocytic pathway are known to act as major 
mechanisms for receptor downregulation, as they ultimately result in receptor 
proteolysis and termination of signalling (Beguinot et al. 1984, Stoscheck and Carpenter 
1984). However they can also contribute to spatio-temporal regulation of signal 
transduction, by influencing the duration and correct subcellular location of the signalling 
output generated (von Zastrow and Sorkin 2007; Di Fiore and De Camilli 2001). Thus, it is 
not surprising that defects in the endocytic machinery may result in abnormal cell 
signalling (Bache et al. 2004, Parachoniak and Park 2012) and that deregulation of RTK 
endocytosis is emerging as a mechanism of oncogenic activation (Peschard and Park 
2003). 
FGF receptors represent a subfamily of RTKs with established roles in both the 
development and progression of cancer (Haugsten et al. 2010, Wesche et al. 2011). 
Although over the last three decades much effort has been dedicated to studying the 
signalling pathways activated by FGFRs, the endocytic pathway for FGFR internalisation 
and the subsequent intracellular trafficking of receptors are subjects that remain elusive 
and subject to controversy.  
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By employing living-cell–based assay systems, this thesis examines basic aspects of 
receptor trafficking, along with the contribution of downstream effectors in the FGFR 
signalling cascade. The endocytic route for internalisation of FGFR2 is unravelled using 
advanced optical microscopy techniques, and trafficking of the receptor along the 
endocytic pathway is visualized. Recruitment of FGFR2 and clathrin at the plasma 
membrane prior to internalisation is also evaluated and is demonstrated to have similar 
dynamics to that of other members of RTKs. Finally, Eps8 is characterised as a novel 
regulator of endocytosis, and trafficking of FGFR2 and its function are shown to be key in 
coordinating the interplay between FGFR2 trafficking and signalling. 
In Section 3.1, characterisation of a suitable model system to study FGFR2 dynamics in 
living cells is described. This is a critical step, since our analysis is based on employment 
of an ectopically overexpressed FGFR2-GFP. Confocal microscopy analysis of FGFR2-GFP–
expressing HeLa cells reveals correct targeting of the fusion protein both before and after 
FGF stimulation, validating HeLa as an adequate cell model for our live-cell imaging 
studies. These results also indicate that GFP-fused receptor is active and that tagging 
does not interfere with receptor functionality. It must also be underlined that HeLa cells 
have been previously shown to express very low levels of endogenously expressed FGFR2 
(Ahmed et al. 2008). This demonstration is important, because the presence of 
endogenous FGFR2 could interfere with the correct functionality of the overexpressed 
counterpart, affecting our results.  
In Section 3.2, development of live-cell imaging assays based on advanced optical 
microscopy methods is described and shown to be a necessary tool for exploring receptor 
trafficking within a live-cell context. In fact, in contrast to many studies, this work 
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investigates several aspects of receptor trafficking in real-time, by using an established 
living-cell–based assay system. This approach is important, because it allows visualization 
of spatial and temporal endocytic dynamics of the receptor within a live biological 
context. Published works regarding endocytic trafficking of FGFR employ antibody-
labelling methods, limiting their analysis to fixed cell-based techniques (Belleudi et al. 
2009, Belleudi et al. 2007, Citores et al. 1999, Marchese et al. 1998). Thus, the novelty of 
the present work relates to the fact that mechanisms are investigated in a real-time 
system, allowing the characterization of the endocytic trafficking of FGFR2. Visualization 
of the dynamics of activated FGFR2 trafficking in living cells reveals that the first receptor-
containing vesicles begin to appear from the inner surface of the plasma membrane at 5 
minutes after FGF2 addition. Thus, the process of FGFR2 internalisation occurs very 
rapidly, and interestingly, this process recalls the kinetics of internalisation of EGFR, 
which also undergoes internalisation already at 5 minutes following ligand stimulation 
(Schmidt-Glenewinkel et al. 2009). This observation suggests that different members of 
the RTK family share the same dynamics of internalisation, which may in turn reflect a 
common pathway of endocytosis, as demonstrated in Section 3.3. At late time points 
following ligand incubation, the entire pool of surface-bound receptors appears to be 
completely redistributed to intracellular perinuclear compartments. These intracellular 
regions correspond to perinuclear recycling and lysosomal compartments, as 
demonstrated in Section 3.5. This demonstrates that FGFR2 follows both degradation and 
recycling pathways, similar to other members of the RTK family, such as EGFR (Sorkin and 
Goh 2008) or PDGFR (Hellberg et al. 2009). It would be interesting to further investigate 
this characteristic and to evaluate to what extent FGFR2 is targeted to lysosomes for 
degradation rather than to the recycling pathway, or whether discrimination between the 
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two outcomes depends on any specific factor or molecular event, such as the process of 
receptor ubiquitination. 
The live-cell trafficking assay developed in this study also reveals that the kinase activity 
of FGFR2 is required for receptor internalisation. The explanation for this observation is 
not entirely clear. In fact, the kinase domain of RTK is important for initiation of the 
intracellular signalling cascade, a process that occurs at the plasma membrane 
independently from endocytosis of the receptor itself. A plausible hypothesis would be 
that the phosphotyrosine residues generated by the receptor kinase domain serve to 
recruit signalling/adaptor molecules that play a role in the internalisation process. This 
would explain identification of constitutively active mutant RTKs which show enhanced 
endocytosis (Joffre et al. 2011), and identification of mutant receptors with inactive 
kinase which are unable to internalise properly (Sorokin et al. 1994).  
Finally, TIRF microscopy reveals that FGFR2 forms clusters at the plasma membrane in 
response to ligand binding. By clustering together, activated receptors are physically 
concentrated in the same plasma membrane domains. Although this phenomenon is 
already described for other membrane-bound receptors, including members of the RTK 
family (Sako et al. 2000), its function within a cellular context has not yet been clarified. 
One possible explanation for this phenomenon is that it concentrates activated receptors 
in the same microdomains of the plasma membrane specialised for endocytosis, such as 
lipid rafts, caveolae, and clathrin-coated pits, resulting in enclosure of multiple receptors 
in the same endocytic vesicle. In this case, therefore, clustering plays an important role in 
the process of receptor endocytosis. Alternatively, a functional consequence of receptor 
assembly might be enhancement of signalling efficiency: by physically recruiting activated 
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receptors within domains enriched in signalling molecules, or by simply aggregating 
multiple receptors together and enabling them to trans-phosphorylate and activate each 
other. Future studies, based for instance on employment of single-molecule fluorescence 
methods, are necessary to further investigate the spatial organization of FGFR2 on the 
cell surface and to determine which of the three hypotheses best describes the functional 
role of receptor clustering at the plasma membrane.  
In Section 3.3, confocal and TIRF microscopy techniques, combined with employment of 
inhibitors or siRNA sequences are used to define the endocytic pathway(s) by which 
FGFR2 is internalised and trafficked during the early phases of receptor activation. A 
number of previous reports on endocytosis of FGFRs implicated multiple endocytic 
pathways, including both clathrin-mediated and caveolar endocytosis (Gleizes et al. 1996, 
Marchese et al. 1998). Further, few studies find that internalisation of FGFRs proceeds 
independently of both clathrin and caveolin (Citores et al. 2001, Reilly et al. 2004). Thus, 
identification of the specific pathway(s) for internalisation of FGFRs remains 
controversial.  
Data from the present work reveal that treatment of cells with the dynamin inhibitor 
Dynasore entirely blocked uptake of FGFR2. This is a clear demonstration that FGFR2 
endocytosis occurs through a dynamin-dependent process. Similar to FGFR2, the majority 
of RTKs enter cells through a process which is dynamin-dependent. However, in some 
cases, such as that of EGFR (Orth et al. 2006) or PDGFR (Sadowski et al. 2013), 
involvement of multiple alternative pathways which are dynamin-independent has also 
been observed. Our analysis demonstrates that the dynamin-dependent route is the only 
one responsible for internalisation of FGFR2 and that no other alternative pathway 
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occurs. In fact, when visualized in confocal live-cell microscopy, Dynasore-treated cells 
revealed no intracellular trafficking of FGFR2 even following 30 minutes of ligand 
stimulation. It should also be emphasised that when dynamin activity was inhibited, 
receptor-containing vesicles could still be observed forming at the cell periphery, but they 
seemed to fail to leave the plasma membrane. This is further confirmation of the key role 
of GTPase dynamin during the early phases of FGFR2 endocytosis. 
Having demonstrated that FGFR2 enters cells through a dynamin-dependent pathway, 
the next step was to unequivocally identify this specific pathway. Employment of a siRNA-
based approach revealed that endocytosis of FGFR2 is completely blocked in cells 
silenced for α-adaptin. Thus, the presence of an intact functional AP2 complex is a 
necessary requisite for endocytosis of FGFR2, indicating that FGFR2 internalisation occurs 
through clathrin-mediated endocytosis. Conversely, no effect is observed in cells treated 
with caveolin1 siRNA, definitively excluding caveolar endocytosis as a potential 
alternative pathway for internalisation of FGFR2. Thus, the present work demonstrates 
for the first time that FGFR2 endocytosis occurs through CME and that no additional 
pathways function in parallel to it.     
Results from Section 3.2 indicate that FGFR2 aggregates in clusters at the plasma 
membrane in response to ligand-mediated activation. In light of the demonstration that 
FGFR2 is internalised through CME, we hypothesize that receptor clustering on the cell 
surface specifically occurs at clathrin-coated pits (and conversely not at caveolae 
membrane domains). TIRF microscopy experiments verify this hypothesis, revealing that 
activated FGFR2 significantly colocalises with clathrin at the plasma membrane, whereas 
no colocalization is observed with caveolin1.  
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Further high resolution live-cell TIRF microscopy experiments also revealed the dynamics 
of recruitment of FGFR2 and clathrin at sites of prior CME internalisation. These results 
demonstrate that following stimulation, activated FGFR2 is recruited predominantly into 
pre-formed CCPs. Notably, similar dynamics of recruitment are observed for activated 
EGFR (Rappoport and Simon 2009), suggesting that this could be a conserved mechanism 
across RTK members.  
In Section 3.4, another aspect of the dynamics of FGFR2 endocytosis is investigated. 
Preliminary observations reveal that in HeLa cells, FGF stimulation causes an increase in 
the number of CCPs at the cell surface. Notably, the same effect is also observed in 
another cell line, LNCaps, which endogenously expresses FGFR2 (Carstens et al. 1997), 
demonstrating that this is not a cell line-specific phenomenon and, more importantly, 
that it is not due to overexpression conditions in our model system. Further, when the 
kinase activity of FGFR2 is blocked by SU5402 inhibitor, redistribution of clathrin at the 
plasma membrane is prevented, suggesting that this process requires the functional 
kinase activity of the receptor to occur.  
Formation of new clathrin coats induced by receptor activation is already described for 
other members of the RTK family, such as EGFR (Wilde et al. 1999) or NGFR (Beattie et al. 
2000). However, the function of clathrin redistribution at the cellular level remains 
unclear. It is possible that the new pool of clathrin is recruited to the cell surface to be 
employed in the process of receptor endocytosis. In this scenario, the presence of FGF 
ligand on the extracellular matrix would ultimately result in an incremental CME process, 
therefore generating a mechanism for regulating receptor trafficking.  
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Real-time analysis of the number of clathrin spots disappearing from the TIRF field in 
response to FGF stimulation reveals that the presence of FGF ligand also induces an 
increase in the density of endocytic events, verifying our hypothesis on the role of the 
FGF-dependent redistribution of CCPs. Unexpectedly, however, no effect could be 
observed on the uptake of transferrin, suggesting that the increased clathrin puncta 
undergoing endocytosis upon FGFR2 activation may represent a cargo-specific population 
of clathrin-coated pits. 
This latter result may have important implications. First, it implies that only a specific 
subset of productive CCPs is involved in endocytosis in response to ligand-dependent 
FGFR2 activation. This confirms the increasingly clear scenario of CCPs as a highly 
heterogeneous population of endocytic machines at the plasma membrane. Second, it 
suggests that this heterogeneity of CCPs not only depends on factors such as size, 
maturation rate, dynamics, (Merrifield et al. 2005, Rappoport et al. 2005, Yarar et al. 
2005), but it can also reflect differences in their cargo content. Third, data from this 
thesis suggest for the first time that cargo-specific mechanisms, such as ligand-induced 
receptor activation and clustering, can affect the properties and dynamic behaviour of 
specific CCPs at the cell surface, a phenomenon already shown for G protein coupled 
receptors (GPCRs) (Puthenveedu and von Zastrow 2006). 
Finally, data from Section 3.4 reveal that the kinase Src is required for the increase in CCP 
number following FGFR activation. This result is consistent with findings from Wilde et al. 
who identify Src as the kinase responsible for regulating cellular distribution of clathrin 
upon EGFR activation (Wilde et al. 1999). Interestingly, Src inhibition does not result in 
complete inhibition of clathrin recruitment upon FGF stimulation, suggesting the 
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possibility that this regulatory loop, important for regulating the process of CME, can 
bypass Src activity, proceeding through an alternative pathway.  
In light of previous work from our laboratory that identified the protein Eps8 as an Src-
dependent kinase substrate phosphorylated in response to FGF stimulation (Cunningham 
et al. 2010), and of this protein’s documented roles in vesicle trafficking (Lanzetti et al. 
2000), we set out to explore the possibility that Eps8, along with Src, could play a role in 
the redistribution of clathrin observed following FGF stimulation. Employment of a siRNA-
based approach reveals that in the absence of Eps8, the increase in clathrin punctua at 
the cell surface upon ligand stimulation is prevented, confirming our hypothesis.   
From the data described thus far, an updated picture of endocytic trafficking of FGFR2 is 
becoming clear: following ligand binding and activation, FGFR2 distribution at the plasma 
membrane changes and activated receptors specifically cluster at pre-formed CCPs. Here, 
the process of endocytosis begins, and receptors are enclosed into clathrin-coated 
vesicles and trafficked intracellularly. Simultaneously, signalling through Src to Eps8 by 
activated FGFR2 brings new CCPs at the plasma membrane and consequently promotes 
clathrin-mediated endocytosis. Having focused on basic aspects of FGFR2 endocytosis 
before the internalisation process, the next step in this research was to explore the 
intracellular fate of the receptor and how FGFR2 trafficking through specific intracellular 
compartments is regulated.  
In Section 3.5, employment of a live-cell trafficking assay developed in this study, in 
combination with chemical inhibition of Src activity, reveals that Src plays an important 
role in intracellular trafficking of FGFR2. Following Dasatinib treatment, FGFR2-containing 
vesicles are observed to atypically and statically accumulate in peripheral compartments, 
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and redistribution toward perinuclear compartments is entirely prevented. These results 
suggest that Src is not essential for internalisation of FGFR2, but is required for early 
phases of receptor trafficking. Using super-resolution confocal microscopy, clear FGFR2-
positive puncta are observed that localise at the cell periphery of Dasatinib-treated cells, 
further confirming the role of Src in regulating FGFR2 trafficking during its early phases. 
In light of these findings, and of the mechanistic connection between Src and Eps8 
previously demonstrated by our group (Cunningham et al. 2010), we hypothesize that 
Eps8 could represent an Src-dependent regulator of FGFR trafficking within the early 
endocytic system. Analysis of FGFR2 trafficking in a previously established Eps8 
knockdown cell line confirms our hypothesis, revealing a Dasatinib-like phenotype: 
significant attenuation of FGFR2 trafficking with an accumulation of receptor-containing 
vesicles within a peripheral punctuate compartment.   
The work presented in Section 3.5 clearly confirms the connection between Src kinase 
activity and Eps8 function in regulating FGFR2 trafficking within the peripheral endocytic 
system. In a series of colocalisation studies, FGFR2 is observed to colocalise with Eps8 and 
transferrin in peripheral early endosomes during early phases of trafficking, as well as 
with constitutively active Src. However, following ligand stimulation for 30 minutes, 
FGFR2 appears to redistribute away from the cell periphery and colocalisation with Eps8 
in peripheral vesicles is lost.  
A clear demonstration that Eps8 is required to sort FGFR2 out of the early endocytic 
system comes from a series of immunofluorescence analyses performed on the 
previously mentioned Eps8 shRNA cell line. These analyses reveal that in control cells 30 
minutes post-stimulation, FGFR2 poorly colocalises with EEA1-positive compartments, 
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while it is found to localise to the Rab11 positive recycling compartment as well as 
degradative compartments. Conversely, in stimulated Eps8 knockdown cells, FGFR2 is 
observed to be retained in the early endosomes and redistribution to perinuclear 
recycling and degradative compartments is entirely prevented. Thus, these data 
demonstrate for the first time that activated FGFR2 traffics through the EEA1-positive 
compartment and follows both the slow recycling and degradative pathways, and that 
the transition from early endosomal to late lysosomal/recycling compartments is 
controlled by Eps8.   
Emerging evidence suggests that receptor endocytosis and signalling are tightly linked 
processes and that they can profoundly influence each other (Di Fiore and De Camilli 
2001, von Zastrow and Sorkin 2007). Considering this reciprocal regulation and the 
demonstrated role of Eps8 in controlling early endocytic trafficking of FGFR2, it is 
speculated that Eps8 could also play a role in regulating signalling downstream of FGFR2.     
Biochemical analysis reveals that depletion of Eps8 severely inhibits the ability of FGFR2 
to activate the RAS-MAPK pathway, confirming the role of Eps8 in mediating signalling by 
FGFR2 immediately following activation. Whether this is a direct effect of Eps8 on 
receptor signalling dynamics or a feedback effect of Eps8-dependent regulation on 
receptor trafficking through the early endocytic system remains to be determined. 
Interestingly, the significant effect of Eps8 depletion on signalling by FGFR2 is observed 
only at very early time points, specifically at 5 minutes post–FGF stimulation. Bearing in 
mind that during this early phase, receptors containing vesicles are still localised in the 
early endocytic system, this data also suggest that FGFR2 signalling through the RAS-
MAPK pathway can occur from endosomes during receptor endocytosis, similar to what 
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has already been demonstrated for EGFR (Jiang and Sorkin 2002). Thus, in conclusion, the 
work presented in this thesis identifies Eps8 as a novel regulator of FGFR2 endocytosis 
and a key coordinator of the signalling and trafficking of FGFR2, specifically during early 
stages of activation.  
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Abstract
Eps8 is involved in both cell signalling and receptor trafficking. It is a known phosphorylation substrate for two proteins
involved in the fibroblast growth factor receptor (FGFR) signalling pathway: the receptor itself and Src. Here we report
a differential proteomic analysis of Eps8 aimed to identify specific FGFR and Src family kinase dependent phosphosites and
co-associated phosphodependent binding partners. This study reveals a total of 22 Eps8 pTyr and pSer/Thr phosphorylation
sites, including those that are dependent on Src family and FGFR kinase activity. Peptide affinity purification of proteins that
bind to a selection of the pTyr phosphosites has identified a range of novel Eps8 binding partners including members of the
intracellular vesicle trafficking machinery (clathrin and AP-2), proteins which have been shown to regulate activated
receptor trafficking (NBR1 and Vav2), and proteins involved in receptor signalling (IRS4 and Shp2). Collectively this study
significantly extends the understanding of Eps8 post-translational modification by regulated phosphorylation, identifies
novel Eps8 binding partners implicated in receptor trafficking and signalling, and confirms the functions of Eps8 at the
nexus of receptor signalling and vesicular trafficking.
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Introduction
Eps8 is involved in modulating cell signalling and receptor
trafficking, via its range of protein interactions. When bound in
a complex with Abi1and Sos1, Eps8 participates in signal
transduction from Ras to Rac, leading to actin remodelling [1].
The SH3 domain of Eps8 binds Abi1 [1,2] and, essential to its role
in Rac activation, Sos1 binds the C-terminal effector region [3].
Coexpression of this Eps8-Abi1-Sos1 tri-complex has been
correlated with advanced stage ovarian cancer, shown to be
attributed to increased Rac-induced cell migration [4]. Interaction
with the RabGAP, RN-Tre, via its SH3 domain, disrupts this tri-
complex enabling Eps8 to participate in receptor trafficking via de-
activation of Rab5 [5]. In addition, Eps8 is involved in actin
capping and bundling via its interactions with IRSp53 and
monomeric actin [6,7].
Eps8 was originally identified as a novel phosphorylation
substrate for the epidermal growth factor receptor (EGFR) and
is also phosphorylated upon activation of other tyrosine kinases
including fibroblast growth factor receptor (FGFR), platelet-
derived growth factor (PDGF) and erbB-2 [8]. It has since been
identified as a phosphorylation substrate for Src [9] and elevated
expression of Eps8 has been observed in v-Src transformed cells
[9,10] and a variety of human cancers [11,12,13]. Phosphorylation
is an important post-translational modification in the regulation of
protein-protein interactions constituting cellular signal transduc-
tion, and aberrant regulation of phosphorylation can lead to
malignancy. Indeed, constitutive phosphorylation of Eps8 has
been found in a range of tumour cell lines [14].
Previously, we used quantitative proteomics to identify candi-
date mediators of FGFR signalling which are targets for Src family
kinase (SFK)–mediated phosphorylation and functionally impli-
cated in trafficking of activated FGFRs [15]. Eps8 was one such
protein identified in this survey.
Collectively these features identify Eps8 as a potential target for
transmitting FGFR and Src mediated signalling events to
downstream effectors which warranted a detailed investigation of
both FGFR and SFK mediated phosphorylation of Eps8 and
analysis of phospho-dependent Eps8 binding partners to identify
further candidate effectors and provide some insight into the
possible pathways that these phosphorylation events influence.
Using quantitative mass spectrometry techniques [16,17,18]
coupled with chemical inhibition of FGFR and SFK kinase
activity we have carried out phosphopeptide mapping of Eps8 in
PLOS ONE | www.plosone.org 1 April 2013 | Volume 8 | Issue 4 | e61513
order to identify FGFR and SFK-regulated phosphorylation sites.
In addition, differentially recruited phosphodependent protein
partners have been identified using quantitative peptide pull down
(PPD) assays. This technique has revealed many novel Eps8
binding partners including insulin-receptor substrate 4 (IRS4).
Previous proteomic studies have implicated IRS4 in FGFR
signalling [19,20]. Here we have identified IRS4 as a novel
binding partner for an Eps8 peptide containing phosphorylated
Tyr252. Furthermore, we show that the interaction between Eps8
and IRS4 and their colocalisation within cells is increased
following FGFR activation which coincides with tyrosine phos-
phorylation of both Eps8 and IRS4.
These results significantly expand the range of proteins
implicated to interact with Eps8, illustrating further its role as
a multi-functional adaptor molecule mediating FGFR and Src
kinase signalling.
Materials and Methods
Cell Culture
Human embryonic kidney epithelial 293T cells and mouse NIH
3T3s were cultured at 37uC, 5% CO2 in DMEM containing
2 mM L-Glutamine (Lonza), supplemented with 0.1 mg/ml
streptomycin, 0.2 U/ml penicillin (Sigma), and 10% v/v fetal calf
serum (Labtech International). For SILAC labelling, 293T cells
were cultured in SILAC DMEM (Thermo Fisher Scientific)
supplemented with either 0.1 mg/ml ‘‘light’’ isotopically normal
L-Lysine and L-Arginine (R0K0) (Sigma), ‘‘medium’’ 13C6 L-
Lysine and 4,4,5,5-D4 L-Lysine (R6K4), or ‘‘heavy’’ 13C6
15N4 L-
Arginine and 13C6
15N2 L-Lysine (R10K8) (Goss Scientific),
0.5 mg/ml proline (Sigma), 0.1 mg/ml streptomycin, 0.2 U/ml
penicillin, and 10% v/v dialysed fetal bovine serum (Labtech
International).
Cloning and Transfection
The human open reading frames for Eps8 and IRS4 were
supplied in Gateway (InvitrogenTM) pDONR vectors from Open
Biosystems. The insert encoding Eps8 was cloned into the
Gateway compatible mammalian expression vector, Myc-PRK5
(gift from Laura Machesky) using Gateway cloning. The insert
encoding IRS4 was cloned into the Gateway mammalian
expression vector, pDEST53 (GFP-tag) using Gateway cloning.
Eps8-mCherry was a gift from Giorgio Scita (IFOM University of
Milan, Milan, Italy). HEK 293T cells were transfected using
Genejuice (Novagen) and NIH 3T3 cells were transfected using
Lipofectamine2000 (Invitrogen) according to manufacturer’s
instructions. Cells were allowed to overexpress transfected protein
for 48 h.
Cell Treatment and Cell Lysis
Following overnight serum starvation in media containing 0.1%
serum, cells were either pre-treated with SU6656, dasatinib or
SU5402 for 30 min, followed by addition of 20 ng/ml FGF2, or
treated as above in the absence of chemical inhibitor. For
experiments where cells were treated with sodium pervanadate,
2 mM sodiumpervanadate was added to themedia for 20 min prior
Figure 1. Chemical inhibition of Src kinase and FGFR kinase activity. A) HEK 293T cells were treated with SU5402, SU6656, or dasatinib
30 min prior to addition of FGF2 for 15 min. Cells were lysed and analysed by western blotting. B) HEK 293T cells were treated with increasing
concentrations of dasatinib for 30 min prior to addition of FGF2 for 15 min. Cells were lysed and analysed by western blotting.
doi:10.1371/journal.pone.0061513.g001
Phosphoproteomics of Eps8
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to FGF2 stimulation. Cell lysis and measurement of total protein
concentrations were performed as described previously [15].
Immunoprecipitation and Western Blotting
Antibodies were purchased from Roche (Myc 9E10), Santa Cruz
(Eps8 sc-1841; Clathrin HC sc-12734; Vav2 sc-20803; Shp2 sc-424;
IRS4 sc-100854; AP-2 sc-10761; PHB sc-28259; PHB2 sc-133094;
ERK sc-94; p-ERK sc-7383), NEB (Src 2110, p-Src 2101, STAT3
9139), and Abcam (NBR1 ab55474). For IPs, antibodies were
conjugated to Protein G Dynabeads (Invitrogen), as per manufac-
turer’s instructions. For SILAC anti-Myc IPs, anti-Myc antibody
was further cross-linked to the beads: the conjugated Dynabeads
were washed twice in a 10-fold excess of 0.2 M triethanolamine
pH8.2. Beads were then resuspended in a 10-fold excess of freshly
prepared 20 mM dimethyl pimelidate dihydrochloride (DMP)
(Sigma) and mixed for 30 mins at room temperature followed by
washing in a ten-fold excess of 50 mM Tris/HCl for 15 mins at
room temperature and further washes (x3) in a 10-fold excess of
PBS/0.1% Tween 20 (PBS-T). Cross-linked beads were resus-
pended in PBS, prior to addition of whole cell lysate (WCL). WCLs
were mixed at 4uC with anti-Myc beads for 30 min, prior to
washing. For SILAC experiments, WCLs from the heavy, medium,
and light cell populations were immunoprecipitated separately
(10 mg WCL) and beads were mixed following five washes in a 20-
fold excess of lysis buffer. Following addition of reduced sample
buffer, samples were boiled for 5 min, run on 4–12% Bis-Tris gels
(Invitrogen) and Coomassie stained. Western blotting was per-
formed as previously described [15].
Peptide Pull Downs
Phosphorylated and non-phosphorylated peptide pairs were
synthesised by Alta Bioscience, Birmingham, UK. Each peptide
was synthesised with an N-terminal desthiobiotin. Peptides were
bound to MyOne Streptavidin Dynabeads (Invitrogen) (2.5 mg/
50 ml beads) by incubating at room temperature for 1 hour.
Peptide-bound beads were washed for 15 min65 in a 20-fold
excess of PBS-T. Heavy SILAC labelled (R10K8) WCL (10 mg)
was incubated with 50 ml beads bound to the phosphorylated
peptide, medium SILAC labelled (R6K4) WCL (10 mg) was
incubated with 50 ml beads bound to the non-phosphorylated
peptide, and light SILAC labelled (R0K0) WCL (10 mg) was
incubated with 50 ml beads without peptide, overnight at 4uC.
PPDs were washed at least 5 times in a 20-fold excess of PBS-T.
Beads from each peptide pair and a non-peptide control were
combined. Following addition of reduced sample buffer, protein
samples were run on 4–12% Bis-Tris gels (Invitrogen) and
Coomassie stained.
Trypsin Digestion and Phosphopeptide Enrichment of
Samples
Trypsin digestion was carried out as previously described
[15,21]. From the excised band corresponding to Eps8, phospho-
peptides were enriched using TiO2 tips (GLSciences), according to
the manufacturer’s instructions. All resulting peptide mixtures
were analysed by liquid chromatography tandem mass spectrom-
etry (LC-MS/MS).
Figure 2. Representative mass spectra for identification and site localisation of tyrosine phosphorylation on Eps8. A) Eps8 is
phosphorylated on residue 525. B) Eps8 is phosphorylated on residue 540. pY indicates phosphotyrosine.
doi:10.1371/journal.pone.0061513.g002
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Figure 3. Differential regulation of tyrosine phosphorylation on Eps8. Heavy, medium and light SILAC labelled HEK 293T cells were treated
with either 25 nM dasatinib, 20 mM SU5402, or no inhibitor, prior to FGF2 stimulation (20 ng/ml; 15 min). Myc-Eps8 was immunoprecipitated and the
resulting sample was run on an SDS-PAGE gel and, following in-gel trypsin digestion and phophopeptide enrichment, analysed by mass
spectrometry. Each graph represents specific residues on Eps8 as indicated. Each data point represents a single peptide identification. P values were
calculated by an unpaired t-test (0.01–0.05 = *; 0.001–0.01= **; ,0.001 = ***). +, the median of the ratios is,the cut-off value of 0.57 and is deemed
significantly changed (see Method S1). A) Experiment was carried out in the absence of sodium pervanadate. B) Experiment was carried out in the
presence of 2 mM sodium pervanvadate.
doi:10.1371/journal.pone.0061513.g003
Phosphoproteomics of Eps8
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Mass Spectrometry
On-line liquid chromatography was performed by use of an
Dionex Ultimate 3000 LC system (Thermo Fisher Scientific).
Peptides were loaded onto an Acclaim PepMap 100 C18 resolving
column (15 cm length;75 mm internal diameter; LC Packings,
USA) and separated over a 40 minute gradient from 3.2% to 44%
Figure 4. Protein-peptide interaction network for proteins binding specifically to phosphotyrosine-containing Eps8 peptides. A)
Schematic diagram showing locations of the pY residues within the domain structure of Eps8. B) Using SILAC we carried out quantitative peptide
pull-down assays from FGF2 stimulated (20 ng/ml; 15 min) HEK 293T cells to compare protein-peptide interactions for phosphotyrosine versus non-
phosphotyrosine containing Eps8 peptides. Proteins interacting preferentially to phosphotyrosine peptides have been plotted in an interaction
network.
doi:10.1371/journal.pone.0061513.g004
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acetonitrile (Baker, Holland). Peptides eluted directly (350 nL/
min) via a Triversa nanospray source (Advion Biosciences, NY,
USA) into a LTQ Orbitrap Velos mass spectrometer (Thermo
Fisher Scientific). The mass spectrometer alternated between a full
FT-MS scan (m/z 380-1600) and subsequent CID MS/MS scans
of the twenty most abundant ions. Survey scans were acquired in
the Orbitrap cell with a resolution of 60,000 at m/z 400. Precursor
ions were isolated and subjected to CID in the linear ion trap.
Isolation width was 2 Th. Only multiply-charged precursor ions
were selected for MS/MS. CID was performed with helium gas at
a normalized collision energy of 35%. Precursor ions were
activated for 10 ms. Data acquisition was controlled by Xcalibur
2.1 software.
Identification and Quantification of Peptide and Proteins
Mass spectra were processed using the MaxQuant software
(version 1.0.13.13) [22,23]. Data were searched, using MASCOT
version 2.2 (Matrix Science), against a concatenated database
consisting of the human IPI database (version 3.72) supplemented
with common contaminants (including keratins, trypsin, BSA) and
the reversed-sequence version of the same database. The human
database contained 173,046 protein entries (86,523 of which were
reversed-sequence versions). The search parameters were: mini-
mum peptide length 6, peptide tolerance 7 ppm, mass tolerance
0.5 Da, cleavage enzyme trypsin/P, and a total of 2 missed
cleavages were allowed. Carbamidomethyl (C) was set as a fixed
modification and oxidation (M), acetylation (Protein N-term),
Figure 5. Full-length Eps8 interacts with a range of proteins
identified in the peptide pull down assays. HEK 293T cells were
either transfected with Myc-Eps8 or left untransfected. Cells were
stimulated with 20 ng/ml FGF2 for 15 min and immunoprecipitated
using an anti-Myc antibody. Western blot analysis was carried out on
whole cell lysate and immunoprecipitation samples using antibodies
against the indicated proteins.
doi:10.1371/journal.pone.0061513.g005
Figure 6. Eps8 and IRS4 interact in an FGF2 dependent manner that correlates with an increase in their tyrosine phosphorylation. A)
HEK293T cells transfected with Myc-Eps8 were stimulated with 20 ng/ml FGF2 for 15 min either following 30 min pretreatment with SU5402 or
dasatinib or in the absence of inhibitors. Anti-Myc immunoprecipitation and whole cell lysate samples were analysed by western blotting. B) HEK293T
cells were stimulated with 20 ng/ml FGF2 for different lengths of time and tyrosine phosphorylated proteins were immunoprecipitated. Anti-pY
immunoprecipitation and whole cell lysate samples were analysed by western blotting. C) HEK 293T cells were stimulated with 20 ng/ml FGF2 for
15 min and immnoprecipitations carried out using antibodies to either Eps8 or rabbit IgG. Resulting IP samples were analysed by western blotting. d)
Following 30 min treatment with SU5402 or dasatinib and stimulation with 20 ng/ml FGF2 for a further 15 min, endogenous IRS4 was
immunoprecipitated from HEK293T cells. Resulting IP samples were analysed by western blotting.
doi:10.1371/journal.pone.0061513.g006
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Phospho (ST), and Phospho (Y) were set as variable modifications.
The appropriate SILAC labels were selected and the maximum
labelled amino acids was set to 3.
All experiments were filtered to have a peptide and protein
false-discovery rate (FDR) below 1%. Within the MaxQuant
output, phosphorylation sites were considered to be localised
correctly if the localisation score (PTM score) was at least 0.85
(85%). Additional information is listed in Method S1.
Confocal Microscopy and Quantification Analysis
Cells were fixed in 4% paraformaldehyde (PFA; Electron
Microscopy Sciences) in PBS for 10 min prior to analysis.
Confocal laser microscopy was performed with an inverted
microscope (Zeiss LSM 710) using a 4061.3NA oil-immersion
objective and a Transmission-Photomultiplier LSM T-PMT. Data
analysis was performed using NIS-Elements Imaging Software
version 3.2 (Nikon). The experiment was repeated 3 times and an
image that represented the phenotype of most of the cells was
selected.
Results and Discussion
Effects of SU5402 and Dasatinib on Eps8 Phosphorylation
Eps8 is a phosphorylation substrate for FGFR [8] and Src [9].
To identify the residues upon which these phosphorylation events
take place we have used a targeted mass spectrometric approach.
A quantitative SILAC technique coupled with chemical inhibition
of FGFR or SFK activity has been used to examine any differential
regulation in the phosphorylation of Eps8. Dasatinib is an SFK/
ABL kinase inhibitor approved for use in patients with chronic
myelogenous leukemia [24]. Here, dasatinib has been used to
inhibit SFK activity in preference to SU6656 [25], which was our
previous inhibitor of choice prior to dasatinib becoming commer-
cially available [15]. At concentrations needed to inhibit Src kinase
activity in HEK 293T cells, SU6656 also shows some inhibition of
FGFR activation, as measured by levels of phosphorylated ERK
(Figure 1A). Dasatinib does not show inhibition of FGFR induced
ERK activity, even at high concentrations (Figure 1B). SU5402,
has been used to inhibit the tyrosine kinase activity of FGFR1 [26]
and does not have any effect on phospho-Src levels (Figure 1A).
Using these compounds has allowed us to differentiate between
SFK-mediated and FGFR-mediated phosphorylation events on
Eps8 by comparing levels of phosphorylation in the presence of
dasatinib and SU5402.
We transfected three populations of HEK 293T cells, grown in
either ‘Light’ R0K0, ‘Medium’ R6K4, or ‘Heavy’ R10K8 SILAC
media, with Myc-Eps8. Cells were either left untreated (R0K0) or
pre-treated with SU5402 (R6K4) or dasatinib (R10K8) for 30 min
before stimulation with FGF2 for a further 15 min. Prior to mass
spectrometric analysis, phosphopeptide enrichment was carried
out on immunoprecipitated Myc-Eps8.
Figure 7. Eps8 and IRS4 colocalise within cells in an FGF2 dependent manner. NIH 3T3 cells were co-transfected with IRS4-GFP and Eps8-
mCherry. Cells stimulated with FGF2 (20 ng/ml) in the presence and absence of SU5402 (25 mM) were compared to unstimulated cells (control). A)
Confocal microscopy was used to visualise the localisation of IRS4 and Eps8. B) The colocalisation (Pearson’s coefficient) between IRS4 and Eps8 is
significantly increased in the presence of FGF2 and absence of SU5402 (Pearson’s coefficient, mean6SEM, n= 42 cells. Scale bars = 5 mm. ***,
P,0.001).
doi:10.1371/journal.pone.0061513.g007
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A total of 22 distinct sites of phosphorylation (18 serines and 4
tyrosines) on Eps8 were identified (Table S1). Representative mass
spectra for two of the identified phosphopeptides are shown in
Figure 2 (see Figure S3 for additional spectra). The log-ratios for
each identification of phosphorylated peptide and non-phosphor-
ylated counterpart peptide are plotted in Figure 3 (tyrosine
residues) and Figure S1 (serine residues) and provide a visual
comparison of the relative ratios and number of peptide
identifications between non-treated and inhibitor treated samples.
Statistical methods for determining differential phosphorylation
are discussed by de la Fuente van Bentem et al. [27]. Our preferred
statistical method for deciding differential phosphorylation be-
tween samples is to use a t-test to directly compare non-
phosphorylated and phosphorylated counterpart peptides. How-
ever, the t-test has only been applied when there are three or more
replicates for each peptide. Another method to determine
differential phosphorylation is to select a cut-off for significant
statistics which is based on p-values determined from a test sample
(Method S1). This has been applied when only two identifications
have been made. Of the 4 tyrosine residues identified, 3
phosphotyrosine containing peptides (pY525, pY602, pY774)
had reduced SILAC ratios compared to their unphosphorylated
counterpart in the presence of both SU5402 and dasatinib,
indicating that the tyrosine phosphorylation on these particular
sites within Eps8 are sensitive to both FGFR and SFK activity
(Figure 3A).
Eps8 contains 20 tyrosine residues, and according to the
PhosphositePlus database [28], 9 of them have been found in their
phosphorylated form in the human protein. It may be that under
our experimental conditions in which the cells were stimulated
with FGF2, only the 4 tyrosines that we have identified are
phosphorylated. However, it is also possible that the levels of some
phosphopeptides remain too low for mass spectrometric detection.
Thus, in an attempt to increase the number of phosphorylated
tyrosine residues identified, prior to FGF2 stimulation, cells were
treated with sodium pervanadate to inhibit tyrosine phosphatase
activity and maximise the levels of tyrosine phosphorylated
peptides. Under these conditions, an additional 3 phosphotyrosine
containing peptides were identified, and the majority of the
previously identified phosphopeptides were present in greater
abundance (Figure 3B). Several additional serine residues were
also identified (Figure S1). Of the tyrosine residues identified, 5
phosphotyrosine peptides (pY252, pY485, pY525, pY540, pY602,
pY774) had a reduced SILAC ratio in the presence of SU5402
indicating that these particular sites within Eps8 are regulated by
FGFR kinase activity (Figure 3B). Four (pY485, pY525, pY602,
pY774) also had a reduced SILAC ratios in the presence of
dasatinib, indicating that these sites are regulated by SFK activity
(Figure 3B). One phosphopeptide (pY454) was identified but was
of too low abundance for ratio calculation. Data obtained in the
absence and presence of sodium pervandate were in agreement in
terms of the differential regulation of phosphorylation on these
sites. In the absence of tyrosine phosphatase activity, the number
of phosphotyrosine peptide identification events for site pY525 was
hugely increased, suggesting that this site is readily phosphorylated
but has a high turnover rate. Phosphorylation and dephosphor-
ylation of proteins at distinct sites can act as a molecular switch
regulating the association and disassociation of interacting
proteins. It may be that the Y525 is an important regulatory site
that is required to be turned over at a high frequency rate in order
to allow Eps8 function.
Our experiments have identified 16 of the 20 tyrosines present
within the human form of Eps8, the remainder being in regions of
the protein that were not detected. The total sequence coverage of
Eps8 is 68%. In the presence of FGF2, 7 of these tyrosine residues
are phosphorylated and for 6 of these a SILAC ratio could be
calculated. Residue pY540 shows no change in phosphorylation
due to the presence of the inhibitors, residue pY252 shows
a decrease in phosphorylation only in the presence of the FGFR
inhibitor, and the phosphorylation on residues pY485, pY525,
pY602, and pY774 are decreased in the presence of both the
FGFR and SFK inhibitor.
Phosphotyrosine Specific Interactions
In the presence of FGF2, we have identified specific sites of
tyrosine phosphorylation on Eps8. We have demonstrated
differential phosphorylation events on a number of these sites
that are dependent on activity of FGFR or SFKs. The distribution
of these sites on Eps8 is shown graphically in Figure 4A. Our aim
was to then further characterise these sites by identifying phospho-
dependent protein binding partners. To identify such potential
pTyr-dependent interacting partners for these residues in Eps8,
which may be involved in cellular processes downstream of FGFR,
we used a quantitative proteomic peptide pulldown (PPD)
approach [18]. Peptides containing the desired tyrosine residues
were synthesised in their phosphorylated and non-phosphorylated
forms. Using SILAC, we incubated heavy labelled (R10K8) HEK
293T cell lysates with phosphorylated peptide, medium labelled
(R6K4) lysates with non-phosphorylated peptide, and light lysates
(R0K0) were used as a no peptide control. All cells were treated
with FGF2 for 15 min prior to lysis. The huge advantage of using
SILAC over other techniques is that the specific binders can still be
identified in the presence of many non-specific proteins. Typically
a pull-down experiment will isolate not only specific interactors
but also background proteins that are binding to the bead matrix.
Proteins with SILAC ratios close to 1:1 can be discarded and only
those proteins that are significantly enriched in one of the
populations are regarded as ‘hits’. To qualify as a pY-dependent
binder in these PPD experiments, proteins had to have a HpY/
Mnon-pY and HpY/Lcontrol ratio at least 2 standard deviations
higher than the median (95% confidence). H/M and H/L ratios
for all proteins identified in each PPD experiment are plotted in
Figure S2. There are instances when peptides are identified only in
the heavy state and, therefore, not assigned a ratio. In these cases,
the mass spectra were manually checked to identify pY-peptide
specific interactors. Eighty-five distinct proteins with a range of
cellular functions were identified for the 7 pY-peptides (Figure 4B;
Table S2).
We have identified a number of SH2 or PTB domain-
containing proteins from our PPD assays which are likely to be
direct interacting partners for our phosphotyrosine peptides.
These proteins include known phosphotyrosine-binding proteins
Shp2 (PTPN11), Vav2 and Insulin receptor substrate 4 (IRS4). In
addition, four heavy labelled peptides identified as common to
both Src and CSK were enriched in the pY-PPD for residues 252
and 602. From this data it is not possible to discriminate between
these two proteins as they have high sequence homology, however,
Eps8 is known to bind to Src [9]. STAT3, another SH2 domain
containing protein, was identified in the pY525 PPD, with
a significantly increased HpY/Mnon-pY ratio (.95% confidence)
and an increased HpY/Lcontrol (.93% confidence). As both ratios
were not.95% confidence, STAT3 was not included in Figure 4B
and Table S2.
IRS4, Shp2 and WDR6 were identified as a potential novel
binding partners for the pY252 peptide. IRS4 acts as an interface
between receptor tyrosine kinases, such as IGF1R [29] and
FGFR1 [19], and SH2-containing intracellular signalling mole-
cules. It contains an IRS PTB domain, through which it can bind
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to phosphorylated proteins. IRS4 is known to interact with both
Shp2 [30] and WDR6 [31,32,33], and all these proteins have been
implicated in FGFR signalling [19,20,34].
Eps8 has been shown to regulate receptor endocytosis via its
interaction with RN-Tre [5]. When bound to Eps8, RN-Tre,
a RabGAP, acts on Rab5 to inhibit EGFR internalisation [5]. We
have found several potential Eps8 binding proteins that also play
a role in endocytosis. Clathrin heavy chain was enriched
preferentially with pY485, pY525 and pY540 peptides, and
a component of the adaptor protein complex 2 (AP-2), AP-2
complex subunit beta-1 (AP2B1), with the pY525 peptide. AP-2 is
involved in clathrin-dependent endocytosis in which cargo
proteins become incorporated into clathrin-coated vesicles (CCVs)
which fuse with the early endosome. Recently Eps8 has been
shown to be recruited to clathrin-coated structures at the plasma
membrane [35] and, furthermore, we have found that FGFR
activation promotes clathrin-mediated endocytosis through Eps8
and Src [36]. Vav2, found enriched for pY454, regulates EGFR
receptor endocytosis and degradation [37] and NBR1, found
enriched for pY252, regulates the degradation of receptor tyrosine
kinases [38]. These proteins are potential novel Eps8 interactors
that may act downstream of FGFR.
Proteins involved in vesicular trafficking to and from the Golgi
apparatus include Arf5, a protein involved in vesicle budding from
the Golgi, identified in the pY485 PPD, coatamer subunit alpha
(COPA) in the pY774 PPD and both Sec23A and general vesicular
transport factor p115 (USO1) in the pY525 PPD.
A cluster of proteins involved in nucleocytoplasmic transport
were found bound to pY485, pY525, and pY540: the small
GTPase Ran, Importin-5 (IPO5), importin subunit beta 1
(KPNB1), Exportin-2 (CSE1L), Exportin-7 (XPO7), and Trans-
portin-1 (TNPO1). A number of these proteins are known to bind,
either in isolation, or together with an adapter protein, to nuclear
localisation signals (NLSs) in cargo proteins. As an NLS is
a positively charged sequence, it is possible that these proteins can
bind preferentially to peptides containing basic residues. Peptide
540 is a potential candidate for this, having 4 lysine residues in
close proximity. However, each of these proteins is enriched
specifically for the pY form of the peptide, arguing against lysine-
dependent binding. Eps8 contains a putative NLS between
residues 299–309 [8], but has not been reported to be present in
the nucleus.
Out of the many proteins identified that have functions in
protein trafficking, whether it be from the plasma membrane, to
and from the Golgi, or to and from the nucleus, a significant
number of them are associated with the pY525 peptide.
Interestingly this is the site that we find to have a high turnover
rate, suggesting a functional role in a dynamic cellular process.
MAPKAP1 (Sin1) was recruited to the pY252 peptide.
MAPKAP1 interacts with mammalian target of rapamycin
(mTOR) and is found in the mTOR complex 2 (mTORC2)
[39,40,41]. Interestingly, Eps8 has been shown to regulate the
expression of FAK via the mTor/STAT3 pathway [11]. Eps8
overexpression leading to increased activity of FAK via this
pathway has been shown to promote disease progression in colon
cancer [11]. MAPKAP1 may be a physical link to this pathway. As
previously mentioned, STAT3 was also identified in the pY525
PPD. Additionally, STAT3 has been linked to FGFR in tumour
cells where it can interact with amplified receptor [42].
Other potentially interesting putative Eps8 binding partners
that we have identified that could link Eps8 to FGFR signalling
include LRPPRC, which has previously been co-purified with the
FGFR complex [43], and PHB which is required for Ras-
mediated Raf-MEK-ERK activation [44].
Several RNA-binding proteins have been found in our PPDs. It
has been reported previously that RNA-binding proteins can bind
preferentially to the negative charge on the phosphorylated
peptides, thus appearing as specific binders when they are actually
contaminants [18].
Novel Eps8 Binding Partners
Without further validation proteins identified in peptide pull-
down assays can only be described as potential interactors. It may
be that the interactions are not biologically relevant, or when the
full length protein is in its folded conformation the interactions
detected between peptide and protein are not sterically possible. In
addition contaminants arising from interactions with the bead
matrix may be present. Common IP contaminants, described as
the ‘bead proteome’ are listed and scored in the ‘protein frequency
library’ (used to identify the frequency with which proteins appear
in a subset of IPs using a particular type of beads) [45,46]. This
library can help in discriminating between those proteins that are
true interactors and those that may be bead contaminants. The
majority of proteins identified both here, and with a high
frequency (68–92%) in experiments compiled in the protein
frequency library [46] are RNA-binding proteins: 60S ribosomal
protein (RPL22), SERBP1, ATP-dependent RNA helicase
DDX3X, splicing factor 3B subunits 1 and 2 (SF3B1, SF3B2),
DEAD box protein 41 (DDX41). Hence further validation is
required to identify ‘true’ protein-protein interactions.
In an attempt to further validate potential protein-protein
interactions we used co-immunoprecipitation to pull down Myc-
tagged Eps8 protein from FGF2 stimulated HEK 293T cells and
probed for proteins of interest (Figure 5). The interactions between
Eps8 and AP-2 and clathrin, proteins important in clathrin-
mediated endocytosis, have been confirmed. This further supports
evidence that Eps8 plays an important role in endocytic
trafficking. In addition, we confirm the novel interactions between
Eps8 and Shp2, Vav2, NBR1, LRPPRC, PHB, PHB2 and IRS4.
It must be noted that, although co-immunoprecipitation experi-
ments such as these can confirm protein-protein interactions it is
acknowledged that they detect both direct and indirect interac-
tions.
The Novel Interaction between Eps8 and IRS4 is FGF2
Dependent
FGF2 activation of FGFR1 and FGF7 activation of FGFR2
results in phosphorylation of IRS4 on residue 921 [19,20].
Phosphorylation of IRS4 promotes the formation of a complex
with Shc, which may link IRS4 directly to activated receptor, and
also allows recruitment of Grb2, PLCc and PI3K thus promoting
downstream signalling [19]. In our PPDs IRS4 was identified as
a potential novel binding partner for the Eps8 peptide containing
phosphorylated Tyr252, a residue shown to be sensitive to the
addition of the FGFR kinase inhibitor, SU5402 and not the SFK
inhibitor, dasatinib (Figures 3 and 4). Furthermore, the Eps8-IRS4
protein-protein interaction was confirmed by subsequent co-
immunoprecipitation experiments with Myc-Eps8 in FGF2
stimulated cells (Figure 5). Next, as eluded to in the peptide pull
down assays, we investigated whether the Eps8-IRS4 interaction
within cells is dependent upon FGF2 activation and, therefore,
sensitive to the addition of SU5402 but not dasatinib. Co-
immunoprecipitation experiments were performed in the presence
and absence of FGF2, SU5402 and dasatinib (Figure 6). The
association between Myc-Eps8 and IRS4 increases in the presence
of FGF2 (Figure 6A). Pre-treatment with SU5402 causes an
inhibition of this interaction, indicating this increased association is
due to activation of the FGF receptor. This FGF2 dependent
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increase in the association is not affected by the presence of
dasatinib and, therefore, not dependent on SFK phosphorylation.
An increase in phosphorylation of both Eps8 and IRS4 is seen
upon FGF2 activation as previously reported [8,19]. Both Eps8
and IRS4 are tyrosine phosphorylated in response to FGF2 in
HEK 293T cells (Figure 6A) and remain so throughout the
duration of receptor activation (Figure 6B). The interaction
between Eps8 and IRS4 has been confirmed using endogenous
levels of both proteins (Figure 6C). Co-immunoprecipitation of
endogenous levels of Eps8 and IRS4 only in the presence of FGF2
and FGF2 with dasatinib, both conditions where FGF receptor is
active, confirm that this interaction is FGF dependent (Figure 6D)
as seen with overexpressed Eps8. Cell imaging data using
fluorescently tagged proteins confirm these results. Following
FGF2 stimulation, Eps8 colocalises with IRS4 in NIH 3T3 cells
within the cytoplasm (Figure 7). This colocalisation is decreased
following the addition of SU5402 indicating that it is dependent
upon activated FGFR. These data, together with the peptide pull
down data suggests that the interaction between Eps8 and IRS4
may occur on residue 252 of Eps8 when it is a phosphorylated
state and whose phosphorylation is dependent upon FGFR
activation.
Conclusions
Here we have used quantitative proteomics to study the
phosphorylation of Eps8 and phosphotyrosine dependent binding
of proteins to it. Clusters of proteins with distinct cellular functions
have been identified, including a large number involved in
trafficking, either from the cell membrane, the Golgi or from
cytoplasm to nucleus and vice versa. Most of the proteins identify
are potential novel interactors, and further studies are needed to
validate some of these interactions. The validated interactions
between Eps8 and clathrin and AP-2, provide further evidence to
support the role of Eps8 in receptor mediated endocytosis. Also,
the interaction between Eps8 and IRS4, together with the
knowledge that IRS4 is involved in downstream signalling from
the FGF receptor, is an interesting lead into the role of Eps8 in
FGFR signalling. In conclusion, Eps8 is a multi-functional adaptor
protein which may have the capabilities of integrating receptor
trafficking, cellular signalling, and protein degradation.
Supporting Information
Figure S1 Differential regulation of serine phosphory-
lation on Eps8. Heavy, medium and light SILAC labelled HEK
293T cells were treated with either dasatinib, SU5402, or no
inhibitor, prior to FGF2 stimulation. Myc-Eps8 was immunopre-
cipitated and the resulting sample was run on an SDS-PAGE gel
and, following in-gel trypsin digestion and phophopeptide
enrichment, analysed by mass spectrometry. Each graph repre-
sents specific residues on Eps8 as indicated. Each data point
represents a single peptide identification. P values were calculated
by an unpaired t-test (0.01–0.05= *; 0.001–0.01= **; ,0.001=
***). +, the median of the ratios is outside the significance cut-off
values (,0.57 or .1.75) and is deemed significantly changed (see)
A) Experiment was carried out in the absence of sodium
pervanadate. B) Experiment was carried out in the presence of
2 mM sodium pervanvadate.
(PDF)
Figure S2 Relative SILAC ratios for proteins identified
in peptide pull down assays. Biotinylated Eps8 peptides
containing the desired tyrosine residues (the residue number is
indicated at the top of each plot) were synthesised in their
phosphorylated and non-phosphorylated forms. Three peptide
pull down assays for each residue were performed. Using SILAC,
we incubated heavy labelled (R10K8) HEK 293T cell lysates with
phosphorylated peptide, medium labelled (R6K4) lysates with
non-phosphorylated peptide, and light lysates (R0K0) were used as
a no peptide control. All cells were treated with FGF2 for 15 min
prior to lysis. Following washing, the beads from each assay were
combined, the resulting sample run on an SDS-PAGE gel and,
following in-gel trypsin digestion, analysed by mass spectrometry.
Each graph represents specific residues on Eps8 as indicated. Each
data point represents a single protein identification and is shown as
a function of its HpY/Mnon-pY and HpY/Lcontrol ratios. Those
proteins with both ratios at least 2 standard deviations higher than
the median (95% confidence) are shown in red and are considered
pY-specific binders (these protein are named in Figure 4).
(PDF)
Figure S3 Additional Mass Spectra of Phosphorylated
Peptides Identified.
(PDF)
Table S1 Phosphorylated Peptides and non-Phosphory-
lated Counterpart Peptides Identified in Triple SILAC
(+/2 SU5402/dasatinib) Experiments.
(XLS)
Table S2 Proteins Identified as pY-specific binders in
SILAC peptide pull down (PPD) experiments.
(XLS)
Method S1 Supplementary details regarding Peptide
and Protein Identification and Quantification.
(DOC)
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Summary
Fibroblast growth factor receptors (FGFRs) mediate a wide spectrum of cellular responses that are crucial for development and wound
healing. However, aberrant FGFR activity leads to cancer. Activated growth factor receptors undergo stimulated endocytosis, but can
continue to signal along the endocytic pathway. Endocytic trafficking controls the duration and intensity of signalling, and growth factor
receptor signalling can lead to modifications of trafficking pathways. We have developed live-cell imaging methods for studying FGFR
dynamics to investigate mechanisms that coordinate the interplay between receptor trafficking and signal transduction. Activated FGFR
enters the cell following recruitment to pre-formed clathrin-coated pits (CCPs). However, FGFR activation stimulates clathrin-mediated
endocytosis; FGF treatment increases the number of CCPs, including those undergoing endocytosis, and this effect is mediated by Src
and its phosphorylation target Eps8. Eps8 interacts with the clathrin-mediated endocytosis machinery and depletion of Eps8 inhibits
FGFR trafficking and immediate Erk signalling. Once internalized, FGFR passes through peripheral early endosomes en route to
recycling and degredative compartments, through an Src- and Eps8-dependent mechanism. Thus Eps8 functions as a key coordinator in
the interplay between FGFR signalling and trafficking. This work provides the first detailed mechanistic analysis of growth factor
receptor clustering at the cell surface through signal transduction and endocytic trafficking. As we have characterised the Src target Eps8
as a key regulator of FGFR signalling and trafficking, and identified the early endocytic system as the site of Eps8-mediated effects, this
work provides novel mechanistic insight into the reciprocal regulation of growth factor receptor signalling and trafficking.
Key words: Eps8, FGFR, Clathrin, Endocytosis, Src
Introduction
Ligand-mediated activation of receptor tyrosine kinases (RTKs)
initiates a signal transduction cascade that leads to a broad
spectrum of cellular responses including differentiation,
proliferation, survival and migration. These responses are
initiated by recruitment of adaptors, scaffold and signalling
proteins to the phosphorylated cytoplasmic tail of the receptor
(Greenfield et al., 1989; Ullrich and Schlessinger, 1990; Heldin,
1995). Receptor activation also acts as the initiating stimulus for
endocytosis of RTKs following ligand binding and this can occur
via a variety of routes including both clathrin-mediated
endocytosis (CME) and clathrin-independent endocytosis (CIE)
(von Zastrow and Sorkin, 2007; Le Roy and Wrana, 2005).
Endocytosis and subsequent trafficking to intracellular
compartments have been considered to be principally
mechanisms of signal attenuation: the former by controlling the
number of receptors available for activation on the plasma
membrane, the latter by sorting the internalized receptors into the
intralumenal vesicles of multivescicular bodies (MVBs) where
receptor proteolysis takes place and signalling is terminated
(Stoscheck and Carpenter, 1984; Beguinot et al., 1984). There is
mounting evidence, however, that signalling from internalized
receptors persists along the endocytic pathway, and that
endocytosis and intracellular trafficking mechanisms have a
powerful influence on the spatial and temporal dynamics of the
signal (von Zastrow and Sorkin, 2007; Di Fiore and De Camilli,
2001; Kholodenko, 2002; Polo and Di Fiore, 2006; Sorkin and
Von Zastrow, 2002; Disanza et al., 2009; Sandilands and Frame,
2008) which influences biological outcomes (Zhang et al., 2000).
Alternatively, recent evidence suggests that for at least some
RTKs, signalling primarily occurs immediately following ligand
binding prior to endocytosis (Sousa et al., 2012; Brankatschk
et al., 2012). It is also possible that regulated endocytosis and
intracellular trafficking of activated RTKs shape the identity of
the signal as confinement within intracellular compartments
provides a mechanism for regulating the composition of receptor-
associated protein complexes. These considerations place
emphasis on understanding the molecular mechanisms that
coordinate activated RTK signalling and trafficking as key
determinants of the biological outcomes of receptor activation.
Fibroblast growth factor receptors (FGFRs) represent a
subfamily of 4 highly conserved RTKs (FGFR1, FGFR2,
FGFR3 and FGFR4) that regulates fundamental cellular
processes, including proliferation, differentiation and
angiogenesis (Burgess and Maciag, 1989; Basilico and
Moscatelli, 1992). FGFR activation initiates signalling through
a number of pathways including the well characterised Ras/Raf/
ERK and PI3 kinase/PDK/Akt pathways (Mason, 1994). Of
particular interest is the occurrence of somatic or germ-line
mutations in FGFRs which modify the dynamics of signal
propagation via mechanisms such as hyper-sensitivity of kinase
activation, ligand-independent dimerization or receptor
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amplification (Grose and Dickson, 2005; Wesche et al., 2011;
Turner and Grose, 2010; Beenken and Mohammadi, 2009). These
findings indicate that understanding the mechanisms of FGFR
endocytosis and trafficking, and their impact on signalling
dynamics, is an important goal in understanding both
pathological and physiological FGFR biology. We have
previously demonstrated a critical role for non receptor tyrosine
kinases of the Src family (SFKs) in shaping FGFR trafficking and
signalling dynamics (Sandilands et al., 2007). Src is recruited to
activated fibroblast growth factor receptor complexes through the
adaptor protein factor receptor substrate 2 (FRS2) at the plasma
membrane. This localisation requires both active Src and FGFR
kinases, which are interdependent. Internalization of activated
FGFRs involves release from complexes containing activated Src
and trafficking into multiple intracellular compartments
including RhoB and Rab5 endosomes via a mechanism(s)
which require an intact actin cytoskeleton (Sandilands et al.,
2007). Chemical and genetic inhibition studies showed strikingly
different requirements for Src family kinases in FGFR-mediated
signalling; activation of the phosphoinositide-3 kinase–Akt
pathway is severely attenuated, whereas activation of the
extracellular-signal-regulated kinase pathway is delayed in its
initial phase and fails to attenuate. These findings show that Src
kinase activity and Src substrates that mediate exit of activated
FGFRs from the plasma membrane are critical determinants of
the early phases of FGFR signal propagation.
In detailing Src substrates that are phosphorylated in the early
phases of FGFR activation, in order to identify candidates
for mediating Src-regulated trafficking, we identified the
multifunctional scaffolding protein Eps8 as a prominent target
of Src kinase activity (Cunningham et al., 2010). Eps8 is an
attractive subject for further scrutiny as it has well documented
roles in regulating the actin cytoskeleton (Provenzano et al.,
1998) and has been implicated in trafficking of the epidermal
growth factor receptor (EGFR) (Di Fiore and Scita, 2002).
Furthermore, EGFR signalling through Src has previously been
shown as a mechanism for regulating the cellular distribution of
clathrin (Wilde et al., 1999). It is accordingly of interest to
understand the functions of Eps8 in regulating FGFR trafficking
and signalling dynamics.
In this study, we have performed a detailed series of analyses
to investigate the mechanisms responsible for the coordinated
trafficking and signalling of activated FGFR. We have
specifically characterised the mechanisms controlling FGFR
endocytosis and endocytic trafficking in the early phases of
FGFR activation and in particular we have focused on the role of
Src acting through Eps8. Eps8 is thus identified as a key mediator
of the early phases of activated FGFR trafficking and signalling
relevant to regulation of clathrin-mediated endocytosis,
trafficking out of the early endosome into the perinuclear
recycling compartment, and FGF-mediated pErk signalling.
Results
FGFR is internalized though an FGFR-kinase- and
dynamin-dependent pathway
Different pathways have been implicated in the endocytosis of
activated RTKs (von Zastrow and Sorkin, 2007; Le Roy and
Wrana, 2005). Thus, we first set out to document the mechanism
by which FGFR is trafficked following activation. We employed
live-cell confocal microscopy to analyse the trafficking of
activated FGFR2 in HeLa cells, which express very low levels
of endogenous FGFR2 (Ahmed et al., 2008), using a GFP-tagged
form of FGFR2 which was previously validated in published
studies from John Ladbury’s laboratory (Schu¨ller et al., 2008). As
depicted in Fig. 1A, live-cell confocal imaging demonstrates that
following FGF stimulation, FGFR2–GFP undergoes rapid
internalization from the plasma membrane and eventually
traffics to a peri-nuclear endocytic compartment. This
redistribution away from the cell periphery did not occur in the
absence of ligand addition, and SU5402, a potent inhibitor of
FGFR kinase activity, completely prevented FGF stimulated
internalization (Fig. 1A,B) (Sun et al., 1999). Therefore, the
cellular localisation and behaviour of GFP-tagged FGFR2
reflects that of endogenous protein. Thus, we have applied this
quantitative and robust assay for trafficking of activated RTKs in
live cells to the analysis of the routes of FGFR endocytosis and
endocytic trafficking.
Several endocytosis pathways have been implicated in the
internalization of activated FGFRs (Marchese et al., 1998;
Citores et al., 1999; Belleudi et al., 2007; Gleizes et al., 1996;
Haugsten et al., 2011). The large GTPase dynamin has been
clearly demonstrated to be a crucial regulator of numerous
endocytosis pathways (Doherty and McMahon, 2009). Therefore,
we assessed whether inhibition of dynamin function with the
potent dynamin inhibitor Dynasore affected the ligand induced
endocytosis of FGFR (Macia et al., 2006). Importantly, control
endocytosis studies verified the efficacy of Dynasore treatment in
our systems (supplementary material Fig. S1A). As depicted in
Fig. 1C,D, treatment with Dynasore completely prevented
internalization of FGFR following FGF stimulation. Therefore,
activated FGFRs undergo dynamin-dependent endocytosis.
FGFR is internalized through clathrin-mediated
endocytosis
Two of the main endocytosis pathways that are dynamin
dependent include clathrin-mediated endocytosis and entry via
caveolae (Doherty and McMahon, 2009). We employed an
RNAi-based approach utilising previously published siRNA
which we have previously employed to silence expression of a-
adaptin, a critical component of the clathrin-mediated
endocytosis machinery, in HeLa cells (Rappoport and Simon,
2008; Rappoport and Simon, 2009), or caveolin1 (Li et al., 2012),
which is required for caveolae formation (Rothberg et al., 1992).
Control experiments revealed that a-adaptin siRNA treatment
significantly inhibited transferrin endocytosis (supplementary
material Fig. S1B) and potently reduced expression of a-adaptin
(supplementary material Fig. S1C). Similarly, siRNA targeting
caveolin1 significantly inhibited endocytosis of cholera toxin B
sub-unit (supplementary material Fig. S2A) and decreased
caveolin1 protein levels (supplementary material Fig. S2B).
Importantly, these siRNA reagents did not reduce expression of
control protein. Therefore, the utility of these inhibitory strategies
has been sufficiently validated in our systems for usage in live-
cell imaging studies.
As demonstrated in Fig. 2A,B, treatment with a-adaptin
siRNA clearly prevented endocytosis of FGFR following FGF
treatment. However, silencing of caveolin1 expression had no
effect on the internalization of FGFR following stimulation
(Fig. 2C,D). Thus, these results show that active FGFR enters
cells via clathrin-mediated endocytosis and not through caveolae.
In order to verify the potential for clathrin-mediated
endocytosis of activated FGFR we performed a series of
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colocalisation studies with known markers for these same two
endocytosis pathways. Total internal reflection fluorescence
(TIRF) microscopy permits selective illumination of the
plasma-membrane-associated region with a depth of penetration
of only ,100 nm (Axelrod, 2008; Mattheyses et al., 2010) and
has emerged as the technique of choice for imaging trafficking
Fig. 1. Active FGFR is internalized
through dynamin-dependent endocytosis.
HeLa cells transiently transfected with
FGFR2-GFP were incubated for 5 minutes in
the presence or absence of SU5402 (A) or for
30 minutes in the presence or absence of
Dynasore inhibitor (C) and imaged using
confocal live-cell microscopy at 37 C˚ for
30 minutes following stimulation with FGF2
+ heparin. The first and the last frames are
shown, corresponding to the situations before
and after FGF2 treatment, respectively. Scale
bars: 5 mm. (B,D) The experiments shown in
A and C were performed in many cells and
the relative FGFR2–GFP intensity in the PM
region of the cells was calculated (as
described in the Materials and Methods) for
each frame of the time-lapse sequence and
plotted as a function of time (means 6
s.e.m., n514 cells).
Fig. 2. Active FGFR enters cells by
clathrin-mediated endocytosis and not
through caveolae. HeLa cells were co-
transfected with FGFR2–GFP and a-adaptin
siRNA (A) or caveolin1 siRNA (C) and
confocal live-cell microscopy was
performed at 37 C˚ for 30 minutes following
stimulation with FGF2 + heparin. Scale bars:
5 mm. (B,D) The experiments shown in A
and C were performed in many cells and a
quantification of FGFR2–GFP intensity in
the PM region of the cells as function of
time was performed (means 6 s.e.m.,
n510 cells).
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processes at the plasma membrane such as endocytosis
(Rappoport, 2008), and the dynamics of activated RTKs
(Rappoport and Simon, 2009). As depicted in Fig. 3, TIRF
microscopy reveals that following FGF stimulation FGFR2–GFP
significantly colocalises with clathrin–dsRed (Fig. 3A,B), a
previously validated marker for sites of clathrin-mediated
endocytosis (Engqvist-Goldstein et al., 2001). Furthermore,
consistent with our RNAi studies (Fig. 2), no significant
colocalisation was observed between FGFR and a red-tagged
caveolin1 fusion protein known to mark caveolae at the cell
surface (Damm et al., 2005). Therefore, these two lines of
evidence support the conclusion that activated FGFR enters cells
primarily via clathrin-mediated endocytosis. It should be noted
though that, as in our previous studies of EGFR trafficking by
TIRF microscopy (Rappoport and Simon, 2009), colocalisation
of activated FGFR and clathrin at the plasma membrane persists
following time points where a majority of the receptor has been
internalised. This could either suggest differences between
endocytosis kinetics between the adherent and lateral plasma
membranes, or reflect the presence of a population of growth
factor receptor that does not undergo endocytosis following
activation, possibly signalling through clathrin-coated pits
(CCPs).
Live-cell TIRF microscopy can be employed to visualise the
dynamics of RTKs at the plasma membrane, and our previous
results demonstrated that following activation EGFR clusters at
pre-formed CCPs prior to endocytosis (Rappoport and Simon,
2009). Three non-mutually exclusive hypothesis could describe
the dynamics leading to colocalisation of activated FGFR and
clathrin: FGFR could be recruited to CCPs, CCPs could form at
the sites of receptor clustering, and clathrin and FGFR could
accumulate simultaneously. When two-colour live-cell TIRF was
performed on cells expressing FGFR2–GFP and clathrin–dsRed,
it was observed that the vast majority of receptor clusters form at
the sites of pre-existing clathrin (Fig. 4). In nearly all cases
clathrin was observed at the site where subsequently FGFR
would cluster. Thus, it seems that recruitment to pre-existing
CCPs represents an emerging paradigm for the dynamics of
activated RTKs.
FGFR activation promotes clathrin-mediated endocytosis
through Src and Eps8
Previous evidence has identified Src as involved in the
redistribution of clathrin to the cell periphery following RTK
activation (Wilde et al., 1999). Therefore, we assessed whether
FGFR stimulation regulated clathrin-mediated endocytosis. As
depicted in Fig. 5, stimulation of cells with FGF led to a striking
increase in the number of clathrin spots on the plasma membrane
(Fig. 5A,B). Furthermore, this also increased the density of
endocytosis events as gauged by established TIRF microscopy
based criteria (Fig. 5D) (Rappoport, 2008). Interestingly, FGF
treatment did not result in an increase in transferrin entry,
Fig. 3. Activated FGFR colocalises with clathrin at the
plasma membrane but not with caveolin1. HeLa cells
co-transfected with FGFR2–GFP and clathrin–dsRed
(A) or caveolin1–mRFP (C) were stimulated with FGF2 +
heparin for 15 minutes, then fixed and analysed using
dual-colour TIRF microscopy. Higher-magnification
images (insets) of selected regions of the cells show
overlap of FGFR and clathrin/caveolin1 in yellow. Scale
bars: 5 mm. (B,D) Quantification of colocalisation was
performed by analysing the overlap of each clathrin or
cavolin1 spot with an FGFR one. A control of random
colocalisation is also shown (means 6 s.e.m., n524 cells).
*P,0.05; **P,0.01; ***P,0.001.
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suggesting that the increased endocytosis observed following
FGFR activation may reflect a cargo specific pathway
(supplementary material Fig. S3).
The increase in clathrin-mediated endocytosis was a direct
consequence of receptor activity, and not an alternative effect of
FGF treatment, as SU5402 completely abrogated the ability of
Fig. 4. Activated FGFR clusters at sites of pre-formed
clathrin-coated pits. HeLa cells co-expressing FGFR2–GFP
and clathrin–dsRed were imaged using simultaneous two-
colour TIRF microscopy at 37 C˚ (1 frame/30 sec) after
stimulation with FGF2 + heparin. (B) Selected frames from a
time-lapse sequence of two FGFR spots (top) and two clathrin
spots (middle), and the merged images (bottom) showing the
overlap of the two channels in yellow. (C) The kymographic
representation of the spots shown in B reveals that FGFR
appears in the TIRF field and colocalises with pre-existing
clathrin. (A) Quantification of the percentage of clathrin
clusters forming at pre-existing FGFR spots, of FGFR spots
recruited at pre-formed clathrin clusters or FGFR and clathrin
clustering simultaneously at the plasma membrane (means 6
s.e.m., n533 cells). *P,0.05; **P,0.01; ***P,0.001.
Fig. 5. FGFR activation promotes
clathrin-mediated endocytosis via Src
and Eps8. (A–C) HeLa cells transiently
expressing FGFR2–GFP and clathrin–
dsRed and incubated in the presence or
absence of SU5402 (5 minutes), Dasatinib
inhibitor (30 minutes) or treated with Eps8
siRNA, were analysed using TIRF
microscopy before and 30 minutes after
stimulation with FGF2 + heparin.
(A) Upon FGF stimulation, cells show a
significant increase in the number of
clathrin spots on the plasma membrane.
Scale bars: 5 mm. (B,C) Quantification of
the clathrin spots for the different
conditions described above reveals that the
FGF-dependent increase of clathrin at the
plasma membrane is both Src and Eps8
dependent, and requires the full kinase
activity of the receptor. (D) HeLa cells
expressing FGFR2–GFP and Clathrin–
dsRed were imaged using live-cell TIRF
microscopy at 37 C˚ for 2 minutes
(1 frame/200 msec) before and 30 minutes
after stimulation with FGF2 + heparin.
Quantification of the clathrin spots
disappearing from the TIRF field shows a
significant increase in the density of
endocytic events upon FGF stimulation
(means 6 s.e.m., n530 cells for each
condition in B and C, n524 cells in D.
*P,0.05; **P,0.01; ***P,0.001.
(E) Cellular extracts from HeLa cells
transfected with myc–Eps8 (where
indicated) were immunoprecipitated with
anti-myc, resolved by SDS-PAGE and
analysed by immunoblotting for the levels
of specified proteins.
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FGF addition to increase clathrin spot number at the plasma
membrane (Fig. 5B). However, as SU5402 treatment in
unstimulated cells did not alter the steady state number of
clathrin spots on the cell surface, it can be inferred that basal
FGFR signalling does not regulate the baseline level of clathrin-
mediated endocytosis. Treatment with the Src family kinase
inhibitor Dasatinib, which we have previously shown inhibits
Src-dependent FGFR signalling and trafficking events
(Sandilands et al., 2007), significantly inhibited the ability of
FGFR stimulation to increase clathrin spot numbers (Fig. 5B).
However, Dasatinib treatment in unstimulated cells did not
reduce the number of CCPs, suggesting that SFK activity is not
required for constitutive endocytosis.
Our previously published work identified that Eps8 is
phosphorylated in a Src-dependent manner following FGFR
activation (Cunningham et al., 2010). Furthermore, Eps8 has
been implicated as playing a role in clathrin-mediated
endocytosis (Taylor et al., 2011). Consistent with these
observations, treatment with Eps8 siRNA completely prevented
the increased number of clathrin spots following FGFR activation
(Fig. 5C). Importantly, the sequence employed to silencing Eps8
was employed in previously published studies from the
laboratory of Giorgio Scita (Disanza et al., 2006), and western
blot analysis revealed that siRNA targeting Eps8 potently
reduced Eps8 protein levels without affecting expression on
negative control protein, tubulin (supplementary material Fig.
S4A). Therefore, FGFR signalling through Src to Eps8 appears to
be important in recruiting new clathrin at plasma membrane,
consequently promoting clathrin-mediated endocytosis. This
provides evidence for a biologically relevant link between
FGFR-mediated signalling and membrane trafficking mediated
through Src and Eps8. Furthermore, we have performed similar
studies in LNCap cells (supplementary material Fig. S5), which
have previously been shown to endogenously express FGFR2
(Carstens et al., 1997). These studies revealed that in the absence
of expression of GFP-tagged FGFR treatment of cells with FGF2
resulted in a significant increase in plasma membrane clathrin
spot number. Therefore, these results demonstrate this effect is
not cell line specific, and can occur via signalling through
endogenous FGFR2.
In order to verify the suggested link between Eps8 and
clathrin-mediated endocytosis we performed a series of
biochemical studies. Co-immunoprecipitation analyses
demonstrated that Eps8 associates with clathrin heavy chain, a-
adaptin and dynamin2 (Fig. 5E), all proteins involved in clathrin-
mediated endocytosis (Doherty and McMahon, 2009). This
suggests that Eps8 is capable of being incorporated into a
complex with several members of the endocytosis machinery,
further supporting its role in early phases of trafficking following
receptor activation. These associations were also observed in
similar studies performed in HEK293 cells, the proteomic
platform we previously employed to identify the connection
between FGFR, Src and Eps8 (Cunningham et al., 2010)
(supplementary material Fig. S6). Furthermore, in this model
we observed that interactions between Eps8 and the machinery
for clathrin-mediated endocytosis occur with and without FGF
stimulation.
FGFR early endocytic trafficking requires SFK kinase
activity
As the above data suggesting a role for Src and Eps8 in the early
phases of FGFR signalling and clathrin-mediated endocytosis, we
studied the effects of Src inhibition on trafficking of activated
FGFR. As depicted in Fig. 6, treatment with Dasatinib resulted in
Fig. 6. Inhibition of Src kinase activity and
silencing of Eps8 impair the trafficking of
FGFR. (A) HeLa cells transiently expressing
FGFR2–GFP were incubated for 30 minutes
in the presence or absence of Dasatinib and
imaged by confocal live-cell microscopy at
37 C˚ for 30 minutes following stimulation
with FGF2 + heparin. (C) Eps8 knockdown
cells (Eps8 shRNA) transiently expressing
FGFR2–GFP were stimulation with FGF2 +
heparin and imaged as in A. The first and the
last frame of the time-lapse sequences are
shown in A and C. Scale bars: 5 mm. Higher-
magnification images of selected regions
from the cells (insets) show an atypical
peripheral localisation of FGFR-containing
vesicles. (B,D) The quantification of FGFR2–
GFP intensity in the PM region of the cells as
a function of time shows an impaired
trafficking of FGFR in both Src-inhibited and
Eps8shRNA cells (means 6 s.e.m.,
n516 cells).
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pronounced effects on the behaviour of FGFR2–GFP following
FGF stimulation. Almost complete inhibition of redistribution of
FGFR from the cell periphery was observed (Fig. 6A,B).
However, high magnification imaging of the plasma-
membrane-associated region (see Fig. 6A, inset) revealed the
presence of numerous peripheral puncta containing FGFR
following stimulation. This would support our evidence for a
role of Src-kinase-dependent processes in regulating early
endocytic trafficking of activated FGFR.
The role of Eps8 in endocytic trafficking of FGFR
Given the potential role of Eps8 as a downstream effector of Src-
kinase-mediated processes, we next studied the consequences of
Eps8 depletion on activated FGFR trafficking. In order to assess a
role for Eps8 in this process, we made use of a HeLa cell line
engineered with stable silencing of Eps8 expression which was
previously validated in published studies from the laboratory of
Giorgio Scita (Disanza et al., 2006). Western blotting studies
confirmed potent and specific silencing of Eps8 in these cells,
relative to control (supplementary material Fig. S4B). Similar to
our observations in cells treated with the Src inhibitor
(Fig. 6A,B), shRNA-mediated reduction in the expression of
Eps8 also inhibited trafficking of activated FGFR away from the
cellular periphery and towards the perinuclear region
(Fig. 6C,D). Furthermore, peripheral FGFR-positive puncta
were observed in Eps8 knockdown cells, identical to those
observed following Dasatinib treatment (see Fig. 6C, inset).
Interestingly, an effect of Eps8 depletion was not apparent at the
earliest time points following FGF addition; accumulation of
FGFR in a peripheral compartment, rather than direct inhibition
of FGFR endocytosis was evident. Thus, inhibition of Src
function and silencing of Eps8 result in similar effects on FGFR
trafficking further supporting a mechanistic connection between
FGFR activation, Src kinase activity and Eps8 function,
specifically localised in a peripheral endocytic compartment.
In order to further characterise the potential localisation of
Eps8 action on the endocytic trafficking of FGFR we
simultaneously visualised both in cells at various times
following FGF addition. As depicted in Fig. 7, prior to
stimulation both FGFR and Eps8 are observed primarily close
to the lateral plasma membrane, consistent with our other
observations. However, while FGFR and Eps8 colocalise to a
Fig. 7. During early stages of trafficking Eps8 colocalises with FGFR and is required for signal transduction through the MAPK cascade. HeLa cells
transiently expressing FGFR2–GFP and Eps8–mCherry were either stimulated with FGF2 + heparin for 10 or 30 minutes, or not stimulated, then fixed and
analysed using confocal microscopy. (A) During the early stages of activation (10 min FGF), FGFR primarily localises in early endosomal compartments, where it
colocalises with Eps8. 30 minutes after FGF addition, FGFR redistributes to the perinuclear region, whereas Eps8 still resides in peripheral compartments, just
beneath the plasma membrane. Scale bars: 5 mm. (B) Quantification demonstrates significant colocalisation of FGFR and Eps8 only during early phases of
receptor activation, where they both localise in early endocytic compartments (means 6 s.e.m., n514 cells). (C) Eps8 knockdown and vector control HeLa cells
transiently expressing FGFR2–GFP were lysed following stimulation with FGF2 + heparin for the indicated times. Cellular extracts where resolved by SDS-PAGE
and analysed by immunoblotting for the levels of the specified proteins. The time course of Erk phosphorylation in response to FGF shows a significant
attenuation of p44 ERK signal at early times (5 minutes) in Eps8 knockdown cells. (D) Quantification of p44 pERK levels following FGF stimulation in Eps8
knockdown (blue) and vector control HeLa (green) cells (means 6 s.e.m., n55 experiments) by densitometric scanning of western blots. *P,0.05;
**P,0.01; ***P,0.001.
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very large degree in peripheral vesicles 10 minutes post-
stimulation, once FGFR traffics into the juxtanuclear
compartment this coincidence is lost. Quantification revealed
that 30 minutes following addition of FGF, Eps8 is retained at the
periphery and no longer colocalises with the juxtanuclear pool of
FGFR (Fig. 7B). Similarly, Eps8 colocalises with EEA1, a
marker for early endosomes (Stenmark et al., 1996) (data not
shown). Therefore it appears that Eps8 resides in the early
endocytic system, and that activated receptors move through this
compartment following endocytosis.
To further elucidate the site of action of Src/Eps8 in FGFR
trafficking we performed a series of other colocalisation studies.
As depicted in supplementary material Fig. S7, triple
colocalisation of activated FGFR, following 10 minutes FGF
treatment, Eps8, and transferrin, following a 5 minute incubation
places Eps8 in a common early endocytic compartment shared by
activated growth factor receptors and transferrin/transferrin
receptor. Additionally, in supplementary material Fig. S8
colocalisation between Eps8 and constitutively active Src in the
cell periphery, further support our evidence of an early endocytic
compartment regulated by Src and Eps8.
The role of Eps8 in FGFR signalling
As we have clearly identified a role for Eps8 in the early
endocytic trafficking of FGFR, we next tested whether Eps8
regulated FGFR signalling as well. As depicted in Fig. 7C,D,
stimulation with FGF results in a rapid appearance of the p44
form of activated ERK which reaches maximum amplitude at
5 minutes and then declines. In this system, the p42 form of ERK
exhibits tonic basal activation and does not respond to FGF
stimulation. In fact p42/ERK is apparent in non-transfected HeLa
cells subjected to overnight serum starvation (supplementary
material Fig. S9). In cells stably silenced for Eps8 expression the
FGF-mediated activation of p44 ERK was blunted during the
initiating (5 minute) phase of the FGF response. Thus, these
findings show that functional Eps8 is required for early phase
activation of the Ras/Raf/ERK pathway during the period in
which activated FGFRs are recruited away from the plasma
membrane. This finding also suggests that activated FGFR can
connect to the Ras/Raf/ERK pathway in an Eps8-independent
manner which results in lower amplitude signals. Thus this
suggests that Eps8 coordinates the signalling and trafficking of
FGFR immediately following activation.
The role of Eps8 in trafficking FGFR out of the early
endosome
In order to further characterise the role of Eps8 in FGFR
trafficking, we performed a series of colocalisation studies with
well characterised markers within the endocytic system. As in our
previous live-cell imaging studies, 30 minutes following
activation FGFR was observed to localise to an intracellular
region adjacent to the nucleus (Fig. 8A). Thus, the extent of
colocalisation between FGFR and EEA1, was very low
30 minutes post-stimulation (Fig. 8B). However, in the Eps8
knockdown cells the extent of colocalisation between FGFR and
EEA1 was significantly higher (Fig. 8B), suggesting that Eps8
functions to permit exit of FGFR from peripheral early
endosomes. Similarly, while clear colocalisation was observed
between FGFR and Rab11 (Fig. 8C), a marker for the peri-
nuclear recycling compartment (Ullrich et al., 1996), in control
cells 30 minutes post-stimulation, this was significantly reduced
in the Eps8 knockdown cells (Fig. 8D). Finally, we performed
similar studies employing Lysotracker as a marker for endocytic
degradative compartments (Fig. 8E,F), and found that silencing
of Eps8 significantly reduced colocalisation of FGFR and
Lysotracker 30 minutes post-stimulation. Finally, super-
resolution imaging of FGFR–GFP in Dasatinib treated cells
30 minutes after FGF addition revealed clearly the presence of
FGFR in peripheral diffraction limited puncta (supplementary
material Fig. S10). Therefore, these results demonstrate that Eps8
is required for the trafficking of activated FGFR out of the early
endocytic system and into the peri-nuclear recycling
compartment and degradative compartment(s).
Discussion
Growth factor receptors undergo regulated internalization from
the cell surface in response to ligand binding (von Zastrow and
Sorkin, 2007; Le Roy and Wrana, 2005). Endocytosis and
subsequent degradation represent strategies to attenuate
signalling of RTK, and alterations in receptor trafficking have
emerged as a mechanism of oncogenic activation (Peschard and
Park, 2003). Here we have applied imaging based assays for
studying endocytosis and trafficking of FGFRs with cells
expressing a previously validated GFP-tagged FGFR2 (Schu¨ller
et al., 2008). Through use of this system we have demonstrated
the interplay between RTK signalling and trafficking, and
identified a mechanistic role for Eps8 in mediating clathrin-
mediated endocytosis, endocytic trafficking, and MAP kinase
signalling. We have demonstrated that receptor trafficking is
regulated through signalling transduction pathways downstream
of receptor activation, and that the location of the activated
receptor within the endocytic system has significant implications
on the amplitude of signalling readouts.
Although FGFs are extremely relevant in both development
and cancer progression, very little is known about FGFR
trafficking (Marchese et al., 1998; Citores et al., 1999; Belleudi
et al., 2007; Gleizes et al., 1996; Haugsten et al., 2011). Our data
have shown that internalization of FGFR was severely reduced in
cells treated with the dynamin inhibitor Dynasore (Fig. 1),
indicating that endocytosis of activated receptor occurs through a
dynamin-dependent pathway. Using a siRNA approach we
observed a complete block of FGFR endocytosis in cells
silenced for a-adaptin, whereas no effect was detected in cells
treated with caveolin1 siRNA (Fig. 2). We further confirmed
these observations by analysing the colocalisation of FGFR with
clathrin or caveolin1 at the plasma membrane using TIRF
microscopy. Following stimulation, activated FGFR significantly
colocalises with clathrin at the cells surface, while no
colocalisation with caveolin1 was observed (Fig. 3). Thus,
these results identified clathrin-mediated endocytosis as the
major pathway for FGFR internalization. Further analyses via
live cell TIRF microscopy demonstrated that, like activated
EGFR (Rappoport and Simon, 2009), following stimulation
FGFR is recruited into pre-formed CCPs (Fig. 4), suggesting that
this may be a mechanism conserved across multiple different
RTKs.
The next phase of our studies was to characterise mechanistic
links between FGFR signalling and trafficking. Src plays a
central role in FGFR signalling pathway and has been previously
suggested to regulate FGFR trafficking (Sandilands et al., 2007).
Previous analyses from our laboratory identified putative Src
targets involved in the regulation of FGFRs signalling and
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trafficking (Cunningham et al., 2010). In particular the protein
Eps8, previously implicated in vesicle trafficking (Lanzetti et al.,
2000), was identified as a Src-dependent kinase substrate
phosphorylated in response to FGF stimulation. Therefore, we
analysed potential roles for Eps8 in the trafficking and signalling
of activated FGFR.
Previously it was shown that EGFR activation, signalling
through Src, increased the peripheral accumulation of clathrin
(Wilde et al., 1999). Our work demonstrates that FGFR activation
increases both the number of CCPs and the events of clathrin-
mediated endocytosis (Fig. 5). Furthermore, we have
demonstrated that Src kinase activity and Eps8 are required for
the increase in CCP number following FGFR activation (Fig. 5).
Interestingly though, while FGFR activation stimulated clathrin-
mediated endocytosis, it did not increase transferrin uptake
(supplementary material Fig. S3). Thus, the route of entry for
activated RTKs may exist as a cargo specific pathway.
Consistent with live cell imaging studies (Taylor et al., 2011),
our biochemical studies demonstrated that Eps8 interacts with the
clathrin-mediated endocytosis machinery (Fig. 5). Interestingly,
similar studies in HEK293 cells demonstrated these interactions
are not FGF2 stimulus dependent (supplementary material Fig.
S6). However, we have also identified roles for Src and Eps8 in
the further endocytic trafficking of FGFR. Following Dasatinib
treatment, FGFR containing vesicles were observed to
accumulate at the cell periphery, confirming the role for Src in
the early endocytic trafficking of FGFRs (Fig. 6). Similarly, in
Eps8 knockdown cells we observed a Dasatinib-like phenotype: a
strong inhibition of FGFR trafficking with a pool of receptor
localised in a peripheral punctuate compartment (Fig. 6). Thus,
this is consistent with our hypothesis that Eps8 is a Src-dependent
regulator of FGFR trafficking within the early endocytic system.
Further supporting a role for Eps8 in exit from the early
endocytic system, during the early stages of trafficking FGFR
significantly colocalises with Eps8 just beneath the plasma
membrane (Fig. 7). Furthermore, Eps8 colocalised with FGFR
and transferrin in peripheral early endosomes (supplementary
material Fig. S7), as well as with constitutively active Src
(supplementary material Fig. S8). However, 30 minutes post-
stimulation the juxtanuclear pool of FGFR clearly did not
colocalise with Eps8 which was retained in a peripheral
compartment (Fig. 7). Similarly, exit from the EEA1 early
Fig. 8. Eps8 is required for the trafficking of activated FGFR out of
the early endocytic system and into the peri-nuclear recycling and
late degradative compartments. Eps8 knockdown and vector control
HeLa cells transiently expressing FGFR2–GFP were fixed following
stimulation with FGF2 + heparin for 30 minutes, immunostained for
EEA1 (A) or Rab11 (C) or treated with LysoTracker Red (E) and
analysed by confocal microscopy. Higher-magnification images of
selected regions from the cells (insets) show that in Eps8 knockdown
cells, where receptor trafficking is impaired, FGFR is retained in the
peripheral compartment (EEA1) and prevented from sorting to the peri-
nuclear recycling compartment (Rab11) and to the lysosomal
degradative compartment (LysoTracker). Scale bars: 5 mm.
(B,D,F) Colocalisation between FGFR and EEA1, Rab11 or
LysoTracker was quantified in control cells as 0.1960.02, 0.5760.04,
and 0.7460.01, respectively, and in Eps8 knockdown cells as
0.3660.04, 0.2460.05 and 0.1860.01, respectively (Pearson’s
correlation coefficient; means 6 s.e.m., n518 cells).
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endosome was significantly reduced when Eps8 expression was
silenced (Fig. 8). Finally, 30 minutes post-stimulation FGFR was
found to localise to the Rab11-positive peri-nuclear recycling
compartment, as well as degradative compartments, in stimulated
control cells, and this was prevented in Eps8 knockdown cells
(Fig. 8). Thus, activated receptors traffics through the Eps8/
EEA1-positive peripheral compartment en route to the PNRC and
late endosome/lysosome, and in the absence of Eps8 this is
prevented.
Finally, we sought to determine if there is a concomitant
feedback into FGFR2 signalling mediated through Eps8.
Silencing of Eps8 expression had significant effects on a burst
in Erk activation through the p44 form immediately following
receptor activation (Fig. 7), suggesting that, consistent with
recent work with EGFR (Sousa et al., 2012; Brankatschk et al.,
2012), FGFR signalling through the MAP kinase pathway can
occur prior to/during receptor endocytosis. Importantly, the p42/
Erk band revealed in our studies, which was not Eps8 sensitive, is
chronically active in HeLa cells (supplementary material Fig.
S9). Finally, super-resolution imaging on a Leica gSTED system
further elucidated the site of Eps8/Src-dependent FGFR
trafficking (supplementary material Fig. S10). In Dasatinib
treated cells FGFR clearly resides in peripheral puncta.
Therefore, taken together these results identify Eps8 as a key
mediator of activated FGFR trafficking and signalling, and
identify the peripheral early endocytic compartment as a key
crossroads in the regulation of RTKs.
The interplay between receptor tyrosine kinase signalling and
trafficking has been emerging an area critical to understanding
fundamental aspects of cell biology as well as how mis-
regulation of either could potentially lead to pathological
conditions, such as developmental defects or chronic disease.
Our studies point to a response arc leading from RTK activation
through Src via Eps8. Evidence supporting this hypothesis has
been gained from a variety of studies, and is based upon work in
other signalling systems, suggesting potential widespread
significance. In our studies we have demonstrated that
following activation FGFR enters the cell via clathrin-mediated
endocytosis. FGF stimulation increases the number of CCPs, and
events of clathrin-mediated endocytosis. Furthermore, both the
FGF-dependent increase in clathrin at the plasma membrane and
the early endocytic trafficking of activated FGFR depend upon
Src and Eps8. FGFR traffics through an Eps8-positive early
endocytic compartment on the way to the PNRC and lysosome,
and in the absence of Eps8, FGFR is retained in peripheral early
endosomes. Eps8 is also required for early phase pErk activation,
placing this event early in the trafficking of activated FGFR.
Therefore, FGFR activation induces alterations in signalling and
trafficking that are mediated by Src acting through Eps8, and this
alters both early endocytic trafficking and downstream MAPK
signalling. Thus, the correlation between Src- and Eps8-
dependent FGFR signalling and trafficking suggests a direct
link between the two. However, validation and elucidation of the
direct mechanistic coupling between FGFR signalling and
trafficking and the precise role(s) of Src and Eps8 await further
work in this area. In conclusion, while our data suggest that
signalling through activated FGFR promotes clathrin-mediated
endocytosis, and that this effect depends on Src/Eps8, the initial
wave of FGFR endocytosis, although clearly clathrin dependant,
does not seem to critically rely upon Src/Eps8. Finally, as
constitutive endocytosis and the steady state production of
clathrin-coated vesicles do not seem to be Src/Eps8 dependant,
the endocytic cargo removed from the plasma membrane in FGF
treated cells mediated by Src/Eps8 remains presently elusive.
Materials and Methods
Plasmids, siRNA and antibodies
The construct encoding GFP-tagged FGFR2IIIc (FGFR2–GFP) was a gift from J.
Ladbury (M.D. Anderson Cancer Center, The University of Texas). DsRed-tagged
clathrin light chain A (clathrin-dsRed) was a gift from T. Kirchhausen (Harvard
Medical School, Boston, MA). Caveolin1-mRFP was a gift from A. Helenius (ETH
Institute of Biochemistry, Zurich, Switzerland). Eps8-mCherry was a gift from
Giorgio Scita (IFOM University of Milan, Milan, Italy). Constitutively active Src
was provided by Margaret Frame (Edinburgh Cancer Research UK Centre). siRNA
oligos targeting a-adaptin (sequence 59-AAGAGCAUGUGCACGCUGGCCA-39),
caveolin1 (SmartPool l-003467) and Eps8 (sequence 59-TGCAGACCC-
TAGTATACCG-39) were purchased from Dharmacon. Antibodies used were:
anti-Rab11 (Invitrogen); anti-EEA1 (Abcam); anti-caveolin1 (BD Biosciences);
anti-a-adaptin (Santa Cruz); anti-a-tubulin (Sigma); a-ERK1/2 and a-pERK (Santa
Cruz); a-Eps8 (Abcam); anti-phospho-Src family (Tyr416; Cell Signaling);
IRDye680 and IRDye800 conjugated secondary antibodies (Odyssey).
Cells and transfection
Eps8 shRNA and control shRNA HeLa cells were a gift from Giorgio Scita (IFOM
University of Milan, Milan, Italy). HeLa and LNCaP cells were propagated in
DMEM (Invitrogen) supplemented with 10% FBS (Labtech International) in a 5%
CO2 atmosphere at 37 C˚. DNA and siRNA transfection was performed by using
Lipofectamine 2000 transfection reagent (Invitrogen) according to the
manufacturer’s protocol. At 48 hours post-transfection, cells were serum-starved
for 30 min and then stimulated with 20 mg/ml Heparin (Sigma) and 50 ng/ml
FGF2 for the indicated times. For the inhibition assays cells were either treated
with 25 mM SU5402 (Calbiochem) for 5 min, 80 mM Dynasore (Sigma) for
30 min or 50 nM Dasatinib (Sellek Chemicals) for 30 min or treated as above in
the absence of drug before FGF stimulation. For live-cell imaging, cells were
washed once and the medium removed was replaced with prewarmed (37 C˚)
imaging medium [10 mM HEPES–Hank’s balanced salt solution (HBSS; Sigma)
pH 7.4].
Laser scanning confocal microscopy and total internal reflection
fluorescence microscopy
Confocal laser was performed with an inverted microscope (Eclipse Ti, Nikon
A1R) at 37 C˚ using a 606 1.45 NA oil-immersion objective and 12-bit CCD
camera (Ixon 1M EMCCD). GFP constructs were excited with an argon ion 457–
514 nm laser, mRFP and dsRed constructs with a Green Diode 561 nm laser.
Images were prepared with NIS-Elements Imaging Software version 3.2 (Nikon).
TIRF microscopy was performed with the system described above as well as with
an inverted microscope (IX81, Olympus) using a 606 1.49 NA oil-immersion
objective and a 12-bit CCD camera (ORCA-R2 C10600, Hamamatsu). GFP
constructs were excited with a 491-50 Diode type laser, dsRed constructs with a
561-50 DPSS type laser. Images were analysed and prepared with Xcellence
Advanced Lice Cell Imaging System version 1.1 (Olympus). Super-resolution
imaging was performed on a gSTED system (Leica) and image stacks were
deconvolved using Huygens linked within the Leica software.
Immunofluorescence
Cells grown on coverslips were fixed in 4% paraformaldehyde in TBS for 10 min,
washed in TBS/100 mM glycine and permeabilised with TBS/0.1% saponin/
20 mM glycine. After blocking with TBS/0.1% saponin/10% FCS, cells were
incubated with primary antibodies, then washed and incubated with secondary
antibodies. After staining, the coverslips were mounted in Hydromount (National
Diagnostic) and imaged by using a Zeiss LSM 710 confocal microscope, a 406
1.3NA oil-immersion objective and a Transmission-Photomultiplier LSM T-PMT.
Each experiment was repeated a minimum of three times and an image that
represented the phenotype of most of the cells was selected. For lysosomal
staining, cells were incubated with 75 nM LysoTracker Red (Molecular Probes)
for 30 minutes and immediately imaged in imaging media at room temperature.
Transferrin and cholera toxin B uptake assay
Following serum-starvation for 30 min, cells were incubated at 37 C˚ in either
Alexa-Fluor-546–transferrin (Invitrogen), or Alexa-Fluor-555–cholera-toxin-B
(Invitrogen). Cells were then rinsed, fixed and analysed by using a Nikon
TE300 inverted epi-fluorescence microscope using an 6061.40 NA oil-immersion
objective and a cooled CCD camera (Hamamatsu C4742-98-12WRB). For the
triple colocalisation, HeLa cells were incubated with Alexa-Fluor-633–transferrin
(Invitrogen) for 5 minutes, in order to mark the early endosomes. Cells were then
rinsed, fixed and analysed using confocal microscopy.
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Quantification analysis
For the trafficking assays FGFR2–GFP intensity in the plasma-membrane-
associated region of the cells was calculated for each frame of the time-lapse
sequences (1 frame/5 min). From each time point, a background value was
subtracted, corresponding to the cytosolic fluorescence intensity before the
stimulation with FGF (time50 min). Cells were treated with a red membrane stain
(data not shown) in order to define the plasma-membrane-associated region. For
the colocalisation analysis, each spot of FGFR, clathrin, caveolin1 and Eps8 was
identified and a circle was drawn around it. Spots were identified as colocalising
when most of the fluorescence intensity of the pixels within the circular regions
fitted in both the channels. For quantification of transferrin and cholera toxin
uptake, cells randomly located on the coverslips were scanned at fixed intensity
settings below pixel-saturation, and the total cellular intensity was determined.
Data analysis was performed using either NIS-Elements Imaging Software version
3.2 (Nikon) or Xcellence Advanced Lice Cell Imaging System version 1.1
(Olympus).
Biochemical assays
Cultures of HeLa or Hek293T cells were lysed in lysis buffer (50 mM Tris-HCl
pH 7.4, 150 mM NaCl, 1% Triton TX-100, 1 mM sodium orthovanadate, 50 mM
sodium fluoride, 25 mM b-glycerophosphate) supplemented with complete mini
protease inhibitors cocktail (Roche). The extracts were resolved by a 4–12%
NuPAGE Bis-Tris SDS gel (Invitrogen) and transferred to Immobilon PVDF-FL
membrane (Millipore). The membrane was blocked in methanol and incubated
with primary antibodies overnight at 4 C˚. After washing in PBS 0.1% Tween-20
the membrane was incubated with secondary antibodies for 1 hour at room
temperature followed by washing and detected using an Odyssey infrared imaging
system (Li-COR). For the immunoprecipitation assay, cells were lysed and
prepared as described. The extracts were immunoprecipitated with dynabeads
(Invitrogen) crosslinked with anti-myc antibody. Supernatants were loaded on a 4–
12% NuPAGE Bis-Tris SDS gel (Invitrogen) and subjected to immunoblot
analysis with indicated antibodies. Quantification by densitometric scanning of
western blots was performed using Odyssey Application Software version 3.0 (Li-
COR). Since the primary antibodies used in this analysis detected both the 42 kDa
and 44 kDa form of ERK/pERK, two bands were visualized and captured. The
relative p44 phosphoERK levels shown in Fig. 7D were calculated by normalizing,
for each point of the time course, the relative optical density value of the p44
phosphoERKs band to the corresponding total p44 ERK value.
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Fig S1. Silencing a-adaptin subunit of AP2 complex or inhibition of GTPase dynamin significantly reduces transferrin uptake. 
HeLa cells overexpressing FGFR2-GFP were either incubated for 30 minutes in the presence or absence of Dynasore inhibitor (A), 
or treated with a-adaptin siRNA (B). Following incubation with transferrin-Alexa-Fluor-546 (Tf) for 15 minutes at 37°C, cells were 
rinsed, fixed and analysed by epifluorescence microscopy. The quantification of Tf fluorescence intensity shows that both Dynasore 
activity and a-adaptin siRNA treatment significantly reduce transferrin entry (mean ± s.e.m., n=26 cells in (A), n=24 cells in (B) 
(*P<0.05; **P<0.01; ***P<0.001). (C) Western blot of lysates from HeLa cells transfected with a-adaptin siRNA and probed with 
anti-a-adaptin antibody shows potent silencing (mean ± s.e.m., n=3 experiments).
 
 Fig S2. Silencing of caveolin1 leads to a significant reduction of choleratoxinB uptake. (A) HeLa cells overexpressing FGFR2-
GFP were treated with caveolin1 siRNA. Following incubation with choleratoxinB-Alexa-Fluor-555 (CTcB) for 15 minutes at 37°C, 
cells were rinsed, fixed and analysed in epifluorescence microscopy. The quantification of CTcB fluorescence intensity shows that 
caveolin1 siRNA treatment leads to a significant reduction in cholera toxin uptake (mean ± s.e.m., n=15 cells; *P<0.05; **P<0.01; 
***P<0.001). (B) Western blot of lysates from HeLa cells transfected with caveolin1 siRNA and probed with anti cav1 antibody 
shows potent silencing (mean ± s.e.m., n=3 experiments).
Fig S3. FGF treatment does not result in an increase in transferrin uptake. HeLa cells transiently expressing FGFR2-GFP were 
either stimulated with FGF2 + heparin for 15 minutes, or not stimulated, at 37°C in the presence of transferrin-Alexa-Fluor-546. Cells 
were then rinsed, fixed and analysed by epifluorescence microscopy. Quantification of transferrin fluorescence intensity demonstrates 
that FGF stimulation does not induce a significant increase in transferrin entry (mean ± s.e.m., n=49 cells each condition).
 
 
  
Fig S4. Eps8 expression is significantly silenced in the Eps8 knock down cell line and in Eps8 siRNA-treated HeLa cells. 
Cellular extracts from HeLa cells transfected with Eps8 siRNA (A) or from Eps8 knock down (shRNA) or control vector (control) 
HeLa cells (B) were resolved by SDS-PAGE and analysed by immunoblotting with anti-Eps8 antibody (mean ± s.e.m., n=3 
experiments). 
Fig S5. FGF-dependent peripheral accumulation of CCPs in FGFR-expressing LNCaP cells. LNCaP cells endogenously 
expressing FGFR2 and transfected with Clathrin-dsRed were analysed by TIRF microscopy before and 30 minutes after stimulation 
with FGF2 + heparin. (A) Upon FGF stimulation, cells show a significant increase in the number of clathrin spots on the plasma 
membrane. Scale bars: 5 mm. (B) Quantification analysis of clathrin spot number before and after FGF stimulation (mean ± s.e.m., 
n=45 cells; *P<0.05; **P<0.01; ***P<0.001).
 
  
 
  
Fig S6. AP-2, Clathrin, and Dynamin interact with Eps8 in an FGF2-independent manner in HEK293T cells. Cellular extracts 
from HEK293T cells transfected with myc-Eps8 (where indicated) and stimulated or not with 20 ng/ml FGF + 10 mg/ml heparin for 
15 min, were immunoprecipitated with anti-myc antibody, resolved by SDS-PAGE and analysed by immunoblotting for the levels of 
specified proteins.
Fig S7. During early stages of trafficking FGFR colocalises with Eps8 in the early endosomal compartment. HeLa cells 
transiently expressing FGFR2-GFP and Eps8-mCherry were stimulated with FGF + heparin for 10 minutes. Following incubation 
with transferrin-Alexa-Fluor-633 (Tf) during the last 5 minutes of stimulation, cells were rinsed, fixed and analysed by confocal 
microscopy. Higher-magnification in merged image of selected regions from the cells show overlap of FGFR, Eps8 and 5 min 
internalized transferrin in white, demonstrating that during the early stages of activation (10 min FGF), FGFR colocalises with Eps8 
within the early endocytic compartment. Scale bars=5 mm.
 
  
Fig S8. Colocalisation of Eps8 with active Src. HeLa cells transiently expressing constitutive active Src (SrcCA) and Eps8-mCherry 
were immunostained for active Src (P416Src antibody) and imaged in confocal microscopy. Higher-magnification merged image of 
selected regions from the cells show overlap of active Src and Eps8 in yellow. Scale bars=5 mm.
 
  
Fig S9. FGF-dependent kinetics of ERK phosphorylation in non-transfected HeLa cells. HeLa cells starved overnight in serum-
free media were lysed following stimulation with FGF2 + heparin for the indicated times. Cellular extracts where resolved by SDS-
PAGE and analysed by immunoblotting for the levels of specified proteins.
 
 Fig S10. Super-resolution analysis of FGFR-containing vesicles in Dasatinib-treated HeLa cells. HeLa cells transiently 
expressing FGFR2-GFP and incubated for 30 minutes in the presence of Dasatinib inhibitor were stimulated with FGF2 + heparin for 
30 minutes, fixed and analysed by super-resolution confocal microscopy on a Leica gSTED system followed by stack deconvolution. 
The high resolution image reveals the presence of a population of FGFR-containing vesicles accumulating at the cell periphery 
following Src inhibition.
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Functional analysis of Dictyostelium IBARa reveals a conserved role of the
I-BAR domain in endocytosis
Douwe M. VELTMAN*, Giulio AUCIELLO†, Heather J. SPENCE*, Laura M. MACHESKY*, Joshua Z. RAPPOPORT† and
Robert H. INSALL*1
*Beatson Institute for Cancer Research, Switchback Road, Bearsden, Glasgow G61 1BD, U.K., and †School of Biosciences, University of Birmingham, Edgbaston,
Birmingham B15 2TT, U.K.
I-BAR (inverse-Bin/amphiphysin/Rvs)-domain-containing pro-
teins such as IRSp53 (insulin receptor substrate of 53 kDa)
associate with outwardly curved membranes and connect them
to proteins involved in actin dynamics. Research on I-BAR
proteins has focussed on possible roles in filopod and lamellipod
formation, but their full physiological function remains unclear.
The social amoeba Dictyostelium encodes a single I-BAR/SH3
(where SH3 is Src homology 3) protein, called IBARa, along
with homologues of proteins that interact with IRSp53 family
proteins in mammalian cells, providing an excellent model to
study its cellular function. Disruption of the gene encoding
IBARa leads to a mild defect in development, but filopod and
pseudopod dynamics are unaffected. Furthermore, ectopically
expressed IBARa does not induce filopod formation and does
not localize to filopods. Instead, IBARa associates with clathrin
puncta immediately before they are endocytosed. This role
is conserved: human BAIAP2L2 (brain-specific angiogenesis
inhibitor 1-associated protein 2-like 2) also tightly co-localizes
with clathrin plaques, although its homologues IRSp53 and
IRTKS (insulin receptor tyrosine kinase substrate) associate with
other punctate structures. The results from the present study
suggest that I-BAR-containing proteins help generate the mem-
brane curvature required for endocytosis and implies an
unexpected role for IRSp53 family proteins in vesicle trafficking.
Key words: brain-specific angiogenesis inhibitor 1-associated
protein 2-like 2 (BAIAP2L2), clathrin, endocytosis, inverse-
Bin/amphiphysin/Rvs (I-BAR) domain, insulin receptor substrate
of 53 kDa (IRSp53), insulin receptor tyrosine kinase sub-
strate (IRTKS).
INTRODUCTION
The organization of many cellular structures depends on the
coupling between membranes and the cytoskeleton. Adapter
proteins with membrane-binding domains play an important
role in this coupling. The BAR (Bin/amphiphysin/Rvs) domain
folds into an elongated α-helical structure and binds membranes
in vitro and in vivo [1]. BAR domains are unique in their
curvature. Classical BAR and F-BAR (FCH-BAR) domains have a
concave surface and preferentially bind to membranes with inward
(positive) curvature, such as the outside face of vesicles [2,3].
Accordingly, proteins with these domains, such as amphiphysin
and syndapin, are involved in vesicular processes such as clathrin-
mediated endocytosis and endosomal recycling [3,4].
Conversely, I-BAR (inverse-BAR) domains have a convex
surface and bind to outward (negative) membrane curvature [5,6].
Ectopical expression of I-BAR proteins in cultured cells generates
numerous amounts of filopodia and the purified I-BAR domain
is sufficient to tubulate membranes in vitro. The inside face
of a filopodium contains strong negative curvature and these
observations have led to the view that I-BAR proteins such as MIM
(missing in metastasis) and IRSp53 (insulin receptor substrate of
53 kDa) play a role in filopodia formation.
Dictyostelium encodes a single I-BAR-domain-containing
protein (Dictybase code DDB_G0274805). The Dictyostelium
genome also encodes homologues of various proteins that have
been reported to interact with I-BAR proteins in mammalian
systems, in particular SCAR–WAVE [where WAVE is WASP
(Wiskott–Aldrich syndrome protein) verprolin homologous]
[7–9]. The presence of these proteins, in the absence of redundant
paralogues, makes Dictyostelium ideal to study the functional role
of I-BAR proteins.
The results of the present study reveal an unexpected conserved
role for I-BAR domains in clathrin-mediated endocytosis, and
thus that the specific curvature of the I-BAR domain does not
limit its physiological function to protrusion formation.
EXPERIMENTAL
Bioinformatics
Novel I-BAR domain proteins were identified by search-
ing GenBank® (http://blast.ncbi.nlm.nih.gov/Blast.cgi) using
BLASTP and TBLASTN with I-BAR domains of known family
members. Alignments of obtained sequences were performed with
ClustalX and phylogenetic trees were drawn with Treeview.
Strains and constructs
An ibrA knockout was generated in AX2 (sDM8) and in
AX3 (sDM7) as follows. The full-length ibrA gene amplified
from cDNA was cloned into pDONR221. A floxed blasticidin-
resistance cassette was ligated in between the unique MunI
Abbreviations used: BAIAP2L2, brain-specific angiogenesis inhibitor 1-associated protein 2-like 2; BAR, Bin/amphiphysin/Rvs; DIC, differential
interference contrast; GFP, green fluorescent protein; I-BAR, inverse-BAR; IRSp53, insulin receptor substrate of 53 kDa; IRTKS, insulin receptor tyrosine
kinase substrate; MIM, missing in metastasis; mRFP, monomeric red fluorescent protein; NA, numerical aperture; SH3, Src homology 3; TIRF, total internal
reflection; WASP, Wiskott–Aldrich syndrome protein; WAVE, WASP verprolin homologous.
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Figure S1 Alignment of the I-BAR domain
I-BAR domains from the indicated organisms were aligned in ClustalX. Residues are coloured according to the standard ClustalX colour scheme. The second half of the domain is shown below the
first. Species abbreviations are as follows: Hs, Homo sapiens; Mm, Mus musculus; Gg, Gallus gallus; Dr, Danio rerio; Tr, Takifugu rubripes; Sp, Strongylocentrotus purpuratus; Dm, Drosophila
melanogaster; Ta, Trichoplax adhaerens; Dd, Dictyostelium discoideum; Dp, Dictyostelium purpureum; and Pp, Polysphondylium pallidum.
1 To whom correspondence should be addressed (email r.insall@beatson.gla.ac.uk).
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Figure S2 Co-localization between clathrin and BAIAP2L2
(A) Co-expression of fluorescently tagged clathrin with BAIAP2L2 in MDA MB231 cells and BSC1 cells. (B) For each clathrin spot in the respective strains, it was determined if BAIAP2L2 was also
present at that position and vice versa.
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Neighbor of BRCA1 (Nbr1) is a highly conserved multidomain scaffold protein with proposed roles in
endocytic trafficking and selective autophagy. However, the exact function of Nbr1 in these contexts has not
been studied in detail. Here we investigated the role of Nbr1 in the trafficking of receptor tyrosine kinases
(RTKs). We report that ectopic Nbr1 expression inhibits the ligand-mediated lysosomal degradation of RTKs,
and this is probably done via the inhibition of receptor internalization. Conversely, the depletion of endogenous
NBR1 enhances RTK degradation. Analyses of truncation mutations demonstrated that the C terminus of
Nbr1 is essential but not sufficient for this activity. Moreover, the C terminus of Nbr1 is essential but not
sufficient for the localization of the protein to late endosomes. We demonstrate that the C terminus of Nbr1
contains a novel membrane-interacting amphipathic -helix, which is essential for the late endocytic local-
ization of the protein but not for its effect on RTK degradation. Finally, autophagic and late endocytic
localizations of Nbr1 are independent of one another, suggesting that the roles of Nbr1 in each context might
be distinct. Our results define Nbr1 as a negative regulator of ligand-mediated RTK degradation and reveal the
interplay between its various regions for protein localization and function.
Receptor tyrosine kinases (RTKs) are a major superfamily
of membrane-spanning growth factor receptors with intrinsic
kinase activity, which regulate fundamental cellular processes
such as proliferation, migration, differentiation, and survival.
RTKs include, among others, insulin-like growth factor recep-
tor (IGFR), epidermal growth factor (EGF) receptor (EGFR),
fibroblast growth factor (FGF) receptor (FGFR), vascular en-
dothelial growth factor receptor (VEGFR), and platelet-de-
rived growth factor receptor (PDGFR) (26). Most RTKs are
activated by the binding of their cognate ligands, which induces
receptor dimerization and the autophosphorylation of specific
tyrosine residues within the kinase domain and the C-terminal
cytoplasmic tail, as well as the phosphorylation of constitutively
associated scaffold proteins such as FRS2. This results in the
recruitment and subsequent phosphorylation of other signaling
molecules, the assembly of multiprotein signaling complexes,
and the ultimate activation of downstream signal transduction
pathways. Such pathways include, among others, the RAS/
mitogen-activated protein kinase (MAPK) cascade also known
as the extracellular signal-regulated kinase (ERK) pathway,
the phosphatidylinositol-3-OH kinase (PI3K)/AKT pathway,
and the phospholipase C (PLC)/protein kinase C (PKC) path-
way (26). These signaling pathways in turn act on a variety of
transcription factors, the activities of which define the partic-
ular cellular outcome of a given stimulation.
Signaling from RTKs is tightly regulated by a variety of
extrinsic and intrinsic control mechanisms, the deregulation of
which is a major contributor to most cancers (35). In particular,
endocytic trafficking has emerged as a key regulator of RTK
signaling (30). Internalization is often triggered by ligand bind-
ing and the activation of RTKs on the cell surface. Receptor
internalization occurs through clathrin-dependent or -indepen-
dent mechanisms followed by trafficking through different ve-
sicular compartments once inside the cell (30).
Endocytic trafficking can regulate RTK signaling at least at
two levels. First, it can result in selective pathway propagation
or downregulation by compartmentalization. For example, the
removal of activated RTKs from the plasma membrane results
in the termination of those downstream signaling pathways
which require plasma membrane-associated molecules. These
include the PLC/PKC and the PI3K/AKT pathways, both of
which require phosphatidylinositol-4,5-phosphate (PI45P2) as
a substrate, which is absent in endosomes (8). In contrast,
ERK1/2 signaling is not limited to plasma membrane. In fact,
many studies suggested that full ERK1/2 activation depends on
the endocytosis of RTKs (10, 11, 14, 34). This has been attrib-
uted to the ERK1/2 propagating scaffolding complex P14-MP1,
which is localized specifically to late endosomes (19, 32, 33).
Another example of specific endosomal signal propagation has
been shown for AKT. The adaptor protein-containing pleck-
strin homology (PH) domain, the PTB domain, and leucine
zipper motif 1 (APPL1) can bind specifically to AKT on early
endosomes and enhance its activity (25). APPL1 also binds to
the AKT substrate glycogen synthase kinase 3 (GSK-3) and
increases its phosphorylation by AKT without affecting the
phosphorylation of another AKT substrate, tuberous sclerosis
complex protein 2 (TSC2), thereby providing pathway selec-
tivity (25).
Second, it is well established that endocytosis can act to
* Corresponding author. Mailing address: CRUK Growth Factor
Group, School of Biosciences, University of Birmingham, Edgbaston,
Birmingham B15 2TT, United Kingdom. Phone: 44 121 414 7533. Fax:
44 121 414 4534. E-mail: j.k.heath@bham.ac.uk.
 Published ahead of print on 11 October 2010.
5672
downregulate RTK signaling by trafficking receptors to lyso-
somes for degradation. En route, signaling receptors are re-
moved from the limiting membrane of endosomes and en-
closed within intraluminal vesicles of multivesicular bodies
(MVBs), rendering them unable to interact with signaling mol-
ecules and susceptible to degradation by lysosomal hydrolyses
(22, 30). MVB formation begins in early endosomes and con-
tinues in late endosomes before mature MVBs are finally fused
with lysosomes (22). MVB sorting of RTKs depends on ubiq-
uitination by specific ubiquitin ligases such as CBL, followed by
the concerted action of the endosomal sorting complex re-
quired for transport (ESCRT) proteins, which direct ubiquiti-
nated cargos to the intraluminal vesicles of MVBs (22). The
importance of RTK regulation by MVB sorting and lysosomal
degradation is manifested by the fact that a variety of cancer-
associated genetic and epigenetic alterations specifically target
this pathway (18). Once internalized, however, the lysosomal
degradation route is not the only available itinerary for RTKs.
Internalized receptors can undergo recycling back to the
plasma membrane for reusage, and the balance between recy-
cling and lysosomal targeting can be a crucial determinant of
the signaling outcome (27, 28).
Nbr1 is a ubiquitously expressed multidomain scaffold pro-
tein of 988 amino acids with 90% conservation between
mouse and human (4, 37). It contains an N-terminal phox/
Bem1p (PB1) domain, a ZZ-type zinc finger (ZZ), a coiled-
coiled (CC) region, and a C-terminal ubiquitin association
(UBA) domain capable of binding to both K48- and K63-type
polyubiquitin chains (9, 36). The PB1 domain of NBR1 can
bind to the open catalytic domain of the giant muscle kinase
titin and regulate its downstream signaling in muscle cells (12).
In addition, the PB1 domain can heterodimerize with the PB1
domain of P62/sequestosome-1 (SQSTM1) (12), another scaf-
fold protein of similar architecture with proposed roles in
endosomal trafficking (7) and selective autophagy (2, 21). A
role in selective autophagy has also been proposed for NBR1,
as it was shown to associate with the mammalian homologue of
Atg8, an essential autophagosomal protein also known as mi-
crotubule-associated protein 1 light chain 3 (LC3) (9, 36). A
main LC3-interacting region (LIR) as well as a secondary
LC3-interacting region (LIR2) were identified in NBR1 (9),
and it was proposed previously that similarly to P62, NBR1 can
act as a specific adaptor for ubiquitinated cargos destined for
degradation by autophagosomes (9, 36). Recently, an in vivo
role for NBR1 in the regulation of bone mass and density has
been revealed by its genetic truncation in mice (38).
We recently reported that NBR1 associates with Spred2, a
negative regulator of ERK1/2 signaling downstream of RTKs
(15). We showed that Spred2 activity is dependent on its in-
teraction with NBR1 and that Spred2 downregulates ERK1/2
signaling downstream of FGFR by targeting the receptor to the
lysosomal degradation pathway (15). These results led us to
propose NBR1 as a novel regulator of RTK trafficking, but it
remained unclear whether the protein had any effect on RTK
trafficking on its own. Here we investigated the role of NBR1
in the context of RTK trafficking in more detail. We show that
ectopic Nbr1 expression inhibits the ligand-mediated lysoso-
mal degradation of endogenous RTKs. Live-cell imaging re-
vealed that this effect is probably due to the inhibition of
receptor internalization from the cell surface. In contrast,
small interfering RNA (siRNA) depletion of endogenous
NBR1 enhances receptor degradation. The C terminus of Nbr1
is essential but not sufficient for this function. Similarly, the C
terminus of Nbr1 is essential but not sufficient for the late
endocytic localization of the protein. We also show that in
addition to the UBA domain, the C terminus of Nbr1 contains
a membrane-interacting amphipathic -helix, which is neces-
sary for the late endocytic localization of the protein but not
for its effect and RTK degradation. Finally, we demonstrate
that the late endocytic and autophagic localizations of Nbr1
are independent, suggesting that the function of Nbr1 in each
context might be distinct. Our results establish Nbr1 as a novel
negative regulator of RTK trafficking and reveal the relation-
ship between its different regions for protein localization and
function.
MATERIALS AND METHODS
Plasmid constructs. A schematic representation of Nbr1 constructs described
in the study can be found in Fig. 1. N-terminally Myc- and green fluorescent
protein (GFP)-tagged full-length mouse Nbr1 constructs as well as an N-termi-
nally glutathione S-transferase (GST)-tagged C-terminal-only Nbr1 mutation
(P856-Y988) construct were described previously (15). All N- and C-terminal
truncation mutation constructs were made by Gateway cloning (Invitrogen)
according to the manufacturer’s instructions and as described previously (31).
Briefly, forward and reverse primers with in-frame gateway 5 overhangs corre-
sponding to the beginning and end of a target sequence were used in a PCR to
generate Gateway-compatible coding fragments. These fragments were then
recombined into the Gateway pDONR201 entry vector (Invitrogen) using the BP
clonase enzyme (Invitrogen). Myc-tagged constructs were generated by recom-
bining entry vectors into a Myc-pRK5 gateway destination vector described
previously (31) using the LR clonase enzyme (Invitrogen). GFP-tagged con-
structs were similarly generated by using the pcDNA DEST53 destination vector
(Invitrogen). The Y750A point mutation was generated by site-directed mu-
tagenesis using overlapping forward and reverses primers harboring the specific
mutation in the middle. Finally, the Nbr1 juxta-UBA (JUBA) deletion mutation
was generated from a full-length coding construct using primers with AgeI
restriction digestion site 5 overhangs. These forward and reverse primers were
targeted to just after and just before the JUBA coding sequence, respectively,
and were used in a PCR to amplify the whole construct minus the JUBA coding
sequence. The linear product was then circularized by AgeI digestion (NEB) and
FIG. 1. Schematic representation of Nbr1 mutations used in this
study. The arrow is in an N- to C-terminal direction. The indicated
amino acids are the first or last included residues in the constructs.
Nbr1 regions are represented linearly (the JUBA label applies to the
cyan portion).
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self-ligation using T4 ligase (Invitrogen). The C-terminally GFP-tagged EGFR
construct was described previously (3, 23).
Reagents and antibodies. Mouse monoclonal anti-NBR1 antibodies were pur-
chased from Abcam and Abnova (clone 6B11). Mouse monoclonal antibody
against LAMP2 (clone H4B4) was also obtained from Abcam. Mouse monoclo-
nal anti-Myc tag antibody (clone 9E10) was obtained from Roche. Rabbit mono-
clonal anti-Myc tag (clone 71D10) antibody was obtained from Cell Signaling
Technology. Anti-EGFR, GST, EEA1, cleaved procyclic acidic repetitive protein
(PARP), and cleaved CASP-9 rabbit polyclonal antibodies were also obtained
from Cell Signaling Technology. Rabbit polyclonal anti-FGFR2 (Bek), ERK1,
and mouse monoclonal anti-pERK1/2 (clone E4) antibodies were obtained from
Santa Cruz Biotechnology Inc. Mouse monoclonal anti--tubulin (clone DM 1A)
was obtained from Sigma. All fluorescently labeled (Alexa Fluor 488, Alexa
Fluor 594, and Texas Red) secondary antibodies were obtained from Invitrogen.
Horseradish peroxidase-conjugated anti-mouse and anti-rabbit IgG secondary
antibodies were obtained from Amersham Biosciences Inc. IRDye infrared anti-
mouse and anti-rabbit IgG secondary antibodies were obtained from Li-COR
Biosciences.
EGF was purchased from Sigma. z-VAD-FMK and bafilomycin-A1 (BafA)
were also obtained from Sigma. Nontargeting control and NBR1 siRNAs were
purchased from Santa Cruz Biotechnology Inc. The custom-made JUBA peptide
was obtained from Alta Bioscience. The GST-tagged PH domain of PLC-1
(PIP2 Grip) was purchased from Echelon Inc. Membrane lipid strips, phosphati-
dylinositol-phosphate (PIP) arrays, and all phospholipids apart from phosphati-
dylcholine were also purchased from Echelon Inc. Phosphatidylcholine was pur-
chased from Avanti Polar Lipids Inc.
Cell culture, transfection, stimulation, lysis, and Western blotting. Cell cul-
ture and transfections were performed as described previously (15). Briefly,
cells—human embryonic kidney (HEK) 293T and 293A LC3-GFP cells as well as
African green monkey simian virus 40 (SV40)-transformed kidney (COS7)
cells—were grown at 37°C in 5% CO2 in Dulbecco’s modified Eagle medium
(Invitrogen) supplemented with 10% fetal bovine serum (Labtech International).
DNA transfections were performed by using Genejuice transfection reagent
(Novagen) according to the manufacturer’s instructions, and the cells were an-
alyzed at 24 h posttransfection. Lipofectamine RNAiMAX (Invitrogen) was used
for siRNA transfections according to the manufacturer’s instructions for forward
or reverse transfections, and the cells were analyzed after 24, 48, or 72 h, with the
transfection being renewed every 24 h. For EGF and FGF2 stimulations, 293T
cells were serum starved for 6 h, and ligand (plus 10 g/ml heparin in the case
of FGF2) was added to the cells at the indicated concentrations. Lysis was
performed by the addition of 2 SDS sample buffer directly to the cells (50
l/cm2 of cells), followed by rigorous vortexing and heating to 95°C for 10 min.
Lysates were run on 4 to 12% NuPAGE Bis-Tris SDS gels (Invitrogen), and
Western blotting was performed by using Immobilon PVDF-FL (Millipore)
membranes. Membranes were dried and incubated with primary antibodies over-
night at 4°C, followed by washing and incubation with secondary antibodies for
1 h at room temperature. After additional washes, blots were visualized by
Enhanced Chemiluminescence Plus reagent (GE Healthcare) or an Odyssey
infrared imaging system (Li-COR).
Live-cell imaging, immunostaining, and confocal microscopy. Live-cell imag-
ing with a Nikon A1R/TIRF microscope system (Nikon UK) was used to analyze
receptor endocytosis and degradation. Cells transfected with GFP-tagged
EGFR, with or without the cotransfection of Myc-Nbr1, were imaged by time-
lapse epifluorescence microscopy employing a 60 objective and an Andor iXon
885 electron multiplier charge-coupled-device (EM-CCD) camera. Cells were
imaged following stimulation with EGF, and EGFR-GFP fluorescence was an-
alyzed to quantify endocytosis (number of intracellular endosomes positive for
EGFR at each time point) and degradation (total cellular intensity at each time
point). Five cells per group were analyzed, and nonstimulated cells were analyzed
as a photobleaching control. Immunostaining and confocal microscopy were
performed essentially as described previously (15). Briefly, cells grown on glass
coverslips were fixed, permeabilized, blocked, and subjected to primary and
fluorescently labeled secondary antibodies for 1 h per antibody with three washes
in between before being mounted onto Mowiol. Coverslips were subsequently
analyzed by laser scanning confocal microscopy using a Leica TCS SP2 confocal
microscope system. All images were taken sequentially and as a single section at
200 Hz using the 63 objective lens. Final images were generated from the
averages of eight consecutive scans. All presented images are representative of
the majority of cells investigated.
Liposome preparation and circular dichroism. Liposomes were prepared as
described previously (20). Briefly, phosphatidylcholine and the PIP of interest
were mixed in a glass vial at 95:5 molar ratio. The lipid mixture was dried under
an N2 gas stream, redissolved in 1:1 CHCl3-CH3OH, and dried again under an
N2 stream followed by vacuum centrifugation for 1 h to remove residual chlo-
roform. The lipids were subsequently resuspended in ultrapure H2O and sub-
jected to multiple rounds of freezing at 80°C and thawing in a 45°C sonicating
water bath until the mixture became optically clear. Circular dichroism (CD) was
performed as described previously (6). Briefly, spectra were acquired with a
Jasco J715 spectropolarimeter using 0.5-mm cuvettes (Starna/Optiglass) with
peptide concentrations of 1 mg/ml and liposome concentrations of 2 mg/ml
where applicable. Spectra were recorded from 300 nm to 180 nm with a band-
width of 2 nm, a data pitch of 0.2 nm, a scan speed of 100 nm/min, and a response
time of 0.5. Four consecutively recorded spectra were averaged for each sample,
and the relevant buffer baseline spectra were subtracted from each sample
spectrum.
RESULTS
Nbr1 inhibits lysosomal degradation of RTKs. We previ-
ously reported that NBR1 is a specific late endosomal protein
and that the regulation of FGFR trafficking and signaling by
Spred2 depends on its interaction with NBR1 (15). These
results suggested a novel role for NBR1 as a regulator of
receptor trafficking, but it remained unclear whether the pro-
tein had any direct effect on RTK trafficking on its own. We
therefore set out to investigate the trafficking role of NBR1 in
more detail, focusing on its effect on EGFR and FGFR traf-
ficking. We observed that ectopic Nbr1 expression inhibited
the ligand-mediated degradation of endogenous EGFR (Fig.
2A and C). Similarly, the ligand-mediated degradation of en-
dogenous FGFR2 was inhibited by ectopic Nbr1 expression
(Fig. 2B and C). As a result, downstream ERK1/2 signaling was
enhanced in response to both EGF and FGF2 (Fig. 2A and B).
In neither case did Nbr1 have any effect on basal receptor
levels as judged by immunoblotting (Fig. 2C). Moreover, the
effect of ectopic Nbr1 expression on EGFR (Fig. 2D and F) or
FGFR2 (Fig. 2E and F) was minimal in cells pretreated with
the lysosomal inhibitor bafilomycin-A1 (BafA), supporting the
notion that the observed difference in receptor levels is due to
the inhibition of lysosomal degradation (Fig. 2F). These results
demonstrate that Nbr1 acts to abrogate ligand-mediated RTK
degradation.
We next investigated the effect of the depletion of endoge-
nous NBR1 on the degradation of EGFR and FGFR2. In
contrast to ectopic Nbr1 expression, the depletion of endoge-
nous NBR1 in 293T cells by siRNA enhanced EGFR degra-
dation (Fig. 3A and C). Similar results were obtained with
HeLa cells, which express considerably higher endogenous
EGFR levels (Fig. 3B and C). The reduction in receptor levels
could be seen even in the absence of ligand treatment, sug-
gesting that depleting endogenous NBR1 must be sufficient to
force receptors toward the degradative endocytic route (Fig.
3C). However, a similar effect could not be detected for
FGFR2 (data not shown). Since the prolonged knockdown of
NBR1 results in cell death (15), it is very likely that the NBR1
depletion in these experiments was not complete. Thus, a pos-
sible explanation for this variation could be that FGFR2 and
EGFR simply have different sensitivity thresholds toward a
partial NBR1 depletion.
Nbr1 inhibits ligand-mediated receptor internalization
from the cell surface. In order to generate a real-time analysis
of RTK trafficking and degradation in live cells, we made use
of the well-documented GFP-tagged EGFR construct (3, 23).
We imaged the loss of EGFR from the plasma membrane and
its appearance in cytosolic endosomes, followed by subsequent
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degradation, live in HeLa cells. Following stimulation, EGFR-
GFP clearly redistributed to cytosolic punctae (Fig. 4A). How-
ever, the expression of Nbr1 decreased the endocytic traffick-
ing of activated EGFR (Fig. 4A). Quantification of the number
of EGFR-positive spots at each time point following stimula-
tion revealed that endocytosis was significantly delayed in cells
expressing Nbr1 (Fig. 4B). These results suggest that a likely
mechanism by which Nbr1 inhibits RTK degradation is via
trapping the receptor on the cell surface. Furthermore, quan-
tification of whole-cell fluorescence demonstrated that the
degradation of EGFR following EGF stimulation was signifi-
cantly attenuated in cells expressing ectopic Nbr1 (Fig. 4C).
Thus, the results of these imaging-based assays concur with
data from the above-described biochemical studies (Fig. 2C).
The C terminus of Nbr1 is essential but not sufficient for its
function and localization. We next examined the contribution
of different regions of Nbr1 to its inhibition of RTK degrada-
tion. Our previous study implicated the C terminus of NBR1 as
being important for its function, as it was sufficient to mediate
an association with SPRED2 (15). Therefore, we first com-
pared the effect of full-length Nbr1 to that of a C-terminally
deleted mutation lacking the last 133 amino acids on ligand-
mediated RTK degradation. Unlike full-length Nbr1, the C-
terminally deleted mutation did not inhibit EGFR degradation
after EGF treatment (Fig. 5A and C), and similar results were
obtained for FGFR2 (Fig. 5B and C). Accordingly, the en-
hancement of downstream ERK1/2 signaling was also lost
when the C terminus of Nbr1 was deleted (Fig. 5A and B).
Next, we compared full-length Nbr1 with a C-terminal-only
mutation (P856-Y988), which contains just the last 133 amino
acids. We observed that similarly to the prolonged depletion of
NBR1 by siRNA (15), the expression of the C-terminal-only
FIG. 2. Nbr1 abrogates ligand-mediated lysosomal degradation of RTKs and enhances downstream signaling. All error bars represent standard
errors of the means (SEM). P values were calculated by a one-tailed paired t test (n 	 3). (A) Overexpression of Nbr1 inhibits ligand-mediated
EGFR degradation and enhances downstream ERK1/2 signaling. HEK293T cells transfected with Myc-Nbr1 or GFP as a control were serum
starved and stimulated for the indicated time points with 50 ng/ml EGF. Cells were lysed and analyzed by Western blotting. (B) Overexpression
of Nbr1 inhibits ligand-mediated FGFR2 degradation and enhances downstream ERK1/2 signaling. HEK293T cells transfected with Myc-Nbr1 or
GFP as a control were serum starved and stimulated for the indicated time points with 20 ng/ml FGF2 plus 10 g/ml heparin. Cells were lysed
and analyzed by Western blotting. (C) Densitometry analysis of RTK degradation in the presence or absence of Myc-Nbr1 from panels A and B.
(D) Nbr1 inhibition of ligand-mediated EGFR degradation is BafA sensitive. HEK293T cells transfected with Myc-Nbr1 or GFP as a control were
starved and stimulated for the indicated times with 50 ng/ml EGF. Thirty minutes prior to stimulation, the specified cells were pretreated with 200
nM BafA. Cells were lysed and analyzed by Western blotting. (E) Nbr1 inhibition of ligand-mediated FGFR2 degradation is BafA sensitive. HEK293T
cells transfected with Myc-Nbr1 or GFP as a control were starved and stimulated for the indicated times with 20 ng/ml FGF2 plus 10g/ml heparin. Thirty
minutes prior to stimulation, the specified cells were pretreated with 200 nM BafA. Cells were lysed and analyzed by Western blotting. (F) Densitometry
analysis of the effect of BafA treatment on Myc-Nbr1-mediated inhibition of RTK degradation from panels D and E. TUB, -tubulin.
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mutation induced cell death by apoptosis (Fig. 5D), but this
could be inhibited by a general caspase inhibitor, z-VAD-FMK
(Fig. 5E). Unlike full-length Nbr1, the C-terminal-only Nbr1
mutation was not capable of inhibiting ligand-mediated EGFR
(Fig. 5F and H) or FGFR2 (Fig. 5G and H) degradation in
cells treated with z-VAD-FMK. The enhancement of down-
stream ERK1/2 signaling was also lost (Fig. 5F and G). To-
gether, these results suggest that the C terminus of Nbr1 is
essential but not sufficient for the inhibition of RTK degrada-
tion.
As Nbr1 specifically localizes to the limiting membrane of
late endosomes (15), we asked whether this localization might
be important for the effect on RTK trafficking. Using confocal
microscopy, we investigated the late endocytic localization of
different Nbr1 mutations. As expected, full-length Nbr1 exhib-
ited a strong colocalization with the late endocytic marker
LAMP2 (Fig. 6A). The deletion of the two N-terminal do-
mains, the PB1 and ZZ domains, did not have an effect on
protein localization (Fig. 6B). However, the loss of the C-
terminal 133 amino acids (P856-Y988), which results in the loss
of protein function (Fig. 5A, B, and C), had a dramatic impact
on protein localization (Fig. 6C). This deletion resulted in the
loss of colocalization with LAMP2, and the protein exhibited a
diffuse cytosolic localization instead of a vesicular localization
(Fig. 6C). Similarly, when a C-terminal-only (P856-Y988) Nbr1
mutation was investigated, it showed no colocalization with
LAMP2 (Fig. 6D). However, this mutation was still localized to
the limiting membrane of some intracellular vesicular struc-
tures (Fig. 6D). These vesicular structures were larger than full
length (Fig. 6D) and stained positive for the early endosomal
marker EEA1 (data not shown), which is suggestive of a po-
tential defect in vesicle maturation/fission. These results indi-
cate that the C terminus of Nbr1 is essential but not sufficient
for its correct localization.
The C terminus of Nbr1 is constituted of UBA and JUBA.
Having established the importance of the Nbr1 C terminus
(P856-Y988) for protein localization and function, we sought
to study this region in more detail. The C terminus of Nbr1
contains a well-conserved UBA domain (9, 36). However, a
detailed study of the C terminus also revealed another region
of high conservation that was located 10 amino acids N termi-
nal to the UBA domain (Fig. 7A). Due to its proximity to the
UBA domain, we called this region juxta-UBA (JUBA). JUBA
is only 22 amino acids long and does not seem to be conserved
in P62 (Fig. 7A). Secondary-structure prediction by JPRED-3
(5) suggests that it predominantly has an -helical fold. Pro-
jection along the helical axis of the predicted -helix of JUBA
showed a highly amphipathic conformation, with charged or
polar amino acids arranged on one side of the helix and hy-
drophobic amino acids on the other (Fig. 7A). Amphipathic
-helices are found in many proteins that peripherally associ-
ate with membrane bilayers. Examples include the epsin, am-
phiphysin, endophilin, Arf, and Arl proteins (16). These heli-
ces are characterized by being unfolded until they come into
contact with a target lipid membrane. This induces -helical
folding, and the hydrophobic side gets inserted into the bilayer,
while the polar/charged side remains outside and makes ionic
contacts with the negatively charged headgroups of membrane
lipids such as phosphatidylinositol-phosphates (PIPs) (16).
To find out whether JUBA is in fact one such -helix, we
used circular dichroism (CD) spectroscopy. CD spectroscopy is
a powerful method to determine the secondary structure of
peptides, as each secondary structure exhibits unique spectrum
signatures: unfolded peptides give spectra with a single mini-
FIG. 3. Depletion of endogenous NBR1 enhances EGFR degradation. All error bars represent SEM. P values were calculated by a one-tailed
paired t test (n 	 5). (A) 293T cells were transfected with NBR1 or nonsilencing control siRNAs for 48 h, with the transfection being renewed
after 24 h. Cells were serum starved and stimulated for the indicated times with 50 ng/ml EGF before being lysed and analyzed by Western blotting.
(B) HeLa cells were transfected with NBR1 or nonsilencing control siRNAs for 48 h. Cells were starved and stimulated for the indicated times
with 50 ng/ml EGF before being lysed and analyzed by Western blotting. (C) Densitometry analysis of EGFR levels in control or NBR1-depleted
cells from panels A and B. Note that NBR1 depletion results in a reduction of EGFR levels even prior to stimulation.
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mum at around 200 nm, whereas -helical peptides give a
maximum at around 192 nm and two minima at around 208 nm
and 222 nm (6). When we subjected a peptide corresponding to
the predicted -helix of JUBA (L907-S924) to CD spectros-
copy, it gave an unfolded signature spectrum (Fig. 7B). The
addition of phosphatidylcholine liposomes did not affect the
folding (Fig. 7B). However, when liposomes additionally con-
taining various PIPs were added to the peptide solution, they
all induced an -helical fold, as judged by the disappearance of
the 200-nm minimum as well as the appearance of the
192-nm maximum and 208- and 222-nm minima (Fig.
7B). Finally, as a positive control the addition of trifluoroetha-
nol (TFE), an -helix-inducing agent (6), also resulted in the
induction of an -helical fold (Fig. 7B). These results show that
JUBA folds into an -helix in the presence of PIP-containing
membranes. Since every tested PIP could similarly induce an
FIG. 4. Nbr1 traps EGFR on the cell surface and inhibits its degradation. All error bars represent SEM. P values were calculated by a nonpaired
t test (n 	 5 cells under each condition) (*, P 
 0.05; **, P 
 0.01; ***, P 
 0.001). (A) HeLa cells were transfected with EGFR-GFP, with or
without Myc-Nbr1, and subjected to live-cell imaging by epifluorescence microscopy for 30 min following the addition of EGF (50 ng/ml). A
nonstimulated control was also included (bottom). Scale bars, 10 m. (B) Quantification of the number of EGFR-GFP-internalizing spots per area.
The overexpression of Myc-Nbr1 induces a delay of 8 min in EGFR internalization. (C) Normalized total EGFR-GFP fluorescence from whole-cell
areas. The overexpression of Myc-Nbr1 abrogates the degradation of EGFR.
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-helical fold (Fig. 7B), the results also suggest that JUBA on
its own does not display specificity toward a particular PIP.
Having shown that JUBA forms a membrane-interacting
-helix, we next tested whether the C terminus of Nbr1 exhibits
a lipid binding capacity in vitro. We used membrane strips
dotted with different physiologically relevant membrane lipids
in a technique commonly known as fat blotting. In this method,
the membrane is blotted with a GST-tagged protein of interest,
and bound proteins are subsequently detected by blotting with
a GST antibody. While GST on its own did not associate with
any of the lipids, the GST-tagged C terminus of Nbr1 (P856-
Y988) could bind to all present PIPs as well as phosphatidic
acid (PA) (Fig. 7C). As a positive control we used the pleck-
strin homology domain of PLC-1 that specifically binds
PI45P2 (13), which gave the expected result (Fig. 7C). Similarly
to PIPs, PA has a bivalent phosphate group, suggesting that
JUBA might be interacting with bivalent phosphates of the
lipid headgroups. To further confirm that the C terminus of
Nbr1 does not display specificity toward a particular PIP, we
performed fat blots using membranes dotted with increasing
concentrations of each of seven PIPs. No significant preference
was detected between different PIPs, while the pleckstrin ho-
mology domain of PLC-1 bound only PI45P2 (Fig. 7C). As
before, GST on its own did not show any lipid binding (Fig.
7C). The results confirm that at least in vitro, the C terminus of
Nbr1 binds PIPs with broad specificity.
As we reported previously, Nbr1 associates with the limiting
membrane of late endosomes (15). To determine whether the
vesicular membrane association of Nbr1 in vivo depends on
JUBA, we compared the localization of full-length Nbr1 and
the C-terminal-only Nbr1 (P856-Y988) mutation with that of a
JUBA-deleted mutation. Full-length Nbr1 was specifically lo-
FIG. 5. The C terminus of Nbr1 is essential but not sufficient for its function. All error bars represent SEM. P values were calculated by a
one-tailed paired t test (n	 3). (A and B) A C-terminally deleted mutation of Nbr1 lacking the last 133 amino acids does not inhibit ligand-induced
RTK degradation. HEK293T cells were transfected with Myc-Nbr1, Myc-Nbr1Cterm, or GFP as a control. Cells were serum starved and
stimulated with 50 ng/ml EGF (A) or 20 ng/ml FGF2 plus 10 g/ml heparin (B) for the indicated times before being lysed and analyzed by Western
blotting. (C) Densitometry analysis of RTK degradation by Myc-Nbr1 and Myc-Nbr1Cterm from panels A and B. (D) Expression of a
C-terminal-only Nbr1 mutation containing the last 133 amino acids (P856-Y988) induces cell death by apoptosis. HEK293T cells were transfected
for the indicated times with Myc-Nbr1Cterm only or GFP as a control. Cells were lysed and analyzed by Western blotting for the apoptotic markers
cleaved PARP and cleaved CASP-9. (E) Apoptosis induced by a C-terminal-only Nbr1 mutation can be inhibited by a general caspase inhibitor.
HEK293T cells transfected with Myc-Nbr1Cterm only or GFP as a control were treated with increasing concentrations of z-VAD-FMK. Cells were
lysed and analyzed by Western blotting for the apoptotic marker cleaved PARP. (F and G) The C-terminal-only Nbr1 mutation (P856-Y988) does
not inhibit ligand-induced RTK degradation. HEK293T cells were transfected with Myc-tagged full-length Nbr1 (Myc-Nbr1), Myc-Nbr1Cterm
only, or GFP as a control. A total of 50 M z-VAD-FMK was added to all cells in order to block cell loss by apoptosis. Cells were serum starved
and stimulated with 50 ng/ml EGF (F) or 20 ng/ml FGF2 plus 10 g/ml heparin (G) for the indicated times before being lysed and analyzed by
Western blotting. (H) Densitometry analysis of RTK degradation by Myc-Nbr1 and Myc-Nbr1Cterm only from panels F and G.
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calized to the limiting membrane of vesicular structures in vivo
(Fig. 7D). Similarly, the C-terminal-only mutation (P856-
Y988) exhibited localization to the vesicular limiting mem-
branes, although as mentioned above, the vesicles were rela-
tively enlarged compared to that of full-length Nbr1 (Fig. 7D).
However, a JUBA-deleted Nbr1 showed no localization to
vesicular limiting membranes and instead exhibited an aggre-
gate-like localization (Fig. 7D). These results reveal that JUBA
is essential for the Nbr1 association with vesicular limiting
membranes in vivo.
FIG. 6. The C terminus of Nbr1 is essential but not sufficient for its correct localization. Scale bars, 10 m. (A) Full-length Nbr1 colocalizes
with the late endocytic marker LAMP2. COS7 cells transfected with GFP-Nbr1 were fixed, immunostained for LAMP2, and analyzed by confocal
microscopy. (B) PB1-ZZ-deleted Nbr1 colocalizes with the late endocytic marker LAMP2. COS7 cells transfected with GFP-Nbr1PB1-ZZ were
fixed, immunostained for LAMP2, and analyzed by confocal microscopy. (C) C-terminally deleted Nbr1 lacking the last 133 amino acids does not
colocalize with the late endocytic marker LAMP2. COS7 cells transfected with GFP-Nbr1Cterm were fixed, immunostained for LAMP2, and
analyzed by confocal microscopy. (D)The C-terminal-only Nbr1 mutation (P856-Y988) does not colocalize with the late endocytic marker LAMP2.
COS7 cells transfected with GFP-Nbr1Cterm only were fixed, immunostained for LAMP2, and analyzed by confocal microscopy.
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Having established that the C terminus of Nbr1 consists of
UBA and JUBA and that JUBA is an amphipathic membrane-
interacting -helix that targets Nbr1 to vesicular limiting mem-
branes, we next sought to determine the contribution of each
region to the late endosomal localization of Nbr1. The deletion
of either UBA or JUBA resulted in the loss of Nbr1 late
endosomal localization, suggesting that both domains are cru-
cial for the correct localization of the protein (Fig. 7E). Inter-
estingly, the effect of the loss of both regions together (Fig. 6C)
is more dramatic than that of each region individually (Fig.
7E), suggesting that the two regions cooperate to localize
Nbr1.
UBA but not JUBA is necessary for Nbr1 function. Having
established the role of JUBA in Nbr1 localization, we next
sought to assess its importance in the Nbr1-mediated inhibition
of RTK degradation. While the deletion of the C-terminal
UBA domain abrogated the effect of Nbr1 on the degradation
of EGFR (Fig. 8A and C) and FGFR2 (Fig. 8B and C), the
deletion of JUBA did not have any functional impact on the
degradation of either receptor (Fig. 8A, B, and C). Thus, while
both the UBA and JUBA regions are important for the late
endocytic localization of Nbr1 (Fig. 7E), only UBA seems to be
important for the Nbr1-mediated inhibition of RTK degrada-
tion.
Late endocytic localization of Nbr1 is LIR independent.
Nbr1 contains two LIRs, which can bind to LC3 and target
Nbr1 to autophagosomes (9). As the C-terminal-only (P856-
Y988) Nbr1 mutation that lacks both LIRs (Fig. 1) cannot
correctly localize to late endosomes (Fig. 6D), we asked
whether the interaction with autophagosomes via LIRs is im-
portant for the late endosomal localization of Nbr1 since au-
tophagosomes commonly fuse with endosomes on their route
toward lysosomal degradation (29). The main Nbr1 LIR is
located close to the C terminus of the protein (V739-E779) and
contains a pivotal tyrosine (Y750), the mutation of which re-
sults in the loss of LC3 interactions (9). The second LIR
(LIR2) is located further N terminally (A543-P634) and can
compensate for the loss of the main LIR (9). When we tested
FIG. 7. The C terminus of Nbr1 contains UBA and JUBA, both of which are essential for its correct localization. Scale bars, 10 m. (A, left)
Cross-species multiple alignment of the C-terminal 93 amino acids of NBR1 reveals JUBA, a novel conserved stretch of amino acids next to the
UBA domain, which is not present in P62. (Right) Projection along the helical axis of the predicted -helix of JUBA (L907-S924) suggests that
it would be amphipathic, with polar (light green) and charged (dark green) amino acids on one side and hydrophobic amino acids (yellow) on the
other. (B) The JUBA peptide exhibits unfolded CD spectrum signatures in water or in the presence of PC and -helical spectrum signatures in
the presence of PIPs or the -helix-inducing agent TFE. CD spectra of the JUBA peptide in water (W) and water plus phosphatidylcholine (PC)
liposomes, plus phosphatidylinositol-3-phosphate (PIP3)-containing liposomes, plus phosphatidylinositol-4,5-phosphate (PI45P2)-containing lipo-
somes, plus phosphatidylinositol-3,4,5-phosphate(PI345P3)-containing liposomes, or plus 20% TFE. (C) The C terminus of Nbr1 binds to PIPs.
(Top) The C terminus of Nbr1 associates with PIPs and PA. Membranes prespotted with 15 different biologically relevant lipids were incubated
with the GST-tagged C terminus of Nbr1 (GST-Nbr1Cterm only), GST alone as a negative control, or the GST-tagged pleckstrin homology (PH)
domain of PLC-1 (GST–PLC-1–PH) as a positive control. Membranes were analyzed by blotting with an anti-GST antibody. (Bottom) The C
terminus of Nbr1 does not show specificity to any PIP. Membranes prespotted with increasing amounts of various PIPs were incubated with
GST-Nbr1Cterm only, GST, or GST–PLC-1–PH as described above and blotted with an anti-GST antibody. (TG, triglyceride; DAG, diacyl-
glycerol; PA, phosphatidic acid; PS, phosphatidylserine; PE, phosphatidylethanolamine; PC, phosphatidylcholine; PG, phosphatidylglycerol; CL,
cardiolipin; PI, phosphatidylinositol; Ch, cholesterol; SM, sphingomyelin; SGC, 3-sulfogalactosylceramide). (D) Deletion of JUBA abrogates
membrane associations in vivo. COS7 cells transfected with GFP-Nbr1, GFP-Nbr1Cterm only, or GFP-Nbr1JUBA were fixed and analyzed by
confocal microscopy. (E) Both JUBA and UBA are necessary for late endocytic localization of Nbr1. (Top) Deletion of the UBA domain abrogates
Nbr1 colocalization with LAMP2. COS7 cells transfected with GFP-Nbr1UBA were fixed, immunostained for LAMP2, and analyzed by confocal
microscopy. (Bottom) Deletion of JUBA also abrogates Nbr1 colocalization with LAMP2. COS7 cells transfected with GFP-Nbr1JUBA were
fixed, immunostained for LAMP2, and analyzed by confocal microscopy.
FIG. 8. UBA is necessary but JUBA is dispensable for Nbr1 function. All error bars represent SEM. P values were calculated by a one-tailed
paired t test (n 	 4). (A) Deletion of UBA but not JUBA abrogates Nbr1-mediated inhibition of EGFR degradation. HEK293T cells were
transfected with Myc-Nbr1, Myc-Nbr1UBA, Myc-Nbr1JUBA, or GFP as a control. Cells were serum starved and stimulated with 50 ng/ml EGF
for the indicated times before being lysed and analyzed by Western blotting. (B) Deletion of UBA but not JUBA abrogates Nbr1-mediated
inhibition of FGFR2 degradation. HEK293T cells were transfected with Myc-Nbr1, Myc-Nbr1UBA, Myc-Nbr1JUBA, or GFP as a control. Cells
were serum starved and stimulated with 20 ng/ml FGF2 plus 10 g/ml heparin for the indicated times before being lysed and analyzed by Western
blotting. (C) Densitometry analysis of RTK degradation by Myc-Nbr1, Myc-Nbr1UBA, and Myc-Nbr1JUBA from panels A and B.
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an N-terminal truncation mutation of Nbr1 expressing residues
C terminal to G694, it could still colocalize with the late en-
docytic marker LAMP2 (Fig. 9A). As this mutation lacks LIR2
(Fig. 1), this result suggests that the loss of LIR2 alone does
not have an effect on Nbr1 localization. However, like full-
length Nbr1 (Fig. 10A), this mutation could still associate with
autophagosomes (Fig. 10B). Therefore, we further mutated
the pivotal tyrosine in the main LIR (Y750 to A) to assess
whether the complete loss of LC3 binding affects the late
endocytic localization of Nbr1. The association with autopha-
gosomes was lost with this additional mutation (Fig. 10C), but
colocalization with the late endocytic marker LAMP2 was not
affected (Fig. 9B). These results reveal that the late endocytic
localization of Nbr1 is independent of LC3 binding and auto-
phagosomal association. Interestingly, we also observed that
the C terminus of Nbr1 (P856-Y988), which is crucial for the
late endocytic localization of the protein (Fig. 6C), is not
needed for autophagosomal localization (Fig. 10D). There-
fore, we conclude that the late endocytic and autophagic lo-
calizations of Nbr1 are independent of one another: the auto-
phagic localization of Nbr1 requires the LIR but not the C
terminus, while the late endocytic localization of Nbr1 requires
the C terminus but not the LIRs.
DISCUSSION
The evidence presented in this study establishes Nbr1 as an
inhibitor of ligand-mediated RTK degradation (Fig. 2 and 3).
Live-cell imaging analysis suggests that the likely mechanism
by which Nbr1 inhibits receptor degradation is via inhibiting
receptor internalization from the cell surface (Fig. 4). The
C-terminal 133 amino acids of Nbr1 are essential for its inhi-
bition of RTK degradation (Fig. 5A, B, and C). We previously
reported that the same region of Nbr1 also binds to Spred2 and
that this binding is essential for the Spred2-mediated down-
regulation of ERK1/2 signaling by targeting the activated re-
ceptors to the lysosomal degradation pathway (15). As Nbr1
inhibits receptor degradation and consequently leads to an
enhancement of downstream ERK1/2 signaling (Fig. 2A and
B), it is possible that Spred2 binding to the critical C terminus
of Nbr1 could be interfering with Nbr1 activity. Alternatively,
Spred2 binding could be altering Nbr1 function from an inhib-
itor to an enhancer of RTK degradation. This is supported by
the fact that while NBR1 does not have a negative impact on
ERK1/2 signaling on its own, its coexpression with Spred2
results in a synergistic inhibition of ERK1/2 (15), which is
suggestive of a cooperative rather than a simply antagonistic
mechanism of functional interaction. Our results also reveal
that further regions of functional significance other than the C
terminus must exist within Nbr1, as a C-terminal-only mutation
on its own is not sufficient to inhibit RTK degradation (Fig. 5F,
G, and H).
The molecular interactions involved in the Nbr1-mediated
inhibition of RTK internalization and degradation are not de-
fined at the moment. A number of known binding partners of
Nbr1, such as P62 (12), P14, transmembrane emp24-like traf-
ficking protein 10 (Tmp21), and ubiquitin carboxyl-terminal
hydrolase 8 (USP8/UBPY) (36), have roles in vesicular traf-
ficking. USP8 is in particular very interesting in this regard, as
its loss results in the inhibition of EGFR degradation (1, 24).
USP8 deubiquitinates EGFR, and this is essential for ESCRT-
dependent MVB sorting and the subsequent degradation of
FIG. 9. Late endocytic localization of Nbr1 is independent of LIR. Scale bars, 10 m. (A) A truncated Nbr1 mutation lacking LIR2
(Nbr1G694) colocalizes with LAMP2. COS7 cells transfected with GFP-Nbr1G694 were fixed, immunostained for LAMP2, and analyzed by
confocal microscopy. (B) This truncated mutation with an additional point mutation in the main LIR (Nbr1G694Y750A) can still colocalize with
LAMP2. COS7 cells transfected with GFP-Nbr1G694Y750A were fixed, immunostained for LAMP2, and analyzed by confocal microscopy.
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FIG. 10. Colocalization of Nbr1 with accumulated autophagosomes depends on LIR but not the C terminus. Scale bars, 10 m. (A) Full-length
Nbr1 can colocalize with autophagosomes. 293A cells stably expressing GFP-tagged LC3 were transfected with Myc-Nbr1. Cells were treated with
200 nM BafA for 4 h to accumulate autophagosomes before being fixed, immunostained for Myc, and analyzed by confocal microscopy. (B) The
Nbr1G694 mutation lacking LIR2 can colocalize with autophagosomes. 293A cells stably expressing GFP-tagged LC3 were transfected with
Myc-Nbr1G694. Cells were treated with 200 nM BafA for 4 h to accumulate autophagosomes before being fixed, immunostained for Myc, and
analyzed by confocal microscopy. (C) The Nbr1G694Y750A mutation, which lacks the LC3 binding capacity, cannot colocalize with autopha-
gosomes. 293A cells stably expressing GFP-tagged LC3 were transfected with Myc-Nbr1G694Y750A. Cells were treated with 200 nM BafA for
4 h to accumulate autophagosomes before being fixed, immunostained for Myc, and analyzed by confocal microscopy. (D) The C-terminally
deleted Nbr1 mutation lacking the last 133 amino acids (P856-Y988) can still colocalize with autophagosomes. 293A cells stably expressing
GFP-tagged LC3 were transfected with Myc-Nbr1Cterm. Cells were treated with 200 nM BafA for 4 h to accumulate autophagosomes before
being fixed, immunostained for Myc, and analyzed by confocal microscopy.
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the receptor (1, 24). In addition, USP8 has a role in the reg-
ulation of ESCRT ubiquitin recognition machinery itself by
deubiquitinating a number of its components (17). The fact
that the phenotype of ectopic Nbr1 expression mimics that of
the USP8 loss could be suggestive of a functional relationship.
It remains to be determined whether a functional epistasis
exists between the two proteins and, if so, how their interaction
regulates endocytosis and receptor degradation.
We previously demonstrated that Nbr1 is a specific late
endosomal protein (15). Here we reveal that the C terminus of
Nbr1 is essential but not sufficient for its late endosomal lo-
calization (Fig. 6C and D). We also show that unlike its C
terminus, the two LIR regions of Nbr1 are dispensable for late
endocytic localization (Fig. 9). On the other hand, the auto-
phagosomal localization of Nbr1 is dependent solely on the
presence of LIRs and not the C terminus (Fig. 10). The fact
that the late endocytic and autophagic localizations of Nbr1
are independent of each other indicates that the function of
the protein in each context might be independent of one an-
other as well. This is not surprising, as the association of Nbr1
with LC3 seems to result primarily in its removal from the
cytoplasm and degradation via the autophagosomal pathway
(9). In line with the above-described hypothesis, the inhibition
of autophagy by the siRNA-mediated depletion of its key com-
ponents did not affect the inhibition of RTK degradation by
Nbr1 (F. K. Mardakheh and J. K. Heath, unpublished obser-
vations).
As mentioned above, the C terminus of Nbr1 contains a
UBA domain, which can bind to polyubiquitin chains (9, 36).
Here we show that the C terminus also contains a well-con-
served membrane-interacting amphipathic -helix, which we
name JUBA. JUBA is crucial for the Nbr1 association with
vesicular limiting membranes (Fig. 7D), and both UBA and
JUBA are essential for the late endocytic localization of the
protein (Fig. 7E). It was proposed previously that amphipathic
-helices might act as curvature sensors, being thermodynam-
ically capable of inserting themselves into membranes with the
right degree of curvature (16). In this light, JUBA could be
providing further specificity with regard to Nbr1 localization by
acting as a specific curvature sensor. Interestingly, despite nu-
merous similarities at the level of domain architecture between
Nbr1 and P62, JUBA seems to be a unique feature of Nbr1, as
a similar region cannot be found in P62 (Fig. 7A). Thus, it is
likely that the mechanisms by which these two proteins localize
to late endosomes are different.
Finally, our results reveal that while JUBA is essential for
the late endocytic localization of Nbr1 (Fig. 7E), it is dispens-
able for its effect on RTK trafficking (Fig. 8). The late endo-
somal localization per se, therefore, does not seem to be im-
portant for the function of Nbr1 in the context of RTK
trafficking. In fact, the above-mentioned mislocalization of the
C-terminal-only Nbr1 mutation to early endosomes (data not
shown) suggests that it is probably trafficked through the en-
docytic machinery, and its late endocytic localization is there-
fore a steady-state phenomenon. The exact molecular mecha-
nism by which Nbr1 associates with the endocytic machinery
remains to be determined. The identification of novel Nbr1-
interacting partners and determination of their mode of inter-
action should help shed light on this matter.
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